

Protein Sequence Searches - February 2005

All of the sequence databases on ABSS have recently been updated.

- Please note that the curators of the UniProt database have purged some temporary accession numbers from the most recent version of UniProt. These sequences have been assigned new permanent accession numbers. The new UniProt record may not contain the previous temporary accession number.

- If you encounter an accession number from an older search run against UniProt (results file extension .rup) that can no longer be found in the database, the permanent record with the new accession number can be found by searching the old accession number in the UniProt Protein Archive database (UniPARC) at:

<http://www.pir.uniprot.org/database/archive.shtml>

If you have any questions regarding this information or your results, please contact any STIC searcher.

When submitting sequence search results for scanning into IFW, please include a copy of this attachment to assist any future Examiners or members of the public who may encounter UniProt temporary accession numbers.

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
 Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model

Run on: December 21, 2005, 12:44:31 ; Search time 54.0459 Seconds
 (without alignments)
 484.925 Million cell updates/sec

Title: US-09-211-297-39
 Perfect score: 1685
 Sequence: 1 MRRASRDYTKLRGSEEMGG.....LLDPDQDATYFGAKVRDID 317
 Scoring table: BLOSUM62
 Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0
 Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
 Maximum Match 100%
 Listing first 45 summaries

Database :
 Issued_Patents_AA:
 1: /cgn2_6/ptodata/1/iaa/5_COMB.pep: *
 2: /cgn2_6/ptodata/1/iaa/6_COMB.pep: *
 3: /cgn2_6/ptodata/1/iaa/H_COMB.pep: *
 4: /cgn2_6/ptodata/1/iaa/PCTUS_COMB.pep: *
 5: /cgn2_6/ptodata/1/iaa/RE_COMB.pep: *
 6: /cgn2_6/ptodata/1/iaa/backfilesl.pep: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

#	Query	Match Length	DB ID	Description
1	1685	100.0	317 2	US-09-996-139-13
2	1685	100.0	317 2	US-09-995-659-13
3	1685	100.0	317 2	US-09-215-649-13
4	1685	100.0	317 2	US-09-052-521-4
5	1685	100.0	317 2	US-09-577-80-13
6	1685	100.0	317 2	US-09-577-80-13
7	1685	100.0	317 2	US-09-466-496-13
8	1685	100.0	317 2	US-09-871-856-13
9	1685	100.0	317 2	US-09-871-291-13
10	1685	100.0	317 2	US-09-396-937-2
11	1685	100.0	317 2	US-09-877-650-13
12	1685	100.0	317 2	US-09-855-363-13
13	1685	100.0	317 2	US-09-688-459-13
14	1685	100.0	317 2	US-09-957-944-6
15	1424.5	84.5	316 2	US-09-957-944-8
16	1417.5	84.1	316 1	US-09-842-842-7
17	1417.5	84.1	316 2	US-09-989-362-2
18	1417.5	84.1	316 2	US-09-552-521C-2
19	1417.5	84.1	316 2	US-09-671-658A-2
20	1417.5	84.1	316 2	US-09-396-937-4
21	1417.5	84.1	316 2	US-09-396-937-6
22	1326.5	78.7	294 2	US-08-996-139-11
23	1326.5	78.7	294 2	US-08-995-659-11
24	1326.5	78.7	294 2	US-03-215-649A-11
25	1326.5	78.7	294 2	US-09-577-780-11
26	1326.5	78.7	294 2	US-09-577-800-11
27	1326.5	78.7	294 2	US-09-466-496-11

ALIGNMENTS

RESULT 1	US-08-996-139-13
SEQUENCE:	Sequence 13, Application US/08996139
PATENT NO.:	Patent No. 6017729
GENERAL INFORMATION:	
APPLICANT:	Anderson, Dirk M.
APPLICANT:	Maraskovsky, Eugene
APPLICANT:	Galibert, Laurent
TITLE OF INVENTION:	Receptor Activator of NF-kappaB
NUMBER OF SEQUENCES:	19
CORRESPONDENCE ADDRESS:	
ADDRESSEE:	Immunex Corporation, Law Department
STREET:	51 University Street
CITY:	Seattle
STATE:	WA
COUNTRY:	USA
ZIP:	98101
COMPUTER READABLE FORM:	
MEDIUM TYPE:	Floppy disk
COMPUTER:	Apple Power Macintosh
OPERATING SYSTEM:	Apple Operating System 7.5.5
CURRENT APPLICATION DATA:	
CURRENT APPLICATION NUMBER:	US/08/996,139
CURRENT SOFTWARE:	Microsoft Word for Power Macintosh 6.0.1
CURRENT FILING DATE:	22 DECEMBER 1997
CURRENT CLASSIFICATION:	
PRIOR APPLICATION DATA:	
APPLICATION NUMBER:	USSN 60/064,671
APPLICATION DATE:	14 OCTOBER 1997
PRIOR APPLICATION DATA:	
APPLICATION NUMBER:	USSN 08/813,509
APPLICATION DATE:	07 MARCH 1997
PRIOR APPLICATION DATA:	
APPLICATION NUMBER:	USSN 08/772,330
APPLICATION DATE:	23 DECEMBER 1996
ATTORNEY/AGENT INFORMATION:	
NAME:	Perkins, Patricia Anne
REGISTRATION NUMBER:	34,693
REFERENCE/DOCKET NUMBER:	2851-A
TELECOMMUNICATION INFORMATION:	
TELEPHONE:	(206) 587-0430
TELEFAX:	(206) 233-0644
INFORMATION FOR SEQ ID NO: 13:	
SEQUENCE CHARACTERISTICS:	
LENGTH:	317 amino acids
REFERENCE:	amino acid
SEQUENCE:	TOPOLGY: linear
SEQUENCE:	MOLECULE TYPE: protein
SEQUENCE:	US-08-996-139-13

Query Match 100.0%; Score 1685; DB 2; Length 317;
 Best Local Similarity 100.0%; Pred. No. 2e-163; Indels 0; Gaps 0;
 Matches 317; Conservative 0; Mismatches 0;

1 MRRASRDYTKLURGSEMGGGAPHEGPJHAPPAPPHOPPAASRSMFVALIGLGQV 60
 b 1 MRRASRDYTKLURGSEMGGGAPHEGPJHAPPAPPHOPPAASRSMFVALIGLGQV 60

61 VCSVALFYFRAMDPNRISBEDGTCYRILRHENDADPQTTLLESQDTKLIPDSCKRK 120
 b 61 VCSVALFYFRAMDPNRISBEDGTCYRILRHENDADPQTTLLESQDTKLIPDSCKRK 120

121 QAFQAVOKELQHIVGSQHRAEKAMDGSMWLAKSKLEAQPFHALTINATDPSGH 180
 b 121 QAFQAVOKELQHIVGSQHRAEKAMDGSMWLAKSKLEAQPFHALTINATDPSGH 180

181 KVSLSSWYHDKWAKISNMTSNGKLUVNQDFPYLYANICPRHETSGDATEYLQMV 240
 b 181 KVSLSSWYHDKWAKISNMTSNGKLUVNQDFPYLYANICPRHETSGDATEYLQMV 240

241 YVTKTISKIPSHTLMKGGSTKWSGNSEFFHYSINVGGFFKURSGEIESEVNSPLLD 300
 b 241 YVTKTISKIPSHTLMKGGSTKWSGNSEFFHYSINVGGFFKURSGEIESEVNSPLLD 300

301 PDDATYFGAFKVRDID 317
 b 301 PDDATYFGAFKVRDID 317

RESULT 2
 S-08-995-659-13
 Sequence 13, Application US/08995659
 Patent No. 6242213

GENERAL INFORMATION:
 ADDRESSEE: Immunex Corporation, Law Department
 STREET: 51 University Street
 CITY: Seattle
 STATE: WA
 COUNTRY: USA
 ZIP: 98101

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: Apple Power Macintosh
 OPERATING SYSTEM: Apple Operating System 7.5.5
 SOFTWARE: Microsoft Word for Power Macintosh 6.0.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/995, 659
 FILING DATE: 22 DECEMBER 1997
 CLASSIFICATION:
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: USSN 08/813, 509
 FILING DATE: 07 MARCH 1997
 CLASSIFICATION:
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: USSN 08/772, 330
 FILING DATE: 23 DECEMBER 1996
 CLASSIFICATION:
 ATTORNEY/AGENT INFORMATION:
 NAME: Perkins, Patricia Anne
 REGISTRATION NUMBER: 34, 693
 REFERENCE/DOCKET NUMBER: 2852-A
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (206) 587-0430

RESULT 3
 US-09-215-649A-13
 Sequence 13, Application US/09215649A
 ; Patent No. 6271349
 ; GENERAL INFORMATION:
 ; APPLICANT: Anderson, Dirk M.
 ; Galibert, Laurent
 Maraskovsky, Eugene
 TITLE OF INVENTION: Receptor Activator of NF-kappaB
 NUMBER OF SEQUENCES: 19

CORRESPONDENCE ADDRESS:
 ADDRESSEE: Immunex Corporation, Law Department
 STREET: 51 University Street
 CITY: Seattle
 STATE: WA
 COUNTRY: USA
 ZIP: 98101

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: Apple Power Macintosh
 OPERATING SYSTEM: Apple Operating System 7.5.5
 SOFTWARE: Microsoft Word for Power Macintosh 6.0.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/215, 649A
 FILING DATE: 17 DEC 1998
 CLASSIFICATION: <Unknown>
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: 08/995, 139
 FILING DATE: <Unknown>
 APPLICATION NUMBER: USSN 08/813, 509
 FILING DATE: 07 MARCH 1997
 APPLICATION NUMBER: USSN 08/772, 330
 FILING DATE: 23 DECEMBER 1996
 ATTORNEY/AGENT INFORMATION:
 NAME: Perkins, Patricia Anne

TELEFAX: (206) 233-0644
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 317 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-995-659-13

Query Match 100.0%; Score 1685; DB 2; Length 317;
 Best Local Similarity 100.0%; Pred. No. 2e-163; Indels 0; Gaps 0;
 Matches 317; Conservative 0; Mismatches 0;

1 MRRASRDYTKLURGSEMGGGAPHEGPJHAPPAPPHOPPAASRSMFVALIGLGQV 60
 b 1 MRRASRDYTKLURGSEMGGGAPHEGPJHAPPAPPHOPPAASRSMFVALIGLGQV 60

61 VCSVALFYFRAMDPNRISBEDGTCYRILRHENDADPQTTLLESQDTKLIPDSCKRK 120
 b 61 VCSVALFYFRAMDPNRISBEDGTCYRILRHENDADPQTTLLESQDTKLIPDSCKRK 120

121 QAFQAVOKELQHIVGSQHRAEKAMDGSMWLAKSKLEAQPFHALTINATDPSGH 180
 b 121 QAFQAVOKELQHIVGSQHRAEKAMDGSMWLAKSKLEAQPFHALTINATDPSGH 180

181 KVSLSSWYHDKWAKISNMTSNGKLUVNQDFPYLYANICPRHETSGDATEYLQMV 240
 b 181 KVSLSSWYHDKWAKISNMTSNGKLUVNQDFPYLYANICPRHETSGDATEYLQMV 240

241 YVTKTISKIPSHTLMKGGSTKWSGNSEFFHYSINVGGFFKURSGEIESEVNSPLLD 300
 b 241 YVTKTISKIPSHTLMKGGSTKWSGNSEFFHYSINVGGFFKURSGEIESEVNSPLLD 300

301 PDDATYFGAFKVRDID 317
 b 301 PDDATYFGAFKVRDID 317

RESULT 3
 US-09-215-649A-13
 Sequence 13, Application US/09215649A
 ; Patent No. 6271349
 ; GENERAL INFORMATION:
 ; APPLICANT: Anderson, Dirk M.
 ; Galibert, Laurent
 Maraskovsky, Eugene
 TITLE OF INVENTION: Receptor Activator of NF-kappaB
 NUMBER OF SEQUENCES: 19

CORRESPONDENCE ADDRESS:
 ADDRESSEE: Immunex Corporation, Law Department
 STREET: 51 University Street
 CITY: Seattle
 STATE: WA
 COUNTRY: USA
 ZIP: 98101

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: Apple Power Macintosh
 OPERATING SYSTEM: Apple Operating System 7.5.5
 SOFTWARE: Microsoft Word for Power Macintosh 6.0.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/215, 649A
 FILING DATE: 17 DEC 1998
 CLASSIFICATION: <Unknown>
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: 08/995, 139
 FILING DATE: <Unknown>
 APPLICATION NUMBER: USSN 08/813, 509
 FILING DATE: 07 MARCH 1997
 APPLICATION NUMBER: USSN 08/772, 330
 FILING DATE: 23 DECEMBER 1996
 ATTORNEY/AGENT INFORMATION:
 NAME: Perkins, Patricia Anne

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:35:06 ; Search time 218.262 Seconds
(without alignments)
1024.696 Million cell updates/sec

Title: US-09-211-297-39

Perfect score: 1685

Sequence: MRRASRDYTKYLRCSEMGG.....LLDPDQDATYFGAKVARDID 317

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched:

2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters:

2166443

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%*

Listing first 45 summaries

Database : UniProt 05.80;*
1: uniprot_sprot;*
2: uniprot_trembl;*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No. Score Query Match Length DB ID

Description

Result No.	Score	Query	Match	Length	DB	ID	Description
1	1685	100.0	317	1	TNFL1	HUMAN	TNFL1_HUMAN STANDARD; PRT; 317 AA.
2	1685	100.0	317	2	QST914	HUMAN	Q14786; O11723; Q96017; Q9P203; PRT; 317 AA.
3	1417.5	84.1	316	1	TNFL1	MOUSE	Q5235 m tumor nec
4	1396.5	82.9	318	1	TNFL1	MOUSE	Q98E2 r tumor nec
5	1292	76.7	244	2	Q54AB8	HUMAN	Q5a98 homo sapien
6	559.5	33.2	290	2	05HZB8	XENLA	Q51z8 xenopus lae
7	470	27.9	117	2	05A9H0	RABBIT	Q5X1h oryctolagus cuniculus
8	273.5	16.2	289	2	04VS86	PIG	Q4v86 sus scrofa
9	266	15.8	317	2	07ZYX9	CHICK	Q7Zx9 brachydanio
10	265	15.7	304	2	07T1F2	CHICK	Q7t1f2 gallus gallus
11	262.5	15.6	292	2	05ZK93	CHICK	Q5z1k3 gallus gallus
12	251.5	14.9	281	1	TNFL1	HUMAN	P50591 homo sapien
13	251.5	14.9	281	1	06TB45	HUMAN	Q6iba9 homo sapien
14	249.5	14.8	299	2	06DHG9	BRAKE	Q6d1g9 brachydanio
15	249.5	14.8	303	2	05XK03	MOUSE	Q5xk3 mus musculus
16	248	14.7	291	1	TNFO0	MOUSE	P50592 mus musculus
17	245.5	14.6	264	2	Q4S9Q4	TETNG	Q48q4 tetrodon n
18	240.5	14.3	214	2	09DDZ5	BRARE	Q9dz5 brachydanio
19	234	13.9	300	2	05U675	HUMAN	Q5u75 homo sapien
20	216.5	12.8	287	2	090WTS	CHICK	Q90vt3 gallus gallus
21	215.5	12.8	287	2	08K3G0	RET	Q8k3g0 rattus norvegicus
22	211	12.5	285	2	04SKU4	TETNG	Q48ku4 tetraodon n
23	200	11.9	282	1	TNFL6	PIG	Q9ba8 sus scrofa
24	194.5	11.5	280	2	0861W5	PELCA	Q861w5 felis silvestris
25	190.5	11.3	253	2	0SCAQD	CHICK	Q5cq9 gallus gallus
26	189	11.2	281	1	TNFL6	HUMAN	P4823 h tumor nec
27	189	11.2	281	1	0532Z1	HUMAN	Q532z1 homo sapien
28	187.5	11.1	279	2	07TMW9	MOUSE	Q7tmw9 mus musculus
29	186	11.1	280	1	TNFL6	PIG	P63108 m tumor nec
30	185	11.0	280	1	TNPL6	MACMII	P63307 m tumor nec
31	11.0		1		TNFL6	MACNII	P63306 m tumor nec

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched:

2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters:

2166443

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 100%*

Listing first 45 summaries

Database : UniProt 05.80;*
1: uniprot_sprot;*
2: uniprot_trembl;*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No. Score Query Match Length DB ID

Description

Result No.	Score	Query	Match	Length	DB	ID	Description
1	1685	100.0	317	1	TNFL1	HUMAN	TNFL1_HUMAN STANDARD; PRT; 317 AA.
2	1685	100.0	317	2	QST914	HUMAN	Q14786; O11723; Q96017; Q9P203; PRT; 317 AA.
3	1417.5	84.1	316	1	TNFL1	MOUSE	Q5235 m tumor nec
4	1396.5	82.9	318	1	TNFL1	MOUSE	Q98E2 r tumor nec
5	1292	76.7	244	2	Q54AB8	HUMAN	Q5a98 homo sapien
6	559.5	33.2	290	2	05HZB8	XENLA	Q51z8 xenopus lae
7	470	27.9	117	2	05A9H0	RABBIT	Q5X1h oryctolagus cuniculus
8	273.5	16.2	289	2	04VS86	PIG	Q4v86 sus scrofa
9	266	15.8	317	2	07ZYX9	CHICK	Q7Zx9 brachydanio
10	265	15.7	304	2	07T1F2	CHICK	Q7t1f2 gallus gallus
11	262.5	15.6	292	2	05ZK93	CHICK	Q5z1k3 gallus gallus
12	251.5	14.9	281	1	TNFL1	HUMAN	P50591 homo sapien
13	251.5	14.9	281	1	06TB45	HUMAN	Q6iba9 homo sapien
14	249.5	14.8	299	2	06DHG9	BRAKE	Q6d1g9 brachydanio
15	249.5	14.8	303	2	05XK03	MOUSE	Q5xk3 mus musculus
16	248	14.7	291	1	TNFO0	MOUSE	P50592 mus musculus
17	245.5	14.6	264	2	Q4S9Q4	TETNG	Q48q4 tetrodon n
18	240.5	14.3	214	2	09DDZ5	BRARE	Q9dz5 brachydanio
19	234	13.9	300	2	05U675	HUMAN	Q5u75 homo sapien
20	216.5	12.8	287	2	090WTS	CHICK	Q90vt3 gallus gallus
21	215.5	12.8	287	2	08K3G0	RET	Q8k3g0 rattus norvegicus
22	211	12.5	285	2	04SKU4	TETNG	Q48ku4 tetraodon n
23	200	11.9	282	1	TNFL6	PIG	Q9ba8 sus scrofa
24	194.5	11.5	280	2	0861W5	PELCA	Q861w5 felis silvestris
25	190.5	11.3	253	2	0SCAQD	CHICK	Q5cq9 gallus gallus
26	189	11.2	281	1	TNFL6	HUMAN	P4823 h tumor nec
27	189	11.2	281	1	0532Z1	HUMAN	Q532z1 homo sapien
28	187.5	11.1	279	2	07TMW9	MOUSE	Q7tmw9 mus musculus
29	186	11.1	280	1	TNFL6	PIG	P63108 m tumor nec
30	185	11.0	280	1	TNPL6	MACMII	P63307 m tumor nec
31	11.0		1		TNFL6	MACNII	P63306 m tumor nec

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched:

2166443 seqs, 705528306 residues

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 100%*

Listing first 45 summaries

Database : UniProt 05.80;*
1: uniprot_sprot;*
2: uniprot_trembl;*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No. Score Query Match Length DB ID

Description

Result No.	Score	Query	Match	Length	DB	ID	Description
1	1685	100.0	317	1	TNFL1	HUMAN	TNFL1_HUMAN STANDARD; PRT; 317 AA.
2	1685	100.0	317	2	QST914	HUMAN	Q14786; O11723; Q96017; Q9P203; PRT; 317 AA.
3	1417.5	84.1	316	1	TNFL1	MOUSE	Q5235 m tumor nec
4	1396.5	82.9	318	1	TNFL1	MOUSE	Q98E2 r tumor nec
5	1292	76.7	244	2	Q54AB8	HUMAN	Q5a98 homo sapien
6	559.5	33.2	290	2	05HZB8	XENLA	Q51z8 xenopus lae
7	470	27.9	117	2	05A9H0	RABBIT	Q5X1h oryctolagus cuniculus
8	273.5	16.2	289	2	04VS86	PIG	Q4v86 sus scrofa
9	266	15.8	317	2	07ZYX9	CHICK	Q7Zx9 brachydanio
10	265	15.7	304	2	07T1F2	CHICK	Q7t1f2 gallus gallus
11	262.5	15.6	292	2	05ZK93	CHICK	Q5z1k3 gallus gallus
12	251.5	14.9	281	1	TNFL1	HUMAN	P50591 homo sapien
13	251.5	14.9	281	1	06TB45	HUMAN	Q6iba9 homo sapien
14	249.5	14.8	299	2	06DHG9	BRAKE	Q6d1g9 brachydanio
15	249.5	14.8	303	2	05XK03	MOUSE	Q5xk3 mus musculus
16	248	14.7	291	1	TNFO0	MOUSE	P50592 mus musculus
17	245.5	14.6	264	2	Q4S9Q4	TETNG	Q48q4 tetrodon n
18	240.5	14.3	214	2	09DDZ5	BRARE	Q9dz5 brachydanio
19	234	13.9	300	2	05U675	HUMAN	Q5u75 homo sapien
20	216.5	12.8	287	2	090WTS	CHICK	Q90vt3 gallus gallus
21	215.5	12.8	287	2	08K3G0	RET	Q8k3g0 rattus norvegicus
22	211	12.5	285	2	04SKU4	TETNG	Q48ku4 tetraodon n
23	200	11.9	282	1	TNFL6	PIG	Q9ba8 sus scrofa
24	194.5	11.5	280	2	0861W5	PELCA	Q861w5 felis silvestris
25	190.5	11.3	253	2	0SCAQD	CHICK	Q5cq9 gallus gallus
26	189	11.2	281	1	TNFL6	HUMAN	P4823 h tumor nec
27	189	11.2	281	1	0532Z1	HUMAN	Q532z1 homo sapien
28	187.5	11.1	279	2	07TMW9	MOUSE	Q7tmw9 mus musculus
29	186	11.1	280	1	TNFL6	PIG	P63108 m tumor nec
30	185	11.0	280	1	TNPL6	MACMII	P63307 m tumor nec
31	11.0		1		TNFL6	MACNII	P63306 m tumor nec

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched:

2166443 seqs, 705528306 residues

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 100%*

Listing first 45 summaries

Database : UniProt 05.80;*
1: uniprot_sprot;*
2: uniprot_trembl;*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No. Score Query Match Length DB ID

Description

Result No.	Score	Query	Match	Length	DB	ID	Description
1	1685	100.0	317	1	TNFL1	HUMAN	T

RL Biochem. Biophys. Res. Commun. 269:532-536 (2000).
RN [5] NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RP TISSUE=Lung;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strauberg R.D., Fengold F.S., Grouse L.H., Derge J.G., Schleifer K., Klausner R.D., Collins F.S., Wagner L., Shemesh C.M., Schuler G.D., Altenschul S.F., Zeeberg B., Butow K.H., Schaefer C.F., Bhat N.K., Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F., Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L., Stapleton M., Soares M.B., Bandallo M.F., Casavant T.L., Scheetz T.E., Brownstein M.J., Usdin T.B., Tashiro Y., Carninci P., Prange C., Raha S.S., Loquaiello N.A., Peters G.J., Abramson R.D., Mulahy S.J., Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H., Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W., Villaon D.K., Muzyk D.M., Sodergren E.T., Lu X., Gibbs R.A., Fahey J., Helton E., Kettenmeyer M., Madan A., Rodrigues S., Sanchez A., Whiting M., Madan J., Young A.C., Shevchenko A., Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smialius D.E., Scherch A., Schein J.B., Jones S.J.M., Marra M.A., Generation and initial analysis of more than 15,000 full-length human RTT proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RL [6] NUCLOTIDE SEQUENCE OF 73-317.
RN RP
RC TISSUE=Thymocyte;
RX MEDLINE=9146011; PubMed=9312132; DOI=10.1074/jbc.272.40.25190;
RA Kalachikov S., Cayani E., Bartlett F.S. III, Frankel W.N., Lee S.Y., Choi Y.;
RT "TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells";
RL J. Biol. Chem. 272:25190-25194 (1997).
CC -I- FUNCTION: Cytokine that binds to TNFRSF1B/OPG and to TNFRSF1A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naïve T-cell proliferation. May be an important regulator of interactions between T cells and dendritic cells and may play a role in the regulation of the T cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy.
CC -I- SUBUNIT: Homotrimer (By similarity).
CC -I- SUBCELLULAR LOCATION: Type II membrane protein (isoforms 1 and 3); secreted (Isoform 2). A soluble form of isoform 1 arises by proteolytic processing (By similarity).
CC -I- ALTERNATIVE PRODUCTS:
CC Event=alternative splicing; Named isoform=3;
CC Name=1; IsoId=014788-1; Sequence=Displayed;
CC Name=2; Synonyms=SODF;
CC IsoId=014788-2; Sequence=VSP_006447;
CC Name=3;
CC IsoId=014788-3; Sequence=VSP_006446;
CC -I- TISSUE SPECIFICITY: Highest in the peripheral lymph nodes, weak in spleen, peripheral blood leukocytes, bone marrow, heart, placenta, skeletal muscle, stomach and thyroid.
CC -I- INDUCTION: Up-regulated by T cell receptor stimulation.
CC -I- PTM: The soluble form of isoform 1 derives from the membrane form by proteolytic processing (By similarity). The cleavage may be catalyzed by ADAM17.
CC -I- SIMILARITY: Belongs to the tumor necrosis factor family.
CC This Swiss-Prot entry is copyright. It is produced through a collaboration between the European Bioinformatics Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use as long as its content is in no way modified and this statement is not removed.
CC DR EMBL; AF09047; AAB8011.1; mRNA.
DR EMBL; AF053712; AAC39731.1; mRNA.
DR EMBL; AB064269; BAB79694.1; mRNA.

DR EMBL; AB061227; BAB71768.1; mRNA.
DR EMBL; AB064270; BAB79695.1; mRNA.
DR EMBL; AB037599; BAB90488.1; mRNA.
DR EMBL; BC074823; AAH74823.1; mRNA.
DR EMBL; BC074890; AAH74890.1; mRNA.
DR HSSP; C05235; 1J7Z.
DR SMR; O14788; 162-317.
DR Ensemble; ENSG00000120659; Homo sapiens.
DR HGNC; HGNC:11926; TNFSF11.
DR InterPro; IPR03636; TNF_Bub.
DR InterPro; IPR03636; C_extracellular_region; NAS.
DR GO; GO:0005897; C_integral_to_plasma_membrane; NAS.
DR GO; GO:0005164; F_tumor_necrosis_factor_receptor_binding; NAS.
DR GO; GO:0006955; P_immune_response; NAS.
DR GO; GO:0030316; P_osteoclast_differentiation; NAS.
DR InterPro; IPR06052; TNF_family.
DR InterPro; IPR03636; TNF_1.
DR Pfam; PF00229; TNF_1.
DR Problem; PD002012; TNF_subf; 1.
DR SMART; SM0207; TNF_1.
DR PROSITE; PS00251; TNF_1; FALSE_NEG.
DR PROSITE; PS50049; TNF_2; 1.
KW Alternative splicing; Cytokine; Developmental protein; Differentiation; Glycoprotein; Receptor; Signal-anchor; Transmembrane_CHAIN 1 317
FT CHAIN 140 317
FT TRANSMEM 48 68
FT TOPO_DOM 1 47
FT SITE 69 317
FT CARBOHYD 139 140
FT CARBOHYD 171 171
FT VARSPLIC 198 198
FT VARSPLIC 1 73
FT VARSPLIC 1 47
FT CONFLICT 194 194
FT SEQ 317 AA; 354-78 MW; 7616463434097F CRC64;
Query Match 100.0%; Score 1685; DB 1; Length 317;
Best Local Similarity 100.0%; Pred. No. 6.5e-136;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRRASRDYTYKYLROSREBBMGGGGPAGPHEGPILAPPAPPAHQPPAARSMSMFVALLGIGLGQV 60
Db 1 MRRASRDYTYKYLROSREBBMGGGGPAGPHEGPILAPPAPPAHQPPAARSMSMFVALLGIGLGQV 60
QY 61 VCSVALPFYFYRAQMDPNRISEDGTHCITYRIRLHLNADFDTTLSDQTKLIPSCRRIK 120
Db 61 VCSVALPFYFYRAQMDPNRISEDGTHCITYRIRLHLNADFDTTLSDQTKLIPSCRRIK 120
QY 121 QAFQGAVKELQHTVGQSHIRAEMQDSWLDAKRSLKEAQPAFAHTLTINATDPSGH 180
Db 121 QAFQGAVKELQHTVGQSHIRAEMQDSWLDAKRSLKEAQPAFAHTLTINATDPSGH 180
QY 181 KVSLSSWYHRGAWAKISNMIFNSNGKLIVANDGDFYLYAMICPRHETSGDLATEYLQLWV 240
Db 181 KVSLSSWYHRGAWAKISNMIFNSNGKLIVANDGDFYLYAMICPRHETSGDLATEYLQLWV 240
QY 241 YVKVSKIKPSSHTIMKGSTSKYWSGNNSRFHYSINVGGFPKLRSGESEIEVNNSPLID 300
Db 241 YVKVSKIKPSSHTIMKGSTSKYWSGNNSRFHYSINVGGFPKLRSGESEIEVNNSPLID 300
QY 301 PQQDATYFGAKVURID 317
Db 301 PQQDATYFGAKVURID 317

GenCore version 5.1.6.
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model

Run on: December 21, 2005, 12:34:10 ; Search time 215.664 Seconds
(without alignments)

Scoring table: BLOSUM62
Gapopen 10.0 , Gapext 0.5

Title: US-09-211-297-39
Perfect score: 1685
Sequence: MRRASRDRYTKYLRGSEEM3G.....LLDPDQDATYFGAKVURID 317

Searched: 2443163 seqs, 439378781 residues
Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0
Maximum DB seq length: 0
Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :
A_Geneseq_21: *
1: geneseqp1980s: **
2: geneseqp1990s: **
3: geneseqp2000s: **
4: geneseqp2001s: **
5: geneseqp2002s: **
6: geneseqp2003as: **
7: geneseqp2003bs: **
8: geneseqp2004s: **
9: geneseqp2005s: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	1685	100.0	317 2 AAW83195	Raw83195 Human ost
2	1685	100.0	317 2 AAW83195	Raw69957 NF-KB rec
3	1685	100.0	317 2 AAW8293	Raw68293 NF-kB rec
4	1685	100.0	317 2 AAE08738	Aae08738 Human rec
5	1685	100.0	317 3 AAY84417	Aay84417 Amnio aci
6	1685	100.0	317 4 AAE04426	Aae04426 Human rec
7	1685	100.0	317 4 AAE01993	Aae01993 Human full
8	1685	100.0	317 5 ABB08134	Abb08134 Human RAN
9	1685	100.0	317 5 AAE26103	Aae26103 Human RAN
10	1685	100.0	317 5 ABG31631	Abg31631 Human RAN
11	1685	100.0	317 5 AATU8285	Aat78285 Human TRA
12	1685	100.0	317 5 AAO19096	Aao19096 C neoform
13	1685	100.0	317 5 ADR29336	Adr29335 Human RAN
14	1685	100.0	317 6 ABP55108	Abp55108 Human ost
15	1685	100.0	317 6 AAE34364	Aae34364 Human rec
16	1685	100.0	317 6 ABR2314	Abx42314 Human RAN
17	1685	100.0	317 7 ADIB6988	Adb16988 Human rec
18	1685	100.0	317 7 ADC35204	Adc35204 Human TNF
19	1685	100.0	317 7 ADC73002	Adc73002 Human RAN
20	1685	100.0	317 7 ADC78268	Adc78268 Human RAN
21	1685	100.0	317 7 ABW02277	Abw02277 Human RAN
22	1685	100.0	317 7 ADG46723	Adg46723 Human RAN
23	1685	100.0	317 7 ADJ82112	Adj82112 Protein f
24	1685	100.0	317 8 ADM96241	Adm96241 Human rec

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

RESULT 1
ID AAW83195 standard; protein; 317 AA.
XX
AAW83195;
XX
DT 11-FEB-1999 (first entry)
XX
Human osteoprotegerin binding protein from the pcDNA/huOPGbpl.insert.
XX
Human; osteoprotegerin binding protein; OPG binding protein; arthritis;
osteoporosis; osteoclast maturation; bone disease; metastasis; ODR;
hypercalcemia; osteoclast differentiation and activation receptor;
Paget's disease.
XX
OS Homo sapiens.
XX
PN WO9846751-A1.
XX
PD 22-OCT-1998.
XX
PF 15-APR-1998; 98WO-US007584.
XX
PR 16-APR-1997; 97US-00842842.
PR 23-JUN-1997; 97US-00880555.
PR 30-NOV-1998; 98US-00052521.
XX
(AMGE-) AMGEN INC.
PA
XX
Boyle WJ;
XX
DR WPI; 1998-594578/50.
N-PSDB; AAV70285.
XX
PS
Claim 19; Fig 4; 47pp; English.

The present sequence is human osteoprotegerin (OPG) binding protein. Host cells transfected with vectors containing nucleic acid molecules encoding OPG binding protein are used to produce recombinant OPG protein. OPG binding protein is used in binding assays to determine osteoprotegerin (OG) in biological samples, to screen for specific binding agents (particularly agonists and antagonists), including intracellular proteins to raise Ab (useful in immunoassays for detection of OPG binding).

Act08155 Human RAN
Adu6570 Novel bro
Adw09029 Human rec
Ady16469 PRO Polyp
Ady4714 Human rec
Adz2661 Human can
Ady7756 Human RAN
Aaw83018 Osteoclas
Adz29338 Mouse RAN
Adt8815 Murine RA
Adj82113 Protein F
Aaw83017 Osteoclas
Aaw83194 Human ost
Aaw9654 Amino aci
Aay17874 Murine TR
Aay91022 Mouse OBM
Aay84118 Amino aci
Aay84119 Amino aci
Aau78289 Mouse TRA
Aar4071 Human RAN
Abb92477 Amino aci

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:47:51 ; Search time 35.8574 Seconds
(without alignment)
850.612 Million cell updates/sec

Title: US-09-211-297-39
Perfect Score: 1685
Sequence: 1 MRRASRDTYKYLRGSEMGG.....LLDPDQDATYGAFAKVRRID 317

Scoring table:

BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched:

283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

1: pir1:
2: pir2:
3: pir3:
4: pir4:
PIR 80:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No. Score Query Match Length DB ID

Description

1	189	11.2	281	2	I38707	Fas ligand - human
2	184.5	10.9	279	2	A53062	Fas ligand - mouse
3	176.5	10.5	261	2	S53080	CD40 ligand - bovi
4	175.5	10.4	278	2	A49266	Fas ligand - rat
5	158.5	9.4	261	2	153476	CD40 ligand - huma
6	141.5	8.4	235	1	QWMSN	tumor necrosis fac
7	141	8.4	234	1	A25451	tumor necrosis fac
8	137	8.1	234	1	JH0529	tumor necrosis fac
9	133	7.9	233	1	QWHUN	tumor necrosis fac
10	132.5	7.9	235	2	I54490	tumor necrosis fac
11	131.5	7.8	235	2	JU0029	tumor necrosis fac
12	130.5	7.7	306	2	I49139	lymphotoxin-beta -
13	130	7.7	233	1	S22052	tumor necrosis fac
14	128	7.6	234	1	JQ1344	tumor necrosis fac
15	126.5	7.5	233	1	S24642	tumor necrosis fac
16	126	7.5	232	1	S1260	tumor necrosis fac
17	125.5	7.4	185	2	S52715	tumor necrosis fac
18	122	7.2	193	2	S06192	CD40 ligand - mous
19	120	7.1	260	2	S21738	tumor necrosis fac
20	117	6.9	233	2	S11688	lymphotoxin beta -
21	117	6.9	244	2	A46056	collagen alpha 1(I)
22	97.5	5.8	1464	1	GHQHS	probable protein k
23	94.5	5.6	664	2	SG4747	lymphotoxin alpha
24	92.5	5.5	205	1	QWNUX	hypothetical prote
25	92.5	5.5	2	S38114	TIPC protein - sli	
26	91.5	5.4	3848	2	T17414	probable GnrR-fami
27	91	5.4	493	2	AC0937	biaidohesin - mou
28	90.5	5.4	1694	2	S50065	gelatinase B (EC 3
29	90	5.3	730	2	JC1456	

ALIGNMENTS

30	89.5	5.3	331	2	AF3526	homoprotocatshuat
31	89.5	5.3	379	2	A47659	farnesyl-protein
32	89	5.3	202	1	I38703	tum necrosis fac
33	89	5.3	440	2	I49681	glyceraldehyde-3-p
34	89	5.3	479	2	A25052	fibrinogen beta ch
35	89	5.3	639	2	C83624	probable two-compo
36	88.5	5.3	565	2	C89893	hypothetical prote
37	88.5	5.3	578	2	S51379	probable phospho
38	88.5	5.3	684	2	T01267	leucine-rich repea
39	88.5	5.3	883	2	A49733	[heparan sulfate]-
40	87.5	5.2	610	2	T06690	galactonolactone d
41	87.5	5.2	1466	1	CGHUTL	collagen alpha 1(I)
42	87	5.2	639	2	A32935	protein P1 - Entam
43	87	5.2	1114	2	JH0284	125K surface anti
44	87	5.2	592	2	G96722	hypothetical prote
45	86.5	5.1	279	2	F72339	hypothetical prote

RESULT 1
138707
Fas ligand - human
C;Species: Homo sapiens (man)
C;Date: 29-May-1998 #sequence revision 29-May-1998 #text_change 09-Jul-2004
C;Accession: I38707; JJC340; S57565; I38554
R;Takahashi, T.; Tanaka, M.; Inazawa, J.; Abe, T.; Suda, T.; Negata, S.
Int. Immunol. 6, 1567-1574, 1994
A;Title: Human Fas ligand: gene structure, chromosomal location and species specificity.
A;Reference number: 138707; MUID:95127560; PMID:7826947
A;Accession: I38707
A;Status: Preliminary;
A;Molecule type: mRNA
A;Accession: JJC340
A;Molecule type: DNA
A;Residues: 1-281 <MT>
A;Cross-references: UNIPARC:UPI000000D91A; EMBL:X89102; NID:9887455; PID:9887456
R;Schatzlin, C.E
R;submitted to the EMBL Data Library, June 1995
A;Reference number: S57565
A;Accession: S57565
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-281 <SC>
A;Cross-references: UNIPARC:UPI000000D91A; EMBL:X89102; NID:9887455; PID:9887456
R;Alderson, M.R.; Tough, T.W.; Davis-Smith, T.; Braddy, S.; Falk, B.; Schooley, K.A.; Gr
J. Exp. Med. 181, 71-77, 1995
R;Alderson, M.R.; Tough, T.W.; Davis-Smith, T.; Braddy, S.; Falk, B.; Schooley, K.A.; Gr
J. Exp. Med. 181, 71-77, 1995
A;Title: Fas ligand mediates activation-induced cell death in human T lymphocytes.
A;Reference number: I38554; MUID:95105731; PMID:7528780
A;Accession: I38554
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: mRNA
A;Cross-references: UNIPARC:UPI000000D91A; EMBL:U08137; NID:9624627; PIDN: AAC50071.1; PI
A;Residues: 1-281 <SC>
A;Cross-references: UNIPARC:UPI000000D91A; EMBL:U08137; NID:9624627; PIDN: AAC50071.1; PI
A;Genetics:
A;Gene: FasL
A;Intron: 151/1; 11/3
A;Cross-references:
C;Keywords: glycoprotein; transmembrane protein
F;6,184,250,260/Binding site: carbohydrate (asn) (covalent) #status predicted
Query Match 11.2%; Score 189; DB 2; Length 281;
Best Local Similarity 21.7%; Pred. No. 2e-08; Status 98; Mismatches 11; Indels 108; Gaps 11;

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model
Run on: December 21, 2005, 13:02:07 ; Search time 174.61 Seconds
Title: US-09-211-297-39
Perfect Score: 1685
Sequence: MERRASDYTKYRGSEENG...
Scoring table: BLOSSUM62
Gapop 10.0 , Gapext 0.5
Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA_Main:*

1: /cgns_6/prodata/1/pbpaa/us07_PUBCOMB.pep:*
2: /cgns_6/prodata/1/pbpaa/us09_PUBCOMB.pep:*
3: /cgns_6/prodata/1/pbpaa/us10_PUBCOMB.pep:*
4: /cgns_6/prodata/1/pbpaa/us10b_PUBCOMB.pep:*
5: /cgns_6/prodata/1/pbpaa/us11_PUBCOMB.pep:*

Pred. No. 18 is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Length	DB ID	Description
1	1685	100.0	317	US-09-813-329-7
2	1685	100.0	317	US-09-871-856-13
3	1685	100.0	317	US-09-957-944-6
4	1685	100.0	317	US-09-805-365-13
5	1685	100.0	317	US-09-871-291-13
6	1685	100.0	317	US-09-877-650-13
7	1685	100.0	317	US-09-933-912-2
8	1685	100.0	317	US-10-151-071-10
9	1685	100.0	317	US-10-218-547-22
10	1685	100.0	317	US-10-405-871-13
11	1685	100.0	317	US-10-167-182-11
12	1685	100.0	317	US-10-310-793-28
13	1685	100.0	317	US-10-440-621-11
14	1685	100.0	317	US-10-219-455-19
15	1685	100.0	317	US-10-202-621-22
16	1685	100.0	317	US-10-664-801-2
17	1685	100.0	317	US-10-381-160-1
18	1685	100.0	317	US-10-799-345-12
19	1685	100.0	317	US-10-399-116-6
20	1685	100.0	317	US-10-802-131-13
21	1685	100.0	317	US-10-825-898-4
22	1685	100.0	317	US-10-854-300-11
23	1685	100.0	317	US-10-129-591-1
24	1685	100.0	317	US-10-451-200-6
25	1685	100.0	317	US-10-993-522-8
26	1685	100.0	317	US-11-028-781-22
27	1685	100.0	317	US-11-090-059-6

ALIGNMENTS

RESULT 1
US-09-813-329-7
; Sequence 7, Application US/09813329
; Patent No. US20020012968A1
; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; TITLE OF INVENTION: No. US20020012968A1 Drosophila Tumor Necrosis Factor Cla...
; TITLE OF INVENTION: Variants Thereof
; FILE REFERENCE: D0016.mp
; CURRENT APPLICATION NUMBER: US/09/813,329
; CURRENT FILING DATE: 2001-03-20
; PRIOR APPLICATION NUMBER: 60/190,816
; PRIOR FILING DATE: 2000-03-21
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: Patentin version 3.0
; SEQ ID NO: 7
; LENGTH: 317
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
; US-09-813-329-7

Query Match 100.0%; Score 1685; DB 3; Length 317;
Best Local Similarity 100.0%; Freq. No. 4.9e-149;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy | 1 MERRASDYTKYRGSEENG...
Db | 1 MRASDYTKYRGSEENG...
Qy | 61 VCSVALPFYFRQMDNRISDGTHCYTRILRHENADFDTTLSQDTPKLIQPSRRSMFVALLIGLIGQV 60
Db | 61 VCSVALPFYFRQMDNRISDGTHCYTRILRHENADFDTTLSQDTPKLIQPSRRSMFVALLIGLIGQV 60
Qy | 121 QFOGAVQKEQJQIVQSQHRAKAMGDWSMILAKRSKLAQPAQFAHLTNATDPSGH 120
Db | 121 QFOGAVQKEQJQIVQSQHRAKAMGDWSMILAKRSKLAQPAQFAHLTNATDPSGH 120
Qy | 181 KSLSSYHDKWAKSNMTRNSNGKLUNQDPYLYANTICFRHRTSGDQATEYIQLMV 240
Db | 181 KSLSSYHDKWAKSNMTRNSNGKLUNQDPYLYANTICFRHRTSGDQATEYIQLMV 240
Qy | 241 YTKTSKIKPSSHTLMKGGSTKWMSENSEPHFYSINVGCFKRLSCEEISLEVSNSLID 300
Db | 241 YTKTSKIKPSSHTLMKGGSTKWMSENSEPHFYSINVGCFKRLSCEEISLEVSNSLID 300
Qy | 301 PDDATYFGAFKVRDID 317
Db | 301 PDDATYFGAFKVRDID 317
; PODATYFGAFKVRDID 317
; PODATYFGAFKVRDID 317

RESULT 2
US-09-871-856-13
Sequence 13, Application US/09871856
; Patent No. US20020081720A1
; GENERAL INFORMATION:
; APPLICANT: Anderson, Dirk M.
; Galibert, Laurent
; Marakovsky, Eugene
TITLE OF INVENTION: Receptor Activator of NF-kappaB
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
; ADDRESSEE: Immunex Corporation, Law Department
; STREET: 51 University Street
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
ZIP: 98101
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: Apple Power Macintosh
OPERATING SYSTEM: Apple Operating System 7.5.5
SOFTWARE: Microsoft Word for Power Macintosh 6.0.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/871-856
FILING DATE: 31-May-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/996,139
FILING DATE: <Unknown>
APPLICATION NUMBER: USN 08/813,509
FILING DATE: 07 MARCH 1997
APPLICATION NUMBER: USN 08/772,330
FILING DATE: 23 DECEMBER 1996
ATTORNEY/AGENT INFORMATION:
NAME: Perkins, Patricia Anne
REGISTRATION NUMBER: 34,693
REFERENCE/DOCKET NUMBER: 2851-A
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 587-0430
TELEFAX: (206) 23-0644
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 317 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-871-856-13
Query Match 100%; Score 1685; DB 3; Length 317;
Best Local Similarity 100.0%; Pred. No. 4.9e-149;
Matches 317; Conservative 0; Mismatches 0; Gaps 0;
Gaps 0;
QY 1 MRRASRDYTKYLGSEEMGGPGAPHEGPPLHAPPAPHQPPAARSMSMVALGLGQV 60
Db 61 VCSVALFFRAQMDPNRISEDGPHCIRLRLHENAQPDTLESQTKLIDSCRK 120
Db 61 VCSVALFFRAQMDPNRISEDGPHCIRLRLHENAQPDTLESQTKLIDSCRK 120
QY 121 QAFQGAVQKELQHTVGSQHIAEKAMVDSWLDAKRSKLEAQPAFHATINTADIPSSH 180
Db 121 QAFQGAVQKELQHTVGSQHIAEKAMVDSWLDAKRSKLEAQPAFHATINTADIPSSH 180
QY 181 KVSLSSWHDRGWAKISNTTFSNGKLINQDGFLYLYANICFRHETSGDATEYLQMV 240
Db 181 KVSLSSWHDRGWAKISNTTFSNGKLINQDGFLYLYANICFRHETSGDATEYLQMV 240
QY 241 YVKTSIKPSSHILMKGSSTKWSGNBRHFYSINVGGPKURSGEETIEVSNSPLSD 300
Db 241 YVKTSIKPSSHILMKGSSTKWSGNBRHFYSINVGGPKURSGEETIEVSNSPLSD 300
QY 301 PDQDATYFGAKVRDID 317
Db 301 PDQDATYFGAKVRDID 317
RESULT 3
US-09-957-944-6
Sequence 6, Application US/09957944
; Publication No. US20020086312A1
; GENERAL INFORMATION:
; APPLICANT: Douall, William C.
; TITLE OF INVENTION: SCREENING ASSAYS FOR AGONISTS AND ANTAGONISTS OF RECEPTOR ACTIVATOR OF NF-kappa B
; NUMBER OF SEQ ID NOS: 13
; CURRENT APPLICATION NUMBER: US/09/957,944
; CURRENT FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: 60/235,157
; PRIOR FILING DATE: 2000-09-22
; FILE REFERENCE: 3109-A
; SOFTWARE: PatentIn version 3.1
; SBO ID NO: 6
; LENGTH: 317
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-957-944-6
Query Match 100.0%; Score 1685; DB 3; Length 317;
Best Local Similarity 100.0%; Pred. No. 4.9e-149; Mismatches 0; Indels 0; Gaps 0;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRRASRDYTKYLGSEEMGGPGAPHEGPPLHAPPAPHQPPAARSMSMVALGLGQV 60
Db 1 MRRASRDYTKYLGSEEMGGPGAPHEGPPLHAPPAPHQPPAARSMSMVALGLGQV 60
QY 61 VCSVALFFRAQMDPNRISEDGPHCIRLRLHENAQPDTLESQTKLIDSCRK 120
Db 61 VCSVALFFRAQMDPNRISEDGPHCIRLRLHENAQPDTLESQTKLIDSCRK 120
QY 121 QAFQGAVQKELQHTVGSQHIAEKAMVDSWLDAKRSKLEAQPAFHATINTADIPSSH 180
Db 121 QAFQGAVQKELQHTVGSQHIAEKAMVDSWLDAKRSKLEAQPAFHATINTADIPSSH 180
QY 181 KVSLSSWHDRGWAKISNTTFSNGKLINQDGFLYLYANICFRHETSGDATEYLQMV 240
Db 181 KVSLSSWHDRGWAKISNTTFSNGKLINQDGFLYLYANICFRHETSGDATEYLQMV 240
QY 241 YVKTSIKPSSHILMKGSSTKWSGNBRHFYSINVGGPKURSGEETIEVSNSPLSD 300
Db 241 YVKTSIKPSSHILMKGSSTKWSGNBRHFYSINVGGPKURSGEETIEVSNSPLSD 300
QY 301 PDQDATYFGAKVRDID 317
Db 301 PDQDATYFGAKVRDID 317
RESULT 4
US-09-865-363-13
; Sequence 13, Application US/09865363
; Publication No. US20020086826A1
; GENERAL INFORMATION:
; APPLICANT: Anderson, Dirk M.
; Galibert, Laurent
; Marakovsky, Eugene
TITLE OF INVENTION: Ligand for Receptor Activator of NF-kappaB
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
; ADDRESSEE: Immunex Corporation, Law Department
; STREET: 51 University Street
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
ZIP: 98101
COMPUTER READABLE FORM:

Copyright (c) 1993 - 2005 Compugen Ltd.

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: December 21, 2005, 13:03:52 ; Search time 9.87377 Seconds
(without alignments)

228.978 Million cell updates/sec

Title: US-09-211-297-39

Perfect score: 1685

Sequence: 1 MRRASRDYTKYLRGSEEMGG.....LLDPDQDATYFGAKVARDID 317

Scoring table: BLOSUM62

Gappen 10.0 , Gapext 0.5

Searched: 53982 seqs, 7132107 residues

Total number of hits satisfying chosen parameters: 53982

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

```

1: /cggn2_6/ptodata/2/pubpa/us09_NEW_PUB.PEP:*
2: /cggn2_6/ptodata/2/pubpa/us06_NEW_PUB.PEP:*
3: /cggn2_6/ptodata/2/pubpa/us07_NEW_PUB.PEP:*
4: /cggn2_6/ptodata/2/pubpa/us08_NEW_PUB.PEP:*
5: /cggn2_6/ptodata/2/pubpa/us09_NEW_PUB.PEP:*
6: /cggn2_6/ptodata/2/pubpa/us10_NEW_PUB.PEP:*
7: /cggn2_6/ptodata/2/pubpa/us11_NEW_PUB.PEP:*
8: /cggn2_6/ptodata/2/pubpa/us60_NEW_PUB.PEP:*

```

Pred. No. is the number of results by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description			
1	538	31.9	109	7 US-11-065-669-8			
2	251.5	14.9	281	6 US-10-821-234-1288			
3	247.5	14.7	281	7 US-11-077-272-2			
4	235.5	14.0	266	7 US-11-082-544-10			
5	232.5	13.8	391	7 US-11-105-172-4			
6	147.5	8.8	359	7 US-11-105-172-2			
7	134	8.0	240	6 US-11-987-663-5			
8	9	7.9	157	7 US-11-010-954-1			
9	133	7.9	157	7 US-11-053-750-1			
10	133	7.9	157	7 US-11-053-749-1			
11	133	7.9	157	7 US-11-108-001-12			
12	133	7.9	158	7 US-11-082-544-4			
13	133	7.9	164	7 US-11-108-001-2			
14	133	7.9	180	7 US-11-082-544-8			
15	99.5	5.9	438	6 US-10-821-234-051			
16	97.5	5.8	1464	7 US-11-186-284-28			
17	97	5.8	1464	7 US-11-000-463-243			
18	97	5.8	1467	6 US-10-821-334-096			
19	96.5	5.7	6	US-10-995-561-572			
20	92.5	5.5	177	6 US-10-999-866-61			
21	92.5	5.5	205	6 US-10-995-561-028			
22	92.5	5.5	205	6 US-10-995-561-029			
23	90	5.3	432	7 US-11-140-417-4			
24	89	5.3	438	7 US-11-140-417-2			
25	88.5	5.3	1163	7 US-11-044-899-30			
26	88.5	5.3	220	7 US-11-054-515-3233			
27	87.5	5.2	32	7 US-11-054-515-3332			
28	86.5	5.1	33	81	4.8	484	6 US-10-821-234-933
29	86.5	5.1	34	79.5	4.7	903	7 US-11-057-058-65
30	86.5	5.1	35	79	4.7	1001	6 US-10-467-962B-81
31	85	5.0	36	79	4.7	453	6 US-10-131-826A-70
32	81.5	4.8	37	79	4.7	457	6 US-10-821-234-188
33	81	4.8	38	78.5	4.7	400	7 US-11-186-884-155
34	79.5	4.7	39	77.5	4.6	290	7 US-11-054-515-3331
35	79	4.7	40	77	4.6	200	6 US-10-524-198-2
36	77	4.6	41	77	4.6	285	6 US-10-131-826A-24
37	77	4.6	42	77	4.6	285	6 US-10-742-634-2
38	77	4.6	43	77	4.6	285	7 US-11-056-669-1
39	77	4.6	44	77	4.6	285	7 US-11-054-515-3238
40	77	4.6	45	76.5	4.5	219	7 US-11-054-515-3237

ALIGNMENTS

RESULT 1
US-11-065-669-8
; Sequence 8, Application US/11065669
; Publication No. US2005024411A1
; GENERAL INFORMATION:
; APPLICANT: Kalleb, Susan
; TITLE OF INVENTION: BARR, INHIBITORS THEREOF AND THEIR USE IN THE MODULATION OF B-CELL RESPONSE
; FILE REFERENCE: 052201-0024-04000
; CURRENT APPLICATION NUMBER: US/11/065,669
; CURRENT FILING DATE: 2005-02-24
; PRIORITY APPLICATION NUMBER: 10/045,574
; PRIORITY FILING DATE: 2001-11-07
; PRIORITY APPLICATION NUMBER: 09/911,777
; PRIORITY FILING DATE: 2001-07-24
; PRIORITY APPLICATION NUMBER: 60/1143,228
; PRIORITY FILING DATE: 2000-01-25
; PRIORITY APPLICATION NUMBER: 60/117,169
; PRIORITY FILING DATE: 1999-01-25
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 8
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-065-669-8
Query Match Score 538; DB 7; Length 109;
Best Local Similarity 31.9%; Pred. No. 5_9e-44; Mismatches 0; Indels 34; Gaps 2;
Matches 108; Conservative 1; InDel 1; Sequence 1, Appli
Sequence 2, Appli
Sequence 3, Appli
Sequence 4, Appli
Sequence 5, Appli
Sequence 6, Appli
Sequence 7, Appli
Sequence 8, Appli
Sequence 9, Appli
Sequence 10, Appli
Sequence 11, Appli
Sequence 12, Appli
Sequence 13, Appli
Sequence 14, Appli
Sequence 15, Appli
Sequence 16, Appli
Sequence 17, Appli
Sequence 18, Appli
Sequence 19, Appli
Sequence 20, Appli
Sequence 21, Appli
Sequence 22, Appli
Sequence 23, Appli
Sequence 24, Appli
Sequence 25, Appli
Sequence 26, Appli
Sequence 27, Appli
Sequence 28, Appli
Sequence 29, Appli
Sequence 30, Appli
Sequence 31, Appli
Sequence 32, Appli
Sequence 33, Appli
Sequence 34, Appli
Sequence 35, Appli
Sequence 36, Appli
Sequence 37, Appli
Sequence 38, Appli
Sequence 39, Appli
Sequence 40, Appli
Sequence 41, Appli
Sequence 42, Appli
Sequence 43, Appli
Sequence 44, Appli
Sequence 45, Appli
Sequence 46, Appli
Sequence 47, Appli
Sequence 48, Appli
Sequence 49, Appli
Sequence 50, Appli
Sequence 51, Appli
Sequence 52, Appli
Sequence 53, Appli
Sequence 54, Appli
Sequence 55, Appli
Sequence 56, Appli
Sequence 57, Appli
Sequence 58, Appli
Sequence 59, Appli
Sequence 60, Appli
Sequence 61, Appli
Sequence 62, Appli
Sequence 63, Appli
Sequence 64, Appli
Sequence 65, Appli
Sequence 66, Appli
Sequence 67, Appli
Sequence 68, Appli
Sequence 69, Appli
Sequence 70, Appli
Sequence 71, Appli
Sequence 72, Appli
Sequence 73, Appli
Sequence 74, Appli
Sequence 75, Appli
Sequence 76, Appli
Sequence 77, Appli
Sequence 78, Appli
Sequence 79, Appli
Sequence 80, Appli
Sequence 81, Appli
Sequence 82, Appli
Sequence 83, Appli
Sequence 84, Appli
Sequence 85, Appli
Sequence 86, Appli
Sequence 87, Appli
Sequence 88, Appli
Sequence 89, Appli
Sequence 90, Appli
Sequence 91, Appli
Sequence 92, Appli
Sequence 93, Appli
Sequence 94, Appli
Sequence 95, Appli
Sequence 96, Appli
Sequence 97, Appli
Sequence 98, Appli
Sequence 99, Appli
Sequence 100, Appli
Sequence 101, Appli
Sequence 102, Appli
Sequence 103, Appli
Sequence 104, Appli
Sequence 105, Appli
Sequence 106, Appli
Sequence 107, Appli
Sequence 108, Appli
Sequence 109, Appli
Sequence 110, Appli
Sequence 111, Appli
Sequence 112, Appli
Sequence 113, Appli
Sequence 114, Appli
Sequence 115, Appli
Sequence 116, Appli
Sequence 117, Appli
Sequence 118, Appli
Sequence 119, Appli
Sequence 120, Appli
Sequence 121, Appli
Sequence 122, Appli
Sequence 123, Appli
Sequence 124, Appli
Sequence 125, Appli
Sequence 126, Appli
Sequence 127, Appli
Sequence 128, Appli
Sequence 129, Appli
Sequence 130, Appli
Sequence 131, Appli
Sequence 132, Appli
Sequence 133, Appli
Sequence 134, Appli
Sequence 135, Appli
Sequence 136, Appli
Sequence 137, Appli
Sequence 138, Appli
Sequence 139, Appli
Sequence 140, Appli
Sequence 141, Appli
Sequence 142, Appli
Sequence 143, Appli
Sequence 144, Appli
Sequence 145, Appli
Sequence 146, Appli
Sequence 147, Appli
Sequence 148, Appli
Sequence 149, Appli
Sequence 150, Appli
Sequence 151, Appli
Sequence 152, Appli
Sequence 153, Appli
Sequence 154, Appli
Sequence 155, Appli
Sequence 156, Appli
Sequence 157, Appli
Sequence 158, Appli
Sequence 159, Appli
Sequence 160, Appli
Sequence 161, Appli
Sequence 162, Appli
Sequence 163, Appli
Sequence 164, Appli
Sequence 165, Appli
Sequence 166, Appli
Sequence 167, Appli
Sequence 168, Appli
Sequence 169, Appli
Sequence 170, Appli
Sequence 171, Appli
Sequence 172, Appli
Sequence 173, Appli
Sequence 174, Appli
Sequence 175, Appli
Sequence 176, Appli
Sequence 177, Appli
Sequence 178, Appli
Sequence 179, Appli
Sequence 180, Appli
Sequence 181, Appli
Sequence 182, Appli
Sequence 183, Appli
Sequence 184, Appli
Sequence 185, Appli
Sequence 186, Appli
Sequence 187, Appli
Sequence 188, Appli
Sequence 189, Appli
Sequence 190, Appli
Sequence 191, Appli
Sequence 192, Appli
Sequence 193, Appli
Sequence 194, Appli
Sequence 195, Appli
Sequence 196, Appli
Sequence 197, Appli
Sequence 198, Appli
Sequence 199, Appli
Sequence 200, Appli
Sequence 201, Appli
Sequence 202, Appli
Sequence 203, Appli
Sequence 204, Appli
Sequence 205, Appli
Sequence 206, Appli
Sequence 207, Appli
Sequence 208, Appli
Sequence 209, Appli
Sequence 210, Appli
Sequence 211, Appli
Sequence 212, Appli
Sequence 213, Appli
Sequence 214, Appli
Sequence 215, Appli
Sequence 216, Appli
Sequence 217, Appli
Sequence 218, Appli
Sequence 219, Appli
Sequence 220, Appli
Sequence 221, Appli
Sequence 222, Appli
Sequence 223, Appli
Sequence 224, Appli
Sequence 225, Appli
Sequence 226, Appli
Sequence 227, Appli
Sequence 228, Appli
Sequence 229, Appli
Sequence 230, Appli
Sequence 231, Appli
Sequence 232, Appli
Sequence 233, Appli
Sequence 234, Appli
Sequence 235, Appli
Sequence 236, Appli
Sequence 237, Appli
Sequence 238, Appli
Sequence 239, Appli
Sequence 240, Appli
Sequence 241, Appli
Sequence 242, Appli
Sequence 243, Appli
Sequence 244, Appli
Sequence 245, Appli
Sequence 246, Appli
Sequence 247, Appli
Sequence 248, Appli
Sequence 249, Appli
Sequence 250, Appli
Sequence 251, Appli
Sequence 252, Appli
Sequence 253, Appli
Sequence 254, Appli
Sequence 255, Appli
Sequence 256, Appli
Sequence 257, Appli
Sequence 258, Appli
Sequence 259, Appli
Sequence 260, Appli
Sequence 261, Appli
Sequence 262, Appli
Sequence 263, Appli
Sequence 264, Appli
Sequence 265, Appli
Sequence 266, Appli
Sequence 267, Appli
Sequence 268, Appli
Sequence 269, Appli
Sequence 270, Appli
Sequence 271, Appli
Sequence 272, Appli
Sequence 273, Appli
Sequence 274, Appli
Sequence 275, Appli
Sequence 276, Appli
Sequence 277, Appli
Sequence 278, Appli
Sequence 279, Appli
Sequence 280, Appli
Sequence 281, Appli
Sequence 282, Appli
Sequence 283, Appli
Sequence 284, Appli
Sequence 285, Appli
Sequence 286, Appli
Sequence 287, Appli
Sequence 288, Appli
Sequence 289, Appli
Sequence 290, Appli
Sequence 291, Appli
Sequence 292, Appli
Sequence 293, Appli
Sequence 294, Appli
Sequence 295, Appli
Sequence 296, Appli
Sequence 297, Appli
Sequence 298, Appli
Sequence 299, Appli
Sequence 300, Appli
Sequence 301, Appli
Sequence 302, Appli
Sequence 303, Appli
Sequence 304, Appli
Sequence 305, Appli
Sequence 306, Appli
Sequence 307, Appli
Sequence 308, Appli
Sequence 309, Appli
Sequence 310, Appli
Sequence 311, Appli
Sequence 312, Appli
Sequence 313, Appli
Sequence 314, Appli
Sequence 315, Appli
Sequence 316, Appli
Sequence 317, Appli
Sequence 318, Appli
Sequence 319, Appli
Sequence 320, Appli
Sequence 321, Appli
Sequence 322, Appli
Sequence 323, Appli
Sequence 324, Appli
Sequence 325, Appli
Sequence 326, Appli
Sequence 327, Appli
Sequence 328, Appli
Sequence 329, Appli
Sequence 330, Appli
Sequence 331, Appli
Sequence 332, Appli
Sequence 333, Appli
Sequence 334, Appli
Sequence 335, Appli
Sequence 336, Appli
Sequence 337, Appli
Sequence 338, Appli
Sequence 339, Appli
Sequence 340, Appli
Sequence 341, Appli
Sequence 342, Appli
Sequence 343, Appli
Sequence 344, Appli
Sequence 345, Appli
Sequence 346, Appli
Sequence 347, Appli
Sequence 348, Appli
Sequence 349, Appli
Sequence 350, Appli
Sequence 351, Appli
Sequence 352, Appli
Sequence 353, Appli
Sequence 354, Appli
Sequence 355, Appli
Sequence 356, Appli
Sequence 357, Appli
Sequence 358, Appli
Sequence 359, Appli
Sequence 360, Appli
Sequence 361, Appli
Sequence 362, Appli
Sequence 363, Appli
Sequence 364, Appli
Sequence 365, Appli
Sequence 366, Appli
Sequence 367, Appli
Sequence 368, Appli
Sequence 369, Appli
Sequence 370, Appli
Sequence 371, Appli
Sequence 372, Appli
Sequence 373, Appli
Sequence 374, Appli
Sequence 375, Appli
Sequence 376, Appli
Sequence 377, Appli
Sequence 378, Appli
Sequence 379, Appli
Sequence 380, Appli
Sequence 381, Appli
Sequence 382, Appli
Sequence 383, Appli
Sequence 384, Appli
Sequence 385, Appli
Sequence 386, Appli
Sequence 387, Appli
Sequence 388, Appli
Sequence 389, Appli
Sequence 390, Appli
Sequence 391, Appli
Sequence 392, Appli
Sequence 393, Appli
Sequence 394, Appli
Sequence 395, Appli
Sequence 396, Appli
Sequence 397, Appli
Sequence 398, Appli
Sequence 399, Appli
Sequence 400, Appli
Sequence 401, Appli
Sequence 402, Appli
Sequence 403, Appli
Sequence 404, Appli
Sequence 405, Appli
Sequence 406, Appli
Sequence 407, Appli
Sequence 408, Appli
Sequence 409, Appli
Sequence 410, Appli
Sequence 411, Appli
Sequence 412, Appli
Sequence 413, Appli
Sequence 414, Appli
Sequence 415, Appli
Sequence 416, Appli
Sequence 417, Appli
Sequence 418, Appli
Sequence 419, Appli
Sequence 420, Appli
Sequence 421, Appli
Sequence 422, Appli
Sequence 423, Appli
Sequence 424, Appli
Sequence 425, Appli
Sequence 426, Appli
Sequence 427, Appli
Sequence 428, Appli
Sequence 429, Appli
Sequence 430, Appli
Sequence 431, Appli
Sequence 432, Appli
Sequence 433, Appli
Sequence 434, Appli
Sequence 435, Appli
Sequence 436, Appli
Sequence 437, Appli
Sequence 438, Appli
Sequence 439, Appli
Sequence 440, Appli
Sequence 441, Appli
Sequence 442, Appli
Sequence 443, Appli
Sequence 444, Appli
Sequence 445, Appli
Sequence 446, Appli
Sequence 447, Appli
Sequence 448, Appli
Sequence 449, Appli
Sequence 450, Appli
Sequence 451, Appli
Sequence 452, Appli
Sequence 453, Appli
Sequence 454, Appli
Sequence 455, Appli
Sequence 456, Appli
Sequence 457, Appli
Sequence 458, Appli
Sequence 459, Appli
Sequence 460, Appli
Sequence 461, Appli
Sequence 462, Appli
Sequence 463, Appli
Sequence 464, Appli
Sequence 465, Appli
Sequence 466, Appli
Sequence 467, Appli
Sequence 468, Appli
Sequence 469, Appli
Sequence 470, Appli
Sequence 471, Appli
Sequence 472, Appli
Sequence 473, Appli
Sequence 474, Appli
Sequence 475, Appli
Sequence 476, Appli
Sequence 477, Appli
Sequence 478, Appli
Sequence 479, Appli
Sequence 480, Appli
Sequence 481, Appli
Sequence 482, Appli
Sequence 483, Appli
Sequence 484, Appli
Sequence 485, Appli
Sequence 486, Appli
Sequence 487, Appli
Sequence 488, Appli
Sequence 489, Appli
Sequence 490, Appli
Sequence 491, Appli
Sequence 492, Appli
Sequence 493, Appli
Sequence 494, Appli
Sequence 495, Appli
Sequence 496, Appli
Sequence 497, Appli
Sequence 498, Appli
Sequence 499, Appli
Sequence 500, Appli
Sequence 501, Appli
Sequence 502, Appli
Sequence 503, Appli
Sequence 504, Appli
Sequence 505, Appli
Sequence 506, Appli
Sequence 507, Appli
Sequence 508, Appli
Sequence 509, Appli
Sequence 510, Appli
Sequence 511, Appli
Sequence 512, Appli
Sequence 513, Appli
Sequence 514, Appli
Sequence 515, Appli
Sequence 516, Appli
Sequence 517, Appli
Sequence 518, Appli
Sequence 519, Appli
Sequence 520, Appli
Sequence 521, Appli
Sequence 522, Appli
Sequence 523, Appli
Sequence 524, Appli
Sequence 525, Appli
Sequence 526, Appli
Sequence 527, Appli
Sequence 528, Appli
Sequence 529, Appli
Sequence 530, Appli
Sequence 531, Appli
Sequence 532, Appli
Sequence 533, Appli
Sequence 534, Appli
Sequence 535, Appli
Sequence 536, Appli
Sequence 537, Appli
Sequence 538, Appli
Sequence 539, Appli
Sequence 540, Appli
Sequence 541, Appli
Sequence 542, Appli
Sequence 543, Appli
Sequence 544, Appli
Sequence 545, Appli
Sequence 546, Appli
Sequence 547, Appli
Sequence 548, Appli
Sequence 549, Appli
Sequence 550, Appli
Sequence 551, Appli
Sequence 552, Appli
Sequence 553, Appli
Sequence 554, Appli
Sequence 555, Appli
Sequence 556, Appli
Sequence 557, Appli
Sequence 558, Appli
Sequence 559, Appli
Sequence 560, Appli
Sequence 561, Appli
Sequence 562, Appli
Sequence 563, Appli
Sequence 564, Appli
Sequence 565, Appli
Sequence 566, Appli
Sequence 567, Appli
Sequence 568, Appli
Sequence 569, Appli
Sequence 570, Appli
Sequence 571, Appli
Sequence 572, Appli
Sequence 573, Appli
Sequence 574, Appli
Sequence 575, Appli
Sequence 576, Appli
Sequence 577, Appli
Sequence 578, Appli
Sequence 579, Appli
Sequence 580, Appli
Sequence 581, Appli
Sequence 582, Appli
Sequence 583, Appli
Sequence 584, Appli
Sequence 585, Appli
Sequence 586, Appli
Sequence 587, Appli
Sequence 588, Appli
Sequence 589, Appli
Sequence 590, Appli
Sequence 591, Appli
Sequence 592, Appli
Sequence 593, Appli
Sequence 594, Appli
Sequence 595, Appli
Sequence 596, Appli
Sequence 597, Appli
Sequence 598, Appli
Sequence 599, Appli
Sequence 600, Appli
Sequence 601, Appli
Sequence 602, Appli
Sequence 603, Appli
Sequence 604, Appli
Sequence 605, Appli
Sequence 606, Appli
Sequence 607, Appli
Sequence 608, Appli
Sequence 609, Appli
Sequence 610, Appli
Sequence 611, Appli
Sequence 612, Appli
Sequence 613, Appli
Sequence 614, Appli
Sequence 615, Appli
Sequence 616, Appli
Sequence 617, Appli
Sequence 618, Appli
Sequence 619, Appli
Sequence 620, Appli
Sequence 621, Appli
Sequence 622, Appli
Sequence 623, Appli
Sequence 624, Appli
Sequence 625, Appli
Sequence 626, Appli
Sequence 627, Appli
Sequence 628, Appli
Sequence 629, Appli
Sequence 630, Appli
Sequence 631, Appli
Sequence 632, Appli
Sequence 633, Appli
Sequence 634, Appli
Sequence 635, Appli
Sequence 636, Appli
Sequence 637, Appli
Sequence 638, Appli
Sequence 639, Appli
Sequence 640, Appli
Sequence 641, Appli
Sequence 642, Appli
Sequence 643, Appli
Sequence 644, Appli
Sequence 645, Appli
Sequence 646, Appli
Sequence 647, Appli
Sequence 648, Appli
Sequence 649, Appli
Sequence 650, Appli
Sequence 651, Appli
Sequence 652, Appli
Sequence 653, Appli
Sequence 654, Appli
Sequence 655, Appli
Sequence 656, Appli
Sequence 657, Appli
Sequence 658, Appli
Sequence 659, Appli
Sequence 660, Appli
Sequence 661, Appli
Sequence 662, Appli
Sequence 663, Appli
Sequence 664, Appli
Sequence 665, Appli
Sequence 666, Appli
Sequence 667, Appli
Sequence 668, Appli
Sequence 669, Appli
Sequence 670, Appli
Sequence 671, Appli
Sequence 672, Appli
Sequence 673, Appli
Sequence 674, Appli
Sequence 675, Appli
Sequence 676, Appli
Sequence 677, Appli
Sequence 678, Appli
Sequence 679, Appli
Sequence 680, Appli
Sequence 681, Appli
Sequence 682, Appli
Sequence 683, Appli
Sequence 684, Appli
Sequence 685, Appli
Sequence 686, Appli
Sequence 687, Appli
Sequence 688, Appli
Sequence 689, Appli
Sequence 690, Appli
Sequence 691, Appli
Sequence 692, Appli
Sequence 693, Appli
Sequence 694, Appli
Sequence 695, Appli
Sequence 696, Appli
Sequence 697, Appli
Sequence 698, Appli
Sequence 699, Appli
Sequence 700, Appli
Sequence 701, Appli
Sequence 702, Appli
Sequence 703, Appli
Sequence 704, Appli
Sequence 705, Appli
Sequence 706, Appli
Sequence 707, Appli
Sequence 708, Appli
Sequence 709, Appli
Sequence 710, Appli
Sequence 711, Appli
Sequence 712, Appli
Sequence 713, Appli
Sequence 714, Appli
Sequence 715, Appli
Sequence 716, Appli
Sequence 717, Appli
Sequence 718, Appli
Sequence 719, Appli
Sequence 720, Appli
Sequence 721, Appli
Sequence 722, Appli
Sequence 723, Appli
Sequence 724, Appli
Sequence 725, Appli
Sequence 726, Appli
Sequence 727, Appli
Sequence 728, Appli
Sequence 729, Appli
Sequence 730, Appli
Sequence 731, Appli
Sequence 732, Appli
Sequence 733, Appli
Sequence 734, Appli
Sequence 735, Appli
Sequence 736, Appli
Sequence 737, Appli
Sequence 738, Appli
Sequence 739, Appli
Sequence 740, Appli
Sequence 741, Appli
Sequence 742, Appli
Sequence 743, Appli
Sequence 744, Appli
Sequence 745, Appli
Sequence 746, Appli
Sequence 747, Appli
Sequence 748, Appli
Sequence 749, Appli
Sequence 750, Appli
Sequence 751, Appli
Sequence 752, Appli
Sequence 753, Appli
Sequence 754, Appli
Sequence 755, Appli
Sequence 756, Appli
Sequence 757, Appli
Sequence 758, Appli
Sequence 759, Appli
Sequence

Sequence 128, Application US/10821234-178
 Publication No. US20050255114A1
 GENERAL INFORMATION:
 APPLICANT: Labat, Ivan
 APPLICANT: Staciee-Crain, Birgit
 APPLICANT: Andarmani, Susan
 APPLICANT: Tang, Y. Tom
 TITLE OF INVENTION: Methods for Diagnosis and Treatment of Preeclampsia
 FILE REFERENCE: 821A
 CURRENT APPLICATION NUMBER: US/10/821,234
 CURRENT FILING DATE: 2004-04-07
 PRIORITY APPLICATION NUMBER: US 60/462,047
 PRIORITY FILING DATE: 2003-04-07
 NUMBER OF SEQ ID NOS: 1704
 SOFTWARE: pt_seq_genes Version 1.0
 SEQ ID NO 1286
 LENGTH: 281
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-10-821-234-1288

Query Match 14.9%; Score 251.5; DB 6; Length 281;
 Best Local Similarity 24.1%; Pred. No. 1.7e-16;
 Matches 71; Conservative 61; Mismatches 117; Indels 45; Gaps 10;

Db 42 PAASRSMVALIGLGQVCSVALFFYFRAQMD-PNRISEDGTCTYRLHENADEF 99
 Qy |:
 Db 10 PSLGQTCVLIVLIVTFLVLSLCVAVTYVFTNLKQDVKMPSHTLMKG 259
 Qy |:
 Db 100 QDTTLESODTKLIPDSRRRIKQAFQGAVQKELOHIVSQQHIAEKAMYDGSWLDLAKRSK 159
 Qy |:
 Db 62 -DSYWDPNDEESMNSPCQWKW-----OLRQLVRKMLRTSEETI----STVQEKO 107
 Qy |:
 Db 160 LERQPF-----AHLT-----INATDIPSGSHKUSL---SSWYHDR-GWAKISNM 199
 Qy |:
 Db 108 QNISPLVRERGPQRVAAMITGTRGRSNTLSENNSKNEALGRKINNSMMESSRSGHFSLSNL 167
 Qy |:
 Db 200 TFSNGKLUVNQDGFFYLYANICFRHETSGDLATEYLQMVVYVTKSITKRSHTLMKG 259
 Qy |||:
 Db 168 HLRLNGELVVIHEKGFFYLYISQTFRFQEEIKENTKDKNQVQTYKTT-SYPPDILLMSA 226
 Qy 260 STRKWWSENFHRYSYINGGGFKLRSGEBEISLEVSNSLDDPDQDATYFGAKVY 313
 Qy |:
 Db 227 RNSCWSKDAEYGLSYIYQGGIFELKENDRIFVSVTNHLIDMHEASFPGAFLV 280
 Qy |:
 RESULT 3
 US-11-077-272-2
 Sequence 2, Application US/11077272
 Publication No. US20050244927A1
 GENERAL INFORMATION:
 APPLICANT: LEONG, WOON-LAM, SUSAN
 APPLICANT: SWARTZ, JAMES R.
 TITLE OF INVENTION: PROCESSES FOR PRODUCING POLYPEPTIDES
 FILE REFERENCE: P2019R1
 CURRENT APPLICATION NUMBER: US/11/077,272
 CURRENT FILING DATE: 2005-03-10
 PRIORITY APPLICATION NUMBER: US 60/552,678
 PRIORITY FILING DATE: 2004-03-11
 NUMBER OF SEQ ID NOS: 7
 SEQ ID NO 2
 LENGTH: 281
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-11-077-272-2

Query Match 14.0%; Score 235.5; DB 7; Length 266;
 Best Local Similarity 25.3%; Pred. No. 5e-15;
 Matches 65; Conservative 51; Mismatches 98; Indels 43; Gaps 9;

Db 77 NRISEODTHCIVYRLHENADEFQDTTLESODTKLIPDSRRRIKQAFQGAVQKELOHIV 136
 Qy |:
 Db 32 DYSKSGSIACF----LKED----DSYWDPNDEESMNSPCQWKW-----OLRQLVR 74
 Qy |:
 Db 137 SQRHRAEKAMYDGSWLDLAKRSKLEAQOPF-----AHLT-----INATDIPSGSHK 181
 Qy |:
 Db 75 KMILRTSEETI----STVQEKKQNTSPLVRERGPQRVAAMITGTRGRSNTLSSPKNE 129
 Qy |:
 Db 182 VSL---SSWYHDR-GWAKISNMTEFSNGKLINQDGFFYLYANICFRHETSGDLATEYL 236
 Qy |:
 Db 130 KALGRKINSWESESSRSGHFSLSNLHLRNGELVVIHEKGFFYLYISQTFRFQEEIKENTKD 189
 Qy 237 QLMVVYVTKSITKPSHSSTLMKGKSTKWHSGNSBFHYSINVGFFKLRSGEESIEVSNP 296
 Qy |:
 Db 190 QMVOVYVYKTT-SYPPDILLMSA-RNSCWSKDAEYGLSYIYQGGIFELKENDRIFVSVT 248
 Qy 297 SLIDPDQDATYFGAKVY 313
 Db 249 HILDMHEASFPGAFLV 265

RESULT 4
 US-11-082-544-10
 Sequence 10, Application US/11082544
 Publication No. US20050249706A1
 GENERAL INFORMATION:
 APPLICANT: Bermudez, G.
 APPLICANT: King, I.
 APPLICANT: Clairmont, C.
 APPLICANT: Lin, S.
 APPLICANT: Belcourt, M.
 TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR EFFECTOR MOLECULES
 FILE REFERENCE: 8002-059
 CURRENT APPLICATION NUMBER: US/11/082,544
 CURRENT FILING DATE: 2005-03-17
 PRIORITY APPLICATION NUMBER: US/09/645,415
 PRIORITY FILING DATE: 2000-08-24
 PRIORITY APPLICATION NUMBER: 60/157,581
 PRIORITY FILING DATE: 1998-10-04
 PRIORITY APPLICATION NUMBER: 60/157,637
 PRIORITY FILING DATE: 1998-10-04
 NUMBER OF SEQ ID NOS: 61
 SOFTWARE: FastSEQ for Windows Version 3.0
 SEQ ID NO 10
 LENGTH: 266
 TYPE: PRT
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Fusion construct
 US-11-082-544-10

Query Match 14.0%; Score 235.5; DB 7; Length 266;
 Best Local Similarity 25.3%; Pred. No. 5e-15;
 Matches 65; Conservative 51; Mismatches 98; Indels 43; Gaps 9;

Db 77 NRISEODTHCIVYRLHENADEFQDTTLESODTKLIPDSRRRIKQAFQGAVQKELOHIV 136
 Qy |:
 Db 32 DYSKSGSIACF----LKED----DSYWDPNDEESMNSPCQWKW-----OLRQLVR 74
 Qy |:
 Db 137 SQRHRAEKAMYDGSWLDLAKRSKLEAQOPF-----AHLT-----INATDIPSGSHK 181
 Qy |:
 Db 75 KMILRTSEETI----STVQEKKQNTSPLVRERGPQRVAAMITGTRGRSNTLSSPKNE 129
 Qy |:
 Db 182 VSL---SSWYHDR-GWAKISNMTEFSNGKLINQDGFFYLYANICFRHETSGDLATEYL 236
 Qy |:
 Db 130 KALGRKINSWESESSRSGHFSLSNLHLRNGELVVIHEKGFFYLYISQTFRFQEEIKENTKD 189
 Qy 237 QLMVVYVTKSITKPSHSSTLMKGKSTKWHSGNSBFHYSINVGFFKLRSGEESIEVSNP 296
 Qy |:
 Db 190 QMVOVYVYKTT-SYPPDILLMSA-RNSCWSKDAEYGLSYIYQGGIFELKENDRIFVSVT 248
 Qy 297 SLIDPDQDATYFGAKVY 313
 Db 249 HILDMHEASFPGAFLV 265

us-09-211-297-39_copy_69_317.rag

GenCore version 5.1.6
 Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:34:10 ; Search time 169.402 Seconds
 (without alignments)

US-09-211-297-39_COPY_69_317

Perfect score: 1319

Sequence: 1 YFRAQMMPNRISBDGTHCIV.....LLDPDQDATYFGAKVYRVID 249

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
 Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq_21:*

1: geneseqP1990s:*

2: geneseqP1990s:*

3: geneseqP2000s:*

4: geneseqP2001s:*

5: geneseqP2002s:*

6: geneseqP2003s:*

7: geneseqP2003bs:*

8: geneseqP2004s:*

9: geneseqP2005s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Query Score Match Length DB ID Description

No. Score Match Length DB ID Description

1	1319	100.0	249	5	ABG94282	Abg94282 Human RAN
2	1319	100.0	249	5	ABG0594	Abg80594 Human rec
3	1319	100.0	249	7	ADJ2115	Adj82115 Protein f
4	1319	100.0	250	6	ADA50079	Ada50079 Human wil
5	1319	100.0	270	7	ADJ2113	Adj82113 Protein f
6	1319	100.0	317	2	AAW83108	AAw83108 Osteoclas
7	1319	100.0	317	2	AAW83195	AAw83195 Human ost
8	1319	100.0	317	2	AAW8957	AAw8957 NF-kB rec
9	1319	100.0	317	2	AAW8293	AAw8293 NF-kB rec
10	1319	100.0	317	2	AABE8738	Aae08738 Human rec
11	1319	100.0	317	3	AAV84417	Aav84417 Amino aci
12	1319	100.0	317	4	AABE04426	Aae04426 Human rec
13	1319	100.0	317	4	AABE01993	Aae01993 Human ful
14	1319	100.0	317	5	ABB0134	Abb0134 Human RAN
15	1319	100.0	317	5	AABE6103	Aae6103 Human RAN
16	1319	100.0	317	5	ABG31631	Abg31631 Human RAN
17	1319	100.0	317	5	AAUH8285	Aauh8285 Human RAN
18	1319	100.0	317	5	AAUO19096	Aauo19096 C neof
19	1319	100.0	317	5	ADR2336	Adr2335 Human RAN
20	1319	100.0	317	6	ABP55108	Abp55108 Human ost
21	1319	100.0	317	6	AABE34364	Aae34364 Human rec
22	1319	100.0	317	6	ABR42314	Abr42314 Human RAN
23	1319	100.0	317	7	ADB16988	Adb16988 Human rec
24	1319	100.0	317	7	ADC35204	Adc35204 Human TNF

ALIGNMENTS

25	1319	100.0	317	7	ADCT73002	Adc73002 Human RAN
26	1319	100.0	317	7	ADCT8268	Adc8268 Human RAN
27	1319	100.0	317	7	ABW0277	Abw0277 Human RAN
28	1319	100.0	317	7	ADG46723	Adg46723 Human RAN
29	1319	100.0	317	7	ADJ82112	Adj82112 Protein F
30	1319	100.0	317	8	ADM96241	Adm96241 Human rec
31	1319	100.0	317	8	ADZ12661	Adz12661 Human can
32	1319	100.0	317	8	ADU08155	Adu08155 Human RAN
33	1319	100.0	317	9	ADU05570	Adu05570 Novel bro
34	1319	100.0	317	9	ADW05029	Adw05029 Human rec
35	1319	100.0	317	9	ADY16469	Ady16469 PRO polyp
36	1319	100.0	317	9	ADY7714	Ady7714 Human rec
37	1319	100.0	317	9	ADY97756	Ady97756 Human RAN
38	1316	99.8	250	6	ADA50095	Ada50095 Human RAN
39	1316	99.8	250	6	ADA50094	Ada50094 Human RAN
40	1316	99.8	250	6	ADA50102	Ada50102 Human RAN
41	1316	99.8	250	6	ADA50098	Ada50098 Human RAN
42	1315	99.7	250	6	ADA50101	Ada50101 Human RAN
43	1315	99.7	250	6	ADA50089	Ada50089 Human RAN
44	1315	99.7	250	6	ADA50086	Ada50086 Human RAN
45	1315	99.7	250	6	ADA50099	Ada50099 Human RAN

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

This invention relates to a novel ordered and repetitive antigen array used in the production of vaccines for infectious diseases. The invention also discloses a composition comprising a non-natural molecular scaffold comprising a core particle selected from a core particle of a non-natural origin and a core particle of natural origin and an organiser comprising at least one first attachment site, where the organiser is connected to the core particle by at least one covalent bond. Also disclosed is an antigen or antigenic determinant with at least one second attachment point.

site, where the antigen or antigenic determinant is amyloid beta peptide (Abeta1-42) or its fragment and where the second attachment site is selected from an attachment site not naturally occurring with the antigen or antigenic determinant and an attachment site naturally occurring with the antigen or antigenic determinant, where the second attachment site is capable of association through at least one non-peptide bond to the first attachment site and where the antigen or antigenic determinant and the scaffold interact through the association to form an ordered and repetitive antigen array. The invention also comprises a coat protein capable of forming a capsid which comprises mutant Obeta coat proteins having an amino acid sequence selected from five amino acid sequences fully defined in the specification. The compounds of the invention may have antimicrobial, antiallergic, immunomodulatory, cyrostatic, antiviral, antidiabetic, or hypoglycaemic activities and may be used in immunation and as a vaccine. The present sequence represents a protein sequence used to create the compositions of the invention

Sequence 249 AA;

Query Match 100.0%; Score 1319; DB 5; Length 249;
Best Local Similarity 100.0%; Pred. No. 9.4e-129; Matches 249; Conservative 0; Mismatches 0; Indels 0; Gaps 0; XX

QY 1 YFRAQMDPNRISEDGTHCIVRLRHENADQDTTLESQDPTKLIPSCRRKQAFQAVQ 60
Db 1 YFRAQMDPNRISEDGTHCIVRLRHENADQDTTLESQDPTKLIPSCRRKQAFQAVQ 60
CC 61 KELQHIVGSQHRAKEAMVDSWLDLAKRSKLEQPAFHLTINATDIPSSGHKVLSWWI 120
CC 61 KELQHIVGSQHRAKEAMVDSWLDLAKRSKLEQPAFHLTINATDIPSSGHKVLSWWI 120
Db 121 HDRGWAKISNMTPSNGLKLIVNQDGFFYLYANICFRRHETSGDLATEYLQLMVVTTSIK 180
QY 121 HDRGWAKISNMTPSNGLKLIVNQDGFFYLYANICFRRHETSGDLATEYLQLMVVTTSIK 180
Db 181 IPSHTTMKGSTTKYNGNSNPFHFSINVGCFPKURSEEEISIEVSNPSLIDPDDATYF 240
QY 181 IPSHTTMKGSTTKYNGNSNPFHFSINVGCFPKURSEEEISIEVSNPSLIDPDDATYF 240
Db 241 GAFKVRDID 249
QY 241 GAFKVRDID 249
Db 241 GAFKVRDID 249

SQ

Sequence 249 AA;

Query Match 100.0%; Score 1319; DB 5; Length 249;
Best Local Similarity 100.0%; Pred. No. 9.4e-129; Matches 249; Conservative 0; Mismatches 0; Indels 0; Gaps 0; XX

QY 1 YFRAQMDPNRISEDGTHCIVRLRHENADQDTTLESQDPTKLIPSCRRKQAFQAVQ 60
Db 1 YFRAQMDPNRISEDGTHCIVRLRHENADQDTTLESQDPTKLIPSCRRKQAFQAVQ 60
CC 61 KELQHIVGSQHRAKEAMVDSWLDLAKRSKLEQPAFHLTINATDIPSSGHKVLSWWI 120
CC 61 KELQHIVGSQHRAKEAMVDSWLDLAKRSKLEQPAFHLTINATDIPSSGHKVLSWWI 120
Db 121 HDRGWAKISNMTPSNGLKLIVNQDGFFYLYANICFRRHETSGDLATEYLQLMVVTTSIK 180
QY 121 HDRGWAKISNMTPSNGLKLIVNQDGFFYLYANICFRRHETSGDLATEYLQLMVVTTSIK 180
Db 121 HDRGWAKISNMTPSNGLKLIVNQDGFFYLYANICFRRHETSGDLATEYLQLMVVTTSIK 180

XX 19-JAN-2001; 2001US-0262379P.
PR 04-MAY-2001; 2001US-0268549P.
PR 05-OCT-2001; 2001US-036698P.
PR 07-NOV-2001; 2001US-0331045P.
XX (CYTO-) CYTOS BIOTECHNOLOGY AG.
PA (NOVS) NOVARTIS PHARMA AG.
PA (MAUR/) MAURER P.
PA (LECH/) LECHNER F.
PA (ORTM/) ORTMANN R.
PA (LUEO/) LUEOEND R.
PA (STAU/) STAUFENBIEL M.
(FREY/) FREY P.
XX Maurer P, Lechner F, Ortmann R, Lusoend R, Staufenbiel M, Frey P;
PI Renner WA, Bachmann M, Tibbet A, Sebbel P, Piossek C;
XX DR WPI; 2002-636514/68.
XX PT Molecular antigen array used in the production of vaccines for infectious diseases.
XX PS Disclosure; Page 397; 418PP; English.
The invention relates to a composition comprising: (a) a non-natural molecular scaffold comprising: (i) a core particle selected from: (1) a core particle of a non-natural origin; and (2) a core particle of natural origin; and (ii) an organiser comprising at least one first attachment site, where the organiser is connected to the core particle by at least one covalent bond; (b) an antigen or antigenic determinant with at least one second attachment site, where the antigen or antigenic determinant is amyloid beta peptide (Abeta 1-42) or its fragment, and where the second attachment site is selected from: (i) an attachment site not naturally occurring with the antigen or antigenic determinant; and (ii) an attachment site naturally occurring with the antigen or antigenic determinant, where the second attachment site is capable of association through at least one non-peptide bond to the first attachment site; and where the antigen or antigenic determinant and the scaffold interact through the association to form an ordered and repetitive antigen array. Also included is a process for producing a non-naturally occurring ordered and repetitive antigen array. The composition is used in immunisation and as a vaccine for diseases such as influenza, graft versus host disease, IgE-mediated allergic reactions, anaphylaxis, adult respiratory distress syndrome (ARDS), Crohn's disease, allergic asthma, acute lymphoblastic leukemia, non-Hodgkin's lymphoma, Grave's disease, Systemic lupus erythematosus, inflammatory immune diseases, myasthenia gravis, immunoproliferative disease, lymphadenopathy, angioimmunoproliferative lymphadenopathy, immunoblastic lymphadenopathy, rheumatoid arthritis, diabetes, multiple sclerosis, Alzheimer's disease, osteoporosis and infectious diseases. The present sequence is an antigen for use in the array of the invention. The antigen is modified to possess a cleavage site (enterokinase or Factor Xa) and a Cysteine-containing N-terminal linker peptide which serves as the attachment point to a virus like particle or bacterial protein (the scaffold protein).

SQ

Sequence 249 AA;

Query Match 100.0%; Score 1319; DB 5; Length 249;
Best Local Similarity 100.0%; Pred. No. 9.4e-129; Matches 249; Conservative 0; Mismatches 0; Indels 0; Gaps 0; XX

QY 1 YFRAQMDPNRISEDGTHCIVRLRHENADQDTTLESQDPTKLIPSCRRKQAFQAVQ 60
Db 1 YFRAQMDPNRISEDGTHCIVRLRHENADQDTTLESQDPTKLIPSCRRKQAFQAVQ 60
CC 61 KELQHIVGSQHRAKEAMVDSWLDLAKRSKLEQPAFHLTINATDIPSSGHKVLSWWI 120
CC 61 KELQHIVGSQHRAKEAMVDSWLDLAKRSKLEQPAFHLTINATDIPSSGHKVLSWWI 120
Db 121 HDRGWAKISNMTPSNGLKLIVNQDGFFYLYANICFRRHETSGDLATEYLQLMVVTTSIK 180
QY 121 HDRGWAKISNMTPSNGLKLIVNQDGFFYLYANICFRRHETSGDLATEYLQLMVVTTSIK 180
Db 121 HDRGWAKISNMTPSNGLKLIVNQDGFFYLYANICFRRHETSGDLATEYLQLMVVTTSIK 180

RESULT 2
ABG80594 ABG80594 standard; protein; 249 AA.
ID ABG80594
AC ABG80594;
XX 29-NOV-2002 (first entry)
DE Human receptor activator of NFkB ligand, RANKL, extracellular part.
XX Molecular antigen array; vaccine; antigen; antimicrobial; molecular scaffold; amyloid beta; Abeta 1-42; influenza; graft versus host disease; IgG-mediated allergic reaction; anaphylaxis; adult respiratory distress syndrome; ARDS; Crohn's disease; allergic asthma; acute lymphocytic leukaemia; non-Hodgkin's lymphoma; Gravie's disease; IgA-mediated allergic reaction; anaphylaxis; systemic lupus erythematosus; osteoporosis; diabetes; multiple sclerosis; Alzheimer's disease; myasthenia gravis; immunoproliferative disease; lymphadenopathy; angioimmunoproliferative lymphadenopathy; immunoblastic lymphadenopathy; rheumatoid arthritis; Graves' disease; multiple sclerosis; Alzheimer's disease; IgG-mediated allergic reaction; anaphylaxis; systemic lupus erythematosus; osteoporosis; diabetes; infectious disease; factor Xa; enterokinase; cysteine-containing linker.
XX Homo sapiens.
XX WO200256907-A2.
XX 25-JUL-2002.
PP 21-JAN-2002; 2002WO-IB000168.

Query Match 11.9%; Score 157; DB 2; Length 279;
 Best Local Similarity 25.9%; Pred. No. 1.e-05;
 Matches 50; Conservative 38; Mismatches 81; Indels 24; Gaps 8;

QY 59 VOKELHII--VGSQHTRA---EKAMVUDGSMWDLAKRSKLEAQPF AHLTTNATDIPSGSHK 113
 CD40 ligand - human
 CD40 ligand - human
 C;Species: Homo sapiens (man)
 C;Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 09-Jul-2004
 C;Accession: S82017; JH0193; S26694; S28852; I53476; S25684; S10593
 R;Holoubek, D.; Grosman, L.S.; Kullas, C.D.; Chalupny, N.J.; Braesch-Andersen, S.;
 EMBO J. 11, 4313-4321, 1992
 A;Title: The human T cell antigen gp39, a member of the TNF gene family, is a ligand for
 A;Reference number: S28017; MUID:93049181; PMID:1385114
 A;Accession: S28017
 A;Molecule type: mRNA
 A;Cross-references: UNIPROT:P29965; UNIPARC:UPI00000315E7; EMBL:Z15017; NID:928483; PIDN:
 R;Spiggle, M.K.; Armitage, R.J.; Strockbine, L.; Clifford, K.N.; Macduff, B.M.; Sato, T.
 J. Exp. Med. 176, 1543-1550, 1992
 A;Title: Recombinant human Cd40 ligand stimulates B cell proliferation and immunoglobuli
 A;Reference number: JH0793; MUID:93094757; PMID:1281209
 A;Accession: JH0793
 A;Molecule type: mRNA
 A;Residues: 1-61 <RPT>
 A;Cross-references: UNIPARC:UPI00000315E7; GB:X67878; NID:938411; PIDN:CAA48077.1; PID:9
 A;Experimental source: peripheral blood T-cell
 R;Graf, D.; Korrhaeu, U.; Mages, H.W.; Seeger, G.; Krocze, R.A.
 Eur. J. Immunol. 22, 3191-3194, 1992
 A;Title: Cloning of TRAP, a ligand for CD40 on human T cells.
 A;Reference number: S26694; MUID:93076854; PMID:1280226
 A;Accession: S26694
 A;Molecule type: mRNA
 A;Status: preliminary
 A;Residues: 1-261 <RGA>
 A;Cross-references: UNIPARC:UPI00000315E7; EMBL:668550; NID:937269; PIDN:CAA48554.1; PID:
 R;Gachot, J.F.; Aubry, J.P.; Mazzei, G.; Lifé, P.; Jonette, T.; Elson, G.; Bonnefoy, J.
 FEBS Lett. 315, 259-266, 1993
 A;Title: Human CD40-ligand: molecular cloning, cellular distribution and regulation of e
 A;Reference number: S28852; MUID:93138085; PMID:7678552
 A;Accession: S28852
 A;Molecule type: mRNA
 A;Residues: 1-261 <GAU>
 A;Cross-references: UNIPARC:UPI00000315E7; EMBL:J07414; PIDN:9180123; PIDN:AAA35662.1; PI
 A;Note: the sequence from Fig. 3 is inconsistent with that from Fig. 2 in having 6-Gln
 C;Genetics: F;13-44/Domain: transmembrane #status predicted <TM>
 F;45-261/Domain: extracellular #status predicted <EXT>
 F;6-240/Binding site: carbohydrate (Asn) (covalent) #status predicted
 Db 25 LHENDAFFDT--TLESQDTKLIPDSCTRQLQAFQAVKELQHIVGSQHRAEKAMVIDS 82
 QY 114 VSL-S-SWYDROWAKISNMTFSNGKLVINQDGFYIYANICFRRHETSGDIAEVOLQMV 172
 154 DSIPLEDVTGTAALISGVKTKGGIUVNETGLYEVSKYFRGSCN---NQFLHKV 209
 173 YVTKTSKTPSHTLMKGSTKXWGNSEFFYSINVGGFTRLSGEELSTEVSNPSLLD 232
 210 YWRNS--KYPEDLVLMVEKRINCYT-TGQIWAHSSYLGAVENTSADHLVNIQLSLIN 266
 QY 233 PDDQDATYFGAFKV 245
 267 FBESKTFFFGLYKL 279

RESULT 3
 153476
 CD40 ligand - human
 N;Alternate names: glycoprotein 39; hCD40-L protein; T-cell antigen gp39; TRAP protein
 C;Species: Homo sapiens (man)
 C;Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 09-Jul-2004
 C;Accession: S82017; JH0193; S26694; S28852; I53476; S25684; S10593
 R;Holoubek, D.; Grosman, L.S.; Kullas, C.D.; Chalupny, N.J.; Braesch-Andersen, S.;
 EMBO J. 11, 4313-4321, 1992
 A;Title: The human T cell antigen gp39, a member of the TNF gene family, is a ligand for
 A;Reference number: S28017; MUID:93049181; PMID:1385114
 A;Accession: S28017
 A;Molecule type: mRNA
 A;Cross-references: UNIPROT:P29965; UNIPARC:UPI00000315E7; EMBL:Z15017; NID:928483; PIDN:
 R;Spiggle, M.K.; Armitage, R.J.; Strockbine, L.; Clifford, K.N.; Macduff, B.M.; Sato, T.
 J. Exp. Med. 176, 1543-1550, 1992
 A;Title: Recombinant human Cd40 ligand stimulates B cell proliferation and immunoglobuli
 A;Reference number: S28017; MUID:93094757; PMID:1281209
 A;Accession: JH0793
 A;Molecule type: mRNA
 A;Residues: 1-61 <RPT>
 A;Cross-references: UNIPARC:UPI00000315E7; GB:X67878; NID:938411; PIDN:CAA48077.1; PID:9
 A;Experimental source: peripheral blood T-cell
 R;Graf, D.; Korrhaeu, U.; Mages, H.W.; Seeger, G.; Krocze, R.A.
 Eur. J. Immunol. 22, 3191-3194, 1992
 A;Title: Cloning of TRAP, a ligand for CD40 on human T cells.
 A;Reference number: S26694; MUID:93076854; PMID:1280226
 A;Accession: S26694
 A;Molecule type: mRNA
 A;Status: preliminary
 A;Residues: 1-261 <RGA>
 A;Cross-references: UNIPARC:UPI00000315E7; EMBL:668550; NID:937269; PIDN:CAA48554.1; PID:
 R;Gachot, J.F.; Aubry, J.P.; Mazzei, G.; Lifé, P.; Jonette, T.; Elson, G.; Bonnefoy, J.
 FEBS Lett. 315, 259-266, 1993
 A;Title: Human CD40-ligand: molecular cloning, cellular distribution and regulation of e
 A;Reference number: S28852; MUID:93138085; PMID:7678552
 A;Accession: S28852
 A;Molecule type: mRNA
 A;Residues: 1-261 <GAU>
 A;Cross-references: UNIPARC:UPI00000315E7; EMBL:J07414; PIDN:9180123; PIDN:AAA35662.1; PI
 A;Note: the sequence from Fig. 3 is inconsistent with that from Fig. 2 in having 6-Gln
 C;Genetics: F;13-44/Domain: transmembrane #status predicted <TM>
 F;45-261/Domain: extracellular #status predicted <EXT>
 F;6-240/Binding site: carbohydrate (Asn) (covalent) #status predicted
 Db 59 LHEDPVFMKTIQRNTGERSLSILCEERIKSQFEGFV KDIM-----LNKEETKKENS 110
 105 IQLQKELABLREFPTNOSLKVFQKAMPS---TPSEKKEPERSVAHLTGQ-----PHS 153
 QY 83 WLDLAKRSKLEAOPFAHLTTNATDIPSGSHKVSSLSSWHDRGWAKISN-MTFENGK-LI 139
 114 VSL-S-SWYDROWAKISNMTFSNGKLVINQDGFYIYANICFRRHETSGDIAEVOLQMV 172
 154 DSIPLEDVTGTAALISGVKTKGGIUVNETGLYEVSKYFRGSCN---NQFLHKV 209
 173 YVTKTSKTPSHTLMKGSTKXWGNSEFFYSINVGGFTRLSGEELSTEVSNPSLLD 232
 210 YWRNS--KYPEDLVLMVEKRINCYT-TGQIWAHSSYLGAVENTSADHLVNIQLSLIN 266
 QY 233 PDDQDATYFGAFKV 245
 267 FBESKTFFFGLYKL 279

RESULT 4
 138707
 Fas ligand - human
 C;Species: Homo sapiens (man)
 C;Date: 29-May-1998 #sequence_revision 29-May-1998 #text_change 09-Jul-2004
 C;Accession: I38707; JC2340; S5565; I38554
 R;Takahashi, T.; Tanaka, M.; Inazawa, J.; Abe, T.; Suda, T.; Nagata, S.
 Int. Immunol. 6, 1567-1574, 1994
 A;Title: Human Fas ligand: gene structure, chromosomal location and species specificity.
 A;Reference number: I38707; MUID:95127560; PMID:7826947
 A;Accession: I38707
 A;Status: preliminary; translated from GB/EMBL/DDJB
 A;Molecule type: mRNA
 A;Residues: 1-281 <RES>
 A;Cross-references: UNIPROT:P48023; UNIPARC:UPI000000D91A; EMBL:U11821; NID:9595430; PIDN:
 R;Mita, E.; Hayashi, N.; Iio, S.; Takahara, T.; Hijikoka, T.; Kasahara, A.; Furamoto, H.;
 Biochem. Biophys. Res. Commun. 204, 468-474, 1994
 A;Title: Role of Fas ligand in apoptosis induced by hepatitis C virus infection.
 A;Reference number: JCC340; MUID:95071350; PMID:7980502
 A;Accession: JC2340
 A;Molecule type: DNA
 A;Cross-references: UNIPROT:P48023; UNIPARC:UPI000000D91A; GB:D38122; DDBJ:D29820; NID:9601892; PIDN:BAH
 R;Schatzlein, C.E.
 submitted to the EMBL data library, June 1995
 A;Reference number: S57565
 A;Accession: S57565
 A;Status: preliminary
 A;Molecule type: mRNA
 A;Residues: 1-281 <MIT>
 A;Cross-references: UNIPARC:UPI000000D91A; EMBL:X89102; NID:9887455; PID:9887456
 R;Alderson, M.R.; Tough, T.W.; Davis-Smith, T.; Braddy, S.; Falk, B.; Schooley, K.A.; Go
 J. Exp. Med. 181, 71-78, 1995
 A;Title: Fas ligand mediates activation-induced cell death in human T lymphocytes.
 A;Reference number: I38554; MUID:95105731; PMID:7528780
 A;Accession: I38554
 A;Status: preliminary; translated from GB/EMBL/DDJB
 A;Molecule type: mRNA
 A;Residues: 1-281 <RES>
 A;Cross-references: UNIPARC:UPI000000D91A; EMBL:U08137; NID:9624627; PIDN:AAC50071.1; PI
 C;Genetics: F;76, 184, 250, 260/Binding site: carbohydrate (Asn) (covalent) #status predicted
 A;Gene: fasL
 A;Introns: 151/1; 116/3
 C;Keywords: Glycoprotein; transmembrane protein
 C;Genetics: F;80-102/Domain: extracellular #status predicted <TM>
 F;6-240/Binding site: carbohydrate (Asn) (covalent) #status predicted
 Db 140 VNQDGFYIYANICFRRHETSGDIAEVOLQMVVTKISIKPS-SHMLMKGSTKWS 197
 163 VRQGYLYTVAQVFCNSREASSQP-----FIASLCKPSGRPERILRAANTH-S 213
 QY 198 GNSEFHFSYINVGGFTRLSGEELSTEVSNPSLLDPDDQDATYFGAFKV 245
 214 SAKPCGQSO5IHLGGVFELOPGASVFNWTDPSQVSHGCGFTSFGLKL 261

Query Match 11.4%; Score 150; DB 2; Length 261;
 Best Local Similarity 25.4%; Pred. No. 1.e-05;
 Matches 58; Conservative 43; Mismatches 32; Indels 12; Gaps 12;

Query Match 11.3%; Score 149.5; DB 2; Length 281;
 Best Local Similarity 23.9%; Pred. No. 1.e-05;
 Matches 47; Conservative 33; Mismatches 74; Indels 43; Gaps 6;

QY 76 HIRAKKAMVGDGSMWDLAKRSKLEAQ-----PFAHLT--INATDIPSGSHKV 114

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model

Run on: December 21, 2005, 12:35:06 ; Search time 171.443 Seconds
(without alignments)

1024.695 Million cell updates/sec

Title: US-09-211-297-39_COPY_69_317
Perfect score: 1319
Sequence: 1 YFRAQMDPNRISEDGTCHCYI.....LLDPDQDATYFGAKVURID 249

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528106 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database : UniProt 05.80:
1: uniprot_sprot:
2: uniprot_trembl:
*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description	
1	1319	100.0	317	TNFRSF11 HUMAN	
2	1319	100.0	317	2 Q5T9Y4_HUMAN	
3	1292	98.0	244	2 Q54J98_HUMAN	
4	1127	85.4	315	1 TNFL1_MOUSE	
5	1118	84.8	318	1 TNFL11_RAT	
6	482	36.5	2 Q5HZB8_XENLA	Q5HZB8 xenopus lae	
7	470	35.6	1 Q5XLR0_RABIT	Q5XLR0 oryctolagus cuniculus	
8	253.5	19.2	317	2 Q7ZKX9_BRARTE	Q7ZKX9 brachydanio
9	252.5	19.1	289	2 Q4VS86_PIG	Q4VS86 sus scrofa
10	242	18.3	304	2 Q7TRP2_CHICK	Q7TRP2 gallus gallus
11	241.5	18.3	303	2 Q5XKQ3_MOUSE	Q5XKQ3 mus musculus
12	240.5	18.2	2 Q9DD25_BRACK	Q9DD25 brachydanio	
13	239.5	18.2	2 Q5ZK93_CHICK	Q5ZK93 gallus gallus	
14	238.5	18.1	291	1 TNFL10_MOUSE	P50592 mus musculus
15	238	18.0	264	2 Q4S9Q4_TEETING	Q4S9Q4 tetradon n
16	237	18.0	299	2 Q6DKG9_RAT	Q6DKG9 brachydanio
17	236.5	17.9	281	1 TNFL10_HUMAN	P50591 homo sapien
18	236.5	17.9	281	2 Q6IBA9_HUMAN	Q6IBA9 homo sapien
19	16.6	300	2 Q5U675_HUMAN	Q5U675 homo sapien	
20	216.5	16.4	2 Q9WMT9_CHICK	Q9WMT9 homo sapien	
21	211	16.0	2 Q4SKU4_TEETING	Q4SKU4 tetradon n	
22	207.5	15.7	287	2 Q4SKG0_RAT	Q8K390 rattus norvegicus
23	184.5	14.0	252	2 Q8K3J8_MOUSE	Q8K3J8 mus musculus
24	181	13.7	95	2 Q6OWL1_HUMAN	Q6OWL1 homo sapien
25	181	13.7	95	2 Q6UY13_HUMAN	Q6UY13 homo sapien
26	179.5	13.6	252	2 Q8O1Z0_MOUSE	Q8O1Z0 mus musculus
27	177.5	13.5	252	2 Q8K3Y7_RAT	Q8K3Y7 rattus norvegicus
28	172.5	13.1	253	2 Q5CA00_CHICK	Q5CAG9 gallus gallus
29	171	13.0	278	2 Q4STKX_TEETING	Q4STKX tetradon n
30	162	12.3	239	2 Q5OL61_CHICK	Q5OL61 gallus gallus
31	160	12.1	207	2 Q58G74_CHICK	Q58G74 gallus gallus

ALIGNMENTS

32	160	12.1	279	2 Q7TMV9_MOUSE	Q7TMV9 mus musculus
33	158	12.0	98	2 Q4T6H7_TETTING	Q4T6H7 tetrodon n
34	157.5	11.9	282	1 TNFL6_PIG	Q8be8 sus scrofa
35	157	11.9	279	1 TNFL6_BOVIN	F51749 b tumor nec
36	157	11.9	279	1 TNFL6_MOUSE	P41047 mus musculus
37	157	11.9	279	2 Q54AE5_MOUSE	Q54AE9 mus musculus
38	156.5	11.9	192	2 Q5VJK8_HUMAN	Q5VJK8 homo sapiens
39	156.5	11.9	251	2 Q8NFEE9_HUMAN	Q8nfefg homo sapien
40	155	11.8	280	2 Q81W45_FELICA	Q81W45 felis silvestris
41	150	11.4	261	1 TNFL5_AOTTR	Q9bdm3 a tumor nec
42	150	11.4	261	1 TNFL5_CALJA	P29965 h tumor nec
43	150	11.4	261	1 TNFL5_MACFA	P63308 m tumor nec
44	149.5	11.3	280	1 TNFL6_MACMU	P63307 m tumor nec

RL Biochem. Biophys. Res. Commun. 269:532-536 (2000).
 RN [5]
 RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
 RC TISSUE=Lung;
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Klauber R.D., Fengold L.L., Grouse L.H., Derge J.G., Schuler G.D.,
 RA Brownstein M.J., Soares M.B., Bandallo M.F., Casavant T.L., Scheetz T.E.,
 RA Whiting M., Madan C., Shevchenko P., Prange C.,
 RA Blakely R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Villalon D.K., Muny D.M., Soedergren J., Lu X., Gibbs R.A.,
 RA Fahy J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
 RA Schnarch A., Schein J.E., Jones S.J.M., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
 RN [6]
 RP NUCLEOTIDE SEQUENCE OF 73-317.
 RC TISSUE=Thymocyte;
 RX MEDLINE=910112; PubMed=9312132; DOI=10.1074/jbc.272.40.25190;
 RA Kalachikov S., Cayani E., Bartlett F.S., III, Frankel W.N., Lee S.Y.,
 RA Choi Y.; Wong B.R., Rho J., Aron J., Robinton E., Orlinick J., Chao M.,
 RT that activates c-Jun N-terminal kinase in T cells.";
 RL J. Biol. Chem. 272:25190-25194 (1997).
 CC -I- FUNCTION: Cytokine that binds to TNFRSF1B/OPG and to
 TNFRSF1A/RANK. Osteoclast differentiation and activation factor.
 CC Augments the ability of dendritic cells to stimulate naive T-cell
 CC proliferation. May be an important regulator of interactions
 CC between T cells and dendritic cells and may play a role in the
 CC regulation of the T cell-dependent immune response. May also play
 CC an important role in enhanced bone-resorption in humoral
 CC hypercalcemia of malignancy.
 CC -I- SUBUNIT: Homotrimer (By similarity).
 CC -I- SUBCELLULAR LOCATION: Type II membrane protein (isoforms 1 and 3);
 CC Secreted (isoform 2). A soluble form of isoform 1 arises by
 CC proteolytic processing (By similarity).
 CC -I- ALTERNATIVE PRODUCTS:
 CC Event=Alternative splicing; Named isoforms=3;
 CC Name=1; IsoId=014788-1; Sequence=Displayed;
 CC Name=2; Synonyms=SDFD;
 CC IsoId=014788-2; Sequence=vSP_006447;
 CC Name=3;
 CC IsoId=014788-3; Sequence=vSP_006446;
 CC -I- TISSUE SPECIFICITY: Highest in the peripheral lymph nodes, weak in
 CC spleen, peripheral blood leukocytes, bone marrow, heart, placenta,
 CC skeletal muscle, stomach and thyroid.
 CC -I- INDUCTION: Up-regulated by T cell receptor stimulation.
 CC -I- PTM: The soluble form of isoform 1 derives from the membrane form
 CC by proteolytic processing (By similarity). The cleavage may be
 CC catalyzed by ADAM17.
 CC -I- SIMILARITY: Belongs to the tumor necrosis factor family.
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration
 CC between the European Bioinformatics Institute and the EMBL outstation -
 CC use as long as its content is in no way modified and this statement is not
 CC removed.

DR EMBL; AB061227; BAB7179.1; mRNA.
 DR EMBL; AB064270; BAB79635.1; mRNA.
 DR EMBL; AB037539; BAB90488.1; mRNA.
 DR EMBL; BC074823; AAH7823.1; mRNA.
 DR EMBL; AF0074890; AAC74830.1; mRNA.
 DR HSSP; O35225; 1JTZ.
 DR SMR; O14788; 162-317.
 DR Ensemble; ENSG00000120659; Homo sapiens.
 DR HGNC; HGNC:11926; TNFSF11.
 DR InterPro; IPRO06052; TNF Family.
 DR MIM; 602442; -.
 DR GO; GO:0005897; C-extracellular region; NAS.
 DR GO; GO:0005164; F:umor necrosis factor receptor binding; NAS.
 DR GO; GO:0006955; P:immune response; NAS.
 DR GO; GO:0030316; P:osteoclast differentiation; NAS.
 DR InterPro; IPRO03636; TNF subf.
 DR Pfam; PF00229; TNF_1.
 DR ProDom; PD02012; TNF_subf_1.
 DR SMART; SM0207; TNF_1.
 DR PROSITE; PS00251; TNF_1; FALSE_NEG.
 DR PROSITE; PS50049; TNF_2; 1.
 KW Alternative splicing; Cytokine; Developmental protein;
 KW Differentiation; Glycoprotein; Receptor; Signal-anchor; Transmembrane.
 FT CHAIN 1 317 Tumor necrosis factor ligand superfamily
 FT CHAIN 1 317 Tumor necrosis factor ligand superfamily
 FT TRANSMEM 48 68 Signal-anchor for type II membrane
 FT TOPO_DOM 69 317 Tumor necrosis factor ligand superfamily
 FT SITE_ 139 140 member 11, soluble form (By Similarity).
 FT CARBOHYD 171 171 Cytoplasmic (Potential).
 FT CARBOHYD 198 198 N-linked (GlcNAc. . .) (Potential).
 FT VARSPLIC 1 73 Missing (in Isoform 2). /FTid=VSP_006447.
 FT VARSPLIC 1 47 Missing (In Isoform 3). /FTid=VSP_006446.
 FT CONFLICT 194 194 A -> G (In Ref. 6).
 SQ SEQUENCE 317 AA; 35/78 MW; 7661764638097F CRC64;
 Query Match 100.0%; Score 1319; DB 1; Length 317;
 Best Local Similarity 100.0%; Prod. No. 4e-110; Indels 0; Gaps 0;
 Matches 249; Conservative 0; Mismatches 0; InDel 0;

QY 1 YFRAQMDPNRISEDCDTHCIVRLRHLHENADFDQTLESQPTKLIPDSRRRIKQAFQAVQ 60
 Db 69 YFRAQMDPNRISEDCDTHCIVRLRHLHENADFDQTLESQPTKLIPDSRRRIKQAFQAVQ 128
 QY 61 KELQHIVGSORIRAKAMWDGSLWDLAKSKLEAQPFALHTINATDPSGHKYVLSWY 120
 Db 129 KELQHIVGSORIRAKAMWDGSLWDLAKSKLEAQPFALHTINATDPSGHKYVLSWY 188
 QY 121 HDRGAKISMTFSNGKLIVNQDPFYVYANICFRPHETSGDQATEYLQMLVYVTKT 180
 Db 189 HDRGAKISMTFSNGKLIVNQDPFYVYANICFRPHETSGDQATEYLQMLVYVTKT 248
 QY 181 IPSSTLMLKGSKTKWGSNSBFPHYSINTGGFKLRSGBISITSVSNPLLDQDAPTYF 240
 Db 249 IPSSTLMLKGSKTKWGSNSBFPHYSINTGGFKLRSGBISITSVSNPLLDQDAPTYF 308
 QY 241 GAFKVRID 249
 Db 309 GAFKVRID 317

RESULT 2
 OST94 HUMAN
 ID OST94_HUMAN PRELIMINARY; PRT; 317 AA.
 AC OST94;
 DT 01-FEB-2005 (TrEMBLrel. 29, Created)

DR EMBL; AF019047; AAB8911.1; mRNA.
 DR EMBL; AF035712; AAC39731.1; mRNA.
 DR EMBL; AB064269; BAB79694.1; mRNA.

GenCore version 5.1.6
 Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:44:31 ; Search time 42.4525 Seconds
 (without alignments)
 484.925 Million cell updates/sec

Title: US-09-211-297-39_COPY_69_317
 Perfect score: 1319
 Sequence: 1 YFRAQMDPNRISEDGTHCIY.....LLDPDQDATYFGAKVARDID 249
 Scoring table: BLOSUM62
 Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0
 Maximum DB seq length: 0
 Post-processing: Minimum Match 0%
 Maximum Match 100%
 Listing first 45 summaries

Database :
Issued Patents AA:
 1: /cgn2_6/prodata/1/iaa/5_COMB.pep: *
 2: /cgn2_6/prodata/1/iaa/H_COMB.pep: *
 3: /cgn2_6/prodata/1/iaa/H_COMB.pep: *
 4: /cgn2_6/prodata/1/iaa/PCTUS_COMB.pep: *
 5: /cgn2_6/prodata/1/iaa/RE_COMB.pep: *
 6: /cgn2_6/ptodata/1/iaa/backfilest.pep: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	1319	100.0	317 2	US-08-996-139-13
2	1319	100.0	317 2	US-08-995-659-13
3	1319	100.0	317 2	US-09-215-649-13
4	1319	100.0	317 2	US-09-052-521C-4
5	1319	100.0	317 2	US-09-577-780-13
6	1319	100.0	317 2	US-09-577-800-13
7	1319	100.0	317 2	US-09-466-96-13
8	1319	100.0	317 2	US-09-871-856-13
9	1319	100.0	317 2	US-09-871-921-13
10	1319	100.0	317 2	US-09-396-937-2
11	1319	100.0	317 2	US-09-877-650-13
12	1319	100.0	317 2	US-09-865-363-13
13	1319	100.0	317 2	US-09-688-459-13
14	1319	100.0	317 2	US-09-957-944-6
15	1319	86.0	294 2	US-08-995-139-11
16	1319	86.0	294 2	US-08-955-659-11
17	1319	86.0	294 2	US-03-211-649A-11
18	1319	86.0	294 2	US-09-577-800-11
19	1319	86.0	294 2	US-09-577-800-11
20	1319	86.0	294 2	US-03-466-496-11
21	1319	86.0	294 2	US-03-871-291-11
22	1319	86.0	294 2	US-03-871-291-11
23	1134	86.0	294 2	US-03-871-650-11
24	1134	86.0	294 2	US-03-865-363-11
25	1134	86.0	294 2	US-09-688-459-11
26	1134	86.0	316 2	US-09-957-944-8
27	1127	85.4	316 2	US-08-842-842-7

ALIGNMENTS

Result No.	Score	Query Match Length	DB ID	Description	OPERATING SYSTEM: Apple Operating System 7.5.5 COMPUTER: Apple Power Macintosh OPERATING SYSTEM: Apple Operating System 7.5.5 COMPUTER: Apple Power Macintosh CURRENT APPLICATION DATA: APPLICATION NUMBER: US10/996,139 FILING DATE: 22 DECEMBER 1997 CLASSIFICATION: PRIORITY APPLICATION DATA: APPLICATION NUMBER: USSN 60/064,671 FILING DATE: 14 OCTOBER 1997 PRIOR APPLICATION DATA: APPLICATION NUMBER: USSN 08/813,509 FILING DATE: 07 MARCH 1997 PRIORITY APPLICATION DATA: APPLICATION NUMBER: USSN 08/772,330 FILING DATE: 23 DECEMBER 1996 ATTORNEY/AGENT INFORMATION: NAME: Perkins, Patricia Anne REGISTRATION NUMBER: 34,693 REFERENCE/DOCKET NUMBER: 2851-A TELECOMMUNICATION INFORMATION: TELEPHONE: (206) 587-0430 TELEFAX: (206) 233-0644 INFORMATION FOR SEQ ID NO: 13: SEQUENCE CHARACTERISTICS: LENGTH: 317 amino acids TYPE: amino acid TOPOLOGY: linear MOLECULE TYPE: protein US-08-996-139-13
28	1127	85.4	316 2	US-08-989-362-2 Sequence 2, Appli Sequence 2, Appli Sequence 2, Appli Sequence 4, Appli Sequence 6, Appli Sequence 8, Appli Sequence 10, Appli Sequence 12, Appli Sequence 14, Appli Sequence 16, Appli Sequence 18, Appli Sequence 20, Appli Sequence 8, Appli Sequence 11, Appli Sequence 11, Appli Sequence 10, Appli Sequence 6, Appli	
29	1127	85.4	316 2	US-09-521C-2 Sequence 2, Appli Sequence 2, Appli Sequence 2, Appli Sequence 4, Appli Sequence 6, Appli Sequence 8, Appli Sequence 10, Appli Sequence 12, Appli Sequence 14, Appli Sequence 16, Appli Sequence 18, Appli Sequence 20, Appli Sequence 8, Appli Sequence 11, Appli Sequence 11, Appli Sequence 10, Appli Sequence 6, Appli	
30	1127	85.4	316 2	US-09-671-658A-2 Sequence 2, Appli Sequence 2, Appli Sequence 2, Appli Sequence 4, Appli Sequence 6, Appli Sequence 8, Appli Sequence 10, Appli Sequence 12, Appli Sequence 14, Appli Sequence 16, Appli Sequence 18, Appli Sequence 20, Appli Sequence 8, Appli Sequence 11, Appli Sequence 11, Appli Sequence 10, Appli Sequence 6, Appli	
31	1127	85.4	316 2	US-09-396-937-4 Sequence 2, Appli Sequence 2, Appli Sequence 2, Appli Sequence 4, Appli Sequence 6, Appli Sequence 8, Appli Sequence 10, Appli Sequence 12, Appli Sequence 14, Appli Sequence 16, Appli Sequence 18, Appli Sequence 20, Appli Sequence 8, Appli Sequence 11, Appli Sequence 11, Appli Sequence 10, Appli Sequence 6, Appli	
32	1127	85.4	316 2	US-09-396-937-6 Sequence 2, Appli Sequence 2, Appli Sequence 2, Appli Sequence 4, Appli Sequence 6, Appli Sequence 8, Appli Sequence 10, Appli Sequence 12, Appli Sequence 14, Appli Sequence 16, Appli Sequence 18, Appli Sequence 20, Appli Sequence 8, Appli Sequence 11, Appli Sequence 11, Appli Sequence 10, Appli Sequence 6, Appli	
33	771	58.5	187 2	US-09-395-937-8 Sequence 2, Appli Sequence 2, Appli Sequence 2, Appli Sequence 4, Appli Sequence 6, Appli Sequence 8, Appli Sequence 10, Appli Sequence 12, Appli Sequence 14, Appli Sequence 16, Appli Sequence 18, Appli Sequence 20, Appli Sequence 8, Appli Sequence 11, Appli Sequence 11, Appli Sequence 10, Appli Sequence 6, Appli	
34	769	58.3	173 2	US-09-396-937-10 Sequence 2, Appli Sequence 2, Appli Sequence 2, Appli Sequence 4, Appli Sequence 6, Appli Sequence 8, Appli Sequence 10, Appli Sequence 12, Appli Sequence 14, Appli Sequence 16, Appli Sequence 18, Appli Sequence 20, Appli Sequence 8, Appli Sequence 11, Appli Sequence 11, Appli Sequence 10, Appli Sequence 6, Appli	
35	759	57.5	173 2	US-09-396-937-12 Sequence 2, Appli Sequence 2, Appli Sequence 2, Appli Sequence 4, Appli Sequence 6, Appli Sequence 8, Appli Sequence 10, Appli Sequence 12, Appli Sequence 14, Appli Sequence 16, Appli Sequence 18, Appli Sequence 20, Appli Sequence 8, Appli Sequence 11, Appli Sequence 11, Appli Sequence 10, Appli Sequence 6, Appli	
36	721.5	54.7	188 2	US-09-396-937-14 Sequence 2, Appli Sequence 2, Appli Sequence 2, Appli Sequence 4, Appli Sequence 6, Appli Sequence 8, Appli Sequence 10, Appli Sequence 12, Appli Sequence 14, Appli Sequence 16, Appli Sequence 18, Appli Sequence 20, Appli Sequence 8, Appli Sequence 11, Appli Sequence 11, Appli Sequence 10, Appli Sequence 6, Appli	
37	711.5	53.9	182 2	US-09-396-937-16 Sequence 2, Appli Sequence 2, Appli Sequence 2, Appli Sequence 4, Appli Sequence 6, Appli Sequence 8, Appli Sequence 10, Appli Sequence 12, Appli Sequence 14, Appli Sequence 16, Appli Sequence 18, Appli Sequence 20, Appli Sequence 8, Appli Sequence 11, Appli Sequence 11, Appli Sequence 10, Appli Sequence 6, Appli	
38	691	52.4	173 2	US-09-396-937-18 Sequence 2, Appli Sequence 2, Appli Sequence 2, Appli Sequence 4, Appli Sequence 6, Appli Sequence 8, Appli Sequence 10, Appli Sequence 12, Appli Sequence 14, Appli Sequence 16, Appli Sequence 18, Appli Sequence 20, Appli Sequence 8, Appli Sequence 11, Appli Sequence 11, Appli Sequence 10, Appli Sequence 6, Appli	
39	670	50.8	173 2	US-09-396-937-20 Sequence 2, Appli Sequence 2, Appli Sequence 2, Appli Sequence 4, Appli Sequence 6, Appli Sequence 8, Appli Sequence 10, Appli Sequence 12, Appli Sequence 14, Appli Sequence 16, Appli Sequence 18, Appli Sequence 20, Appli Sequence 8, Appli Sequence 11, Appli Sequence 11, Appli Sequence 10, Appli Sequence 6, Appli	
40	538	40.8	109 2	US-09-911-777-8 Sequence 2, Appli Sequence 2, Appli Sequence 2, Appli Sequence 4, Appli Sequence 6, Appli Sequence 8, Appli Sequence 10, Appli Sequence 12, Appli Sequence 14, Appli Sequence 16, Appli Sequence 18, Appli Sequence 20, Appli Sequence 8, Appli Sequence 11, Appli Sequence 11, Appli Sequence 10, Appli Sequence 6, Appli	
41	418	31.7	77 2	US-09-632-287A-11 Sequence 2, Appli Sequence 2, Appli Sequence 2, Appli Sequence 4, Appli Sequence 6, Appli Sequence 8, Appli Sequence 10, Appli Sequence 12, Appli Sequence 14, Appli Sequence 16, Appli Sequence 18, Appli Sequence 20, Appli Sequence 8, Appli Sequence 11, Appli Sequence 11, Appli Sequence 10, Appli Sequence 6, Appli	
42	418	31.7	77 2	US-12-286-696-11 Sequence 2, Appli Sequence 2, Appli Sequence 2, Appli Sequence 4, Appli Sequence 6, Appli Sequence 8, Appli Sequence 10, Appli Sequence 12, Appli Sequence 14, Appli Sequence 16, Appli Sequence 18, Appli Sequence 20, Appli Sequence 8, Appli Sequence 11, Appli Sequence 11, Appli Sequence 10, Appli Sequence 6, Appli	
43	363	27.5	77 2	US-09-632-287A-10 Sequence 2, Appli Sequence 2, Appli Sequence 2, Appli Sequence 4, Appli Sequence 6, Appli Sequence 8, Appli Sequence 10, Appli Sequence 12, Appli Sequence 14, Appli Sequence 16, Appli Sequence 18, Appli Sequence 20, Appli Sequence 8, Appli Sequence 11, Appli Sequence 11, Appli Sequence 10, Appli Sequence 6, Appli	
44	363	27.5	77 2	US-10-286-996-10 Sequence 2, Appli Sequence 2, Appli Sequence 2, Appli Sequence 4, Appli Sequence 6, Appli Sequence 8, Appli Sequence 10, Appli Sequence 12, Appli Sequence 14, Appli Sequence 16, Appli Sequence 18, Appli Sequence 20, Appli Sequence 8, Appli Sequence 11, Appli Sequence 11, Appli Sequence 10, Appli Sequence 6, Appli	
45	238.5	18.1	291 1	US-08-670-354-6 Sequence 2, Appli Sequence 2, Appli Sequence 2, Appli Sequence 4, Appli Sequence 6, Appli Sequence 8, Appli Sequence 10, Appli Sequence 12, Appli Sequence 14, Appli Sequence 16, Appli Sequence 18, Appli Sequence 20, Appli Sequence 8, Appli Sequence 11, Appli Sequence 11, Appli Sequence 10, Appli Sequence 6, Appli	

us-09-211-297-39-copy_69_317.rai

```

Query Match      100.0%; Score 1319; DB 2; Length 317;
Best Local Similarity 100.0%; Pred. No. 1.7e-139;
Matches 249; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-995-659-13

RESULT 2
US-08-995-659-13
. Sammamish 13 Application US/08995659

Patent No. 6,242,213
GENERAL INFORMATION:
APPLICANT: Anderson, Dirk M.
APPLICANT: Galibert, Laurent

APPLICANT: Marabikovsky, Eugene
TITLE OF INVENTION: Ligand for Receptor Activator of NF- κ B
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:

ADRESSEES: Immunex Corporation, Law Department
STREET: 51 University Street,
CITY: Seattle
STATE: WA
COUNTRY: USA

ZIP: 98101
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: Apple Power Macintosh

OPERATING SYSTEM: Apple Operating System 7.5.5
SOFTWARE: Microsoft Word for Power Macintosh 6.0.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/995-659
PRIORITY NUMBER: 22 NOVEMBER 1997

FILING DATE: 22 DECEMBER 1997
CLASSIFICATION:
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: USSN 60/064,671
FILING DATE: 14 OCTOBER 1997

CLASSIFICATION:
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: USSN 08/813,509
FILING DATE: 07 MARCH 1997

PRIOR APPLICATION DATA:
APPLICATION NUMBER: USSN 08/772,330
FILING DATE: 23 DECEMBER 1996
CLASSIFICATION:

ATTORNEY/AGENT INFORMATION:
NAME: Perkins, Patricia Anne
REGISTRATION NUMBER: 34,693
REFERENCE/DOCKET NUMBER: 2852-A

TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 587-0430
TELEFAX: (206) 233-0644
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 317 amino acids

RESULT 2
 US-10-050-898-221
 Sequence 221, Application US/10050898
 Publication No. US2003017571A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Renner, Wolfgang A.
 ; APPLICANT: Bachmann, Martin
 ; APPLICANT: Tissot, Alain
 ; APPLICANT: Maurer, Patrick
 ; APPLICANT: Lechner, Franziska
 ; APPLICANT: Seibel, Peter
 ; APPLICANT: Piossek, Christine
 ; APPLICANT: Ortmann, Rainer
 ; APPLICANT: Staufenbiel, Matthias
 ; APPLICANT: Frey, Peter
 ; TITLE OF INVENTION: Molecular Antigen Array
 ; FILE REFERENCE: 1700.019005
 ; CURRENT APPLICATION NUMBER: US/10/050,898
 ; CURRENT FILING DATE: 2002-01-18
 ; PRIORITY APPLICATION NUMBER: US 60/396,635
 ; PRIORITY FILING DATE: 2002-01-19
 ; PRIORITY APPLICATION NUMBER: US 60/288,549
 ; PRIORITY FILING DATE: 2001-05-04
 ; PRIORITY APPLICATION NUMBER: US 60/326,998
 ; PRIORITY FILING DATE: 2001-10-05
 ; PRIORITY APPLICATION NUMBER: US 60/331,045
 ; PRIORITY FILING DATE: 2001-11-07
 ; NUMBER OF SEQ ID NOS: 350
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO: 82
 ; LENGTH: 249
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; US-10-289-456-82

Query Match 100.0%; Score 1319; DB 4; Length 249;
 Best Local Similarity 100.0%; Pred. No. 5.3e-122;
 Matches 249; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 YFRAQMDPDRNRSBDGTHCIVYRIRLHENADPDTTLESQDTKLIPDSRRRIKOFQAVQ 60
 Db 1 YFRAQMDPDRNRSBDGTHCIVYRIRLHENADPDTTLESQDTKLIPDSRRRIKOFQAVQ 60

Qy 61 KELQHIVGSQHIREAKAMWDGSDLAKESKLEAQPFHLTINATDPSGHKVLSWY 120
 Db 61 KELQHIVGSQHIREAKAMWDGSDLAKESKLEAQPFHLTINATDPSGHKVLSWY 120

Qy 121 HDRGWAKISNTFSNGKLIVNQDFYYLYANICPRHHETSGLATEYQLMVYVTKSIK 180
 Db 121 HDRGWAKISNTFSNGKLIVNQDFYYLYANICPRHHETSGLATEYQLMVYVTKSIK 180

Qy 181 IPSSTLMIKGSTKYWGNSEPHYSINGGFFKLRSREIELEVSNPLLDPDQDATYF 240
 Db 181 IPSSTLMIKGSTKYWGNSEPHYSINGGFFKLRSREIELEVSNPLLDPDQDATYF 240

Qy 241 GAFKURDID 249
 Db 241 GAFKURDID 249

RESULT 4
 US-10-338-785A-1
 Sequence 1, Application US/100338785A
 Publication No. US20030219864A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Desbarais, John R.
 ; APPLICANT: Hubert, Rene S.
 ; APPLICANT: El Yazzal, Jamal
 ; TITLE OF INVENTION: Variants of RANKL Protein
 ; FILE REFERENCE: A-71486
 ; CURRENT APPLICATION NUMBER: US/10/338,785A
 ; CURRENT FILING DATE: 2003-01-06
 ; PRIORITY APPLICATION NUMBER: US 60/345,805
 ; PRIORITY FILING DATE: 2002-01-04
 ; PRIORITY APPLICATION NUMBER: US 60/373,453
 ; PRIORITY FILING DATE: 2002-04-17
 ; NUMBER OF SEQ ID NOS: 6
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO: 1
 ; LENGTH: 250
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; PUBLICATION INFORMATION:
 ; DATABASE ACCESSION NUMBER: Genbank Acc. No. US20030219864A1 AAB86811
 ; DATABASE ENTRY DATE: 1997-11-21

RESULT 3

US-10-289-456-B2
 Sequence 82, Application US/10289456
 Publication No. US2004003321A1
 ; GENERAL INFORMATION:

GenCore version 5.1.6
 Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model

Run on: December 21, 2005, 13:03:52 ; Search time 7.75574 Seconds
 (without alignments)
 228.978 Million cell updates/sec

Title: US-09-211-297-39_COPY_69_317
 Perfect Score: 1319
 Sequence: 1 YFRQMDPNRISDGTHCIV.....LLDPDQDATYFGAPKVRID 249

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 53982 seqs, 7132107 residues

Total number of hits satisfying chosen parameters: 53982

Minimum DB seq length: 0
 Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
 Maximum Match 100%
 Listing first 45 summaries

Database : Published Applications AA New.*
 1: /cggn2_6/ptodat/a/2/pubpaal/us06_NEW_PUB.PEP:*

2: /cggn2_6/ptodat/a/2/pubpaal/us07_NEW_PUB.PEP:*

3: /cggn2_6/ptodat/a/2/pubpaal/PCT_NEW_PUB.PEP:*

4: /cggn2_6/ptodat/a/2/pubpaal/us05_NEW_PUB.PEP:*

5: /cggn2_6/ptodat/a/2/pubpaal/us10_NEW_PUB.PEP:*

6: /cggn2_6/ptodat/a/2/pubpaal/us11_NEW_PUB.PEP:*

7: /cggn2_6/ptodat/a/2/pubpaal/us60_NEW_PUB.PEP:*

8: /cggn2_6/ptodat/a/2/pubpaal/us60_NEW_PUB.PEP:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	538	40.8	109	US-11-065-669-8 Sequence 8, Appli
2	236.5	17.9	281	6 US-10-821-234-1288 Sequence 1288, Ap
3	235.5	17.9	266	7 US-11-082-544-10 Sequence 10, Appli
4	232.5	17.6	281	7 US-11-077-212-2 Sequence 2, Appli
5	232.5	17.6	391	7 US-11-105-172-4 Sequence 4, Appli
6	147.5	11.2	359	7 US-11-105-172-2 Sequence 6, Appli
7	134	10.2	6	6 US-10-987-663-6 Sequence 6, Appli
8	133	10.1	157	7 US-11-108-001-2 Sequence 1, Appli
9	133	10.1	157	7 US-11-053-750-1 Sequence 1, Appli
10	133	10.1	157	7 US-11-053-749-1 Sequence 1, Appli
11	133	10.1	157	7 US-11-108-001-12 Sequence 1, Appli
12	133	10.1	158	7 US-11-082-544-4 Sequence 1, Appli
13	133	10.1	164	7 US-11-108-001-2 Sequence 2, Appli
14	133	10.1	180	7 US-11-082-544-8 Sequence 8, Appli
15	92.5	7.0	177	6 US-10-999-866-61 Sequence 61, Appli
16	92.5	7.0	205	6 US-10-995-561-1028 Sequence 108, Ap
17	92.5	7.0	205	6 US-10-995-561-1029 Sequence 1029, Ap
18	86.5	6.6	104	7 US-11-065-669-5 Sequence 4, Appli
19	85	6.4	107	7 US-11-054-515-3233 Sequence 5, Appli
20	77.5	5.9	290	7 US-11-054-515-3231 Sequence 3231, Ap
21	77	5.8	200	6 US-10-524-198-2 Sequence 2, Appli
22	76.5	5.8	219	7 US-11-054-515-3237 Sequence 3237, Ap
23	76.5	5.8	243	7 US-11-054-515-3236 Sequence 3236, Ap
24	74.5	5.6	239	7 US-11-054-515-3232 Sequence 3232, Ap
25	5.6	5.6	943	6 US-10-475-204-34 Sequence 34, Appli

ALIGNMENTS

RESULT 1
 US-11-065-669-8
 ; Sequence 8, Application US/11065669
 ; Publication No. US20050244411A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Mackay, Fabienne
 ; TITLE OF INVENTION: B-CELL RESPONSE MODULATION BY INHIBITORS THEREOF AND THEIR USE IN THE TREATMENT OF INFLAMMATION
 ; FILE REFERENCE: 08201.0024-04000
 ; CURRENT APPLICATION NUMBER: US/11/065, 669
 ; CURRENT FILING DATE: 2005-02-24
 ; PRIORITY FILING DATE: 2001-11-07
 ; PRIORITY APPLICATION NUMBER: 09/911, 777
 ; PRIORITY FILING DATE: 2001-07-24
 ; PRIORITY APPLICATION NUMBER: 60/143, 228
 ; PRIORITY FILING DATE: 2000-01-25
 ; PRIORITY APPLICATION NUMBER: 60/117, 169
 ; PRIORITY FILING DATE: 1999-01-25
 ; NUMBER OF SEQ ID NOS: 26
 ; SOFTWARE: PatentIn Ver. 2.1
 ; SEQ ID NO: 8
 ; LENGTH: 109
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-11-065-669-8
 Query Match Similarity 40.8%; Score 538; DB 7; Length 109;
 Best Local Similarity 75.5%; Pred. No. 1, 4e-46; Mismatches 0; Indels 34; Gaps 2;
 Matches 108; Conservative 1; Sequence 1, Appli
 Sequence 2, Appli
 Sequence 3, Appli
 Sequence 4, Appli
 Sequence 5, Appli
 Sequence 6, Appli
 Sequence 7, Appli
 Sequence 8, Appli
 Sequence 9, Appli
 Sequence 10, Appli
 Sequence 11, Appli
 Sequence 12, Appli
 Sequence 13, Appli
 Sequence 14, Appli
 Sequence 15, Appli
 Sequence 16, Appli
 Sequence 17, Appli
 Sequence 18, Appli
 Sequence 19, Appli
 Sequence 20, Appli
 Sequence 21, Appli
 Sequence 22, Appli
 Sequence 23, Appli
 Sequence 24, Appli
 Sequence 25, Appli
 Sequence 26, Appli
 Sequence 27, Appli
 Sequence 28, Appli
 Sequence 29, Appli
 Sequence 30, Appli
 Sequence 31, Appli
 Sequence 32, Appli
 Sequence 33, Appli
 Sequence 34, Appli
 Sequence 35, Appli
 Sequence 36, Appli
 Sequence 37, Appli
 Sequence 38, Appli
 Sequence 39, Appli
 Sequence 40, Appli
 Sequence 41, Appli
 Sequence 42, Appli
 Sequence 43, Appli
 Sequence 44, Appli
 Sequence 45, Appli
 Sequence 46, Appli
 Sequence 47, Appli
 Sequence 48, Appli
 Sequence 49, Appli
 Sequence 50, Appli
 Sequence 51, Appli
 Sequence 52, Appli
 Sequence 53, Appli
 Sequence 54, Appli
 Sequence 55, Appli
 Sequence 56, Appli
 Sequence 57, Appli
 Sequence 58, Appli
 Sequence 59, Appli
 Sequence 60, Appli
 Sequence 61, Appli
 Sequence 62, Appli
 Sequence 63, Appli
 Sequence 64, Appli
 Sequence 65, Appli
 Sequence 66, Appli
 Sequence 67, Appli
 Sequence 68, Appli
 Sequence 69, Appli
 Sequence 70, Appli
 Sequence 71, Appli
 Sequence 72, Appli
 Sequence 73, Appli
 Sequence 74, Appli
 Sequence 75, Appli
 Sequence 76, Appli
 Sequence 77, Appli
 Sequence 78, Appli
 Sequence 79, Appli
 Sequence 80, Appli
 Sequence 81, Appli
 Sequence 82, Appli
 Sequence 83, Appli
 Sequence 84, Appli
 Sequence 85, Appli
 Sequence 86, Appli
 Sequence 87, Appli
 Sequence 88, Appli
 Sequence 89, Appli
 Sequence 90, Appli
 Sequence 91, Appli
 Sequence 92, Appli
 Sequence 93, Appli
 Sequence 94, Appli
 Sequence 95, Appli
 Sequence 96, Appli
 Sequence 97, Appli
 Sequence 98, Appli
 Sequence 99, Appli
 Sequence 100, Appli
 Sequence 101, Appli
 Sequence 102, Appli
 Sequence 103, Appli
 Sequence 104, Appli
 Sequence 105, Appli
 Sequence 106, Appli
 Sequence 107, Appli
 Sequence 108, Appli
 Sequence 109, Appli
 Sequence 110, Appli
 Sequence 111, Appli
 Sequence 112, Appli
 Sequence 113, Appli
 Sequence 114, Appli
 Sequence 115, Appli
 Sequence 116, Appli
 Sequence 117, Appli
 Sequence 118, Appli
 Sequence 119, Appli
 Sequence 120, Appli
 Sequence 121, Appli
 Sequence 122, Appli
 Sequence 123, Appli
 Sequence 124, Appli
 Sequence 125, Appli
 Sequence 126, Appli
 Sequence 127, Appli
 Sequence 128, Appli
 Sequence 129, Appli
 Sequence 130, Appli
 Sequence 131, Appli
 Sequence 132, Appli
 Sequence 133, Appli
 Sequence 134, Appli
 Sequence 135, Appli
 Sequence 136, Appli
 Sequence 137, Appli
 Sequence 138, Appli
 Sequence 139, Appli
 Sequence 140, Appli
 Sequence 141, Appli
 Sequence 142, Appli
 Sequence 143, Appli
 Sequence 144, Appli
 Sequence 145, Appli
 Sequence 146, Appli
 Sequence 147, Appli
 Sequence 148, Appli
 Sequence 149, Appli
 Sequence 150, Appli
 Sequence 151, Appli
 Sequence 152, Appli
 YANI 43

US-10-821-234-1288
; Sequence 1288, Application US/10821234
; Publication No. US2005255114A1
; GENERAL INFORMATION:
; APPLICANT: Habat, Ivan
; APPLICANT: Stache-Crain, Birgit
; APPLICANT: Andarmiani, Susan
; APPLICANT: Tang, Y. Tom
; TITLE OF INVENTION: Methods for Diagnosis and Treatment of Preeclampsia
; FILE REFERENCE: 821A
; CURRENT APPLICATION NUMBER: US/10/821.234
; CURRENT FILING DATE: 2004-04-07
; PRIORITY FILING DATE: 2003-04-07
; NUMBER OF SEQ ID NOS: 1704
; SOFTWARE: PT-SEQ_Genes Version 1.0
; SEQ ID NO 1288
; LENGTH: 281
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-821-234-1288
Query Match 17.9%; Score 236.5; DB 6; Length 281;
Best Local Similarity 25.1%; Pred. No. 3.1e-16;
Matches 67; Conservative 53; Mismatches 102; Indels 45; Gaps 10;
Query 1 YFRAQMD--PNRISDGTHCYTRILRHENDADQDTTLSSQTKLIPDSCCRRIKQAFQGA 58
Db 37 YFTNEKLQMOKDVKSGIACF----LKED----DSYWDPDEESMNSPCWQKVW---- 82
Query 59 VOKELQHIVGSQHRAEKAAMDGSWLDAKRSLKEAQPF----AHLT----IN 103
Db 83 --QRLQVRLMRLTSEETI----STVQEQQONISPLVVERGPORVAHTGTRGRSN 134
Query 104 ATDIPSGSHKVSL---SSWHDR-GWAKISNMFTSNGKLVNQDGFPYLYANICFRHRHE 158
Db 135 TLSSPNSKNEKALGRKINSKESRSRGSFSPLSNUHLANGELTHEKGFPYIYSQTYFRFQE 194
Query 159 TSGDLATEDYOLMNVYVTTKTSKIPSSHTLMKGCGSTKTYWGNSEFHFSYNSVGGFKLRS 218
Db 195 EIKENTNDKQMVQYIYKTY-SYPDPILLMSKARNSCWSKDAEYGLSYIQQGIFELKEN 253
Query 219 BEISIEVSNSPLSDPDQDATYFGAKV 245
Db 254 DRIFVSVTNHLLIDMDHEASFFGAFLV 280

RESULT 3
US-11-082-544-10
; Sequence 10, Application US/11082544
; Publication No. US2005249706A1
; GENERAL INFORMATION:
; APPLICANT: Bermudez, G.
; APPLICANT: LEUNG, WOON-LAM SUSAN
; APPLICANT: SMARTZ, JAMES R.
; TITLE OF INVENTION: PROCESS FOR PRODUCING POLYPEPTIDES
; FILE REFERENCE: P2019R1
; CURRENT APPLICATION NUMBER: US/11/077, 272
; CURRENT FILING DATE: 2005-03-10
; PRIORITY FILING DATE: 2004-03-11
; NUMBER OF SEQ ID NOS: 7
; SEQ ID NO 2
; LENGTH: 281
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-077-272-2
Query Match 17.6%; Score 232.5; DB 7; Length 281;
Best Local Similarity 25.1%; Pred. No. 7.6e-16;
Matches 67; Conservative 52; Mismatches 103; Indels 45; Gaps 10;
Query 1 YFRAQMD--PNRISDGTHCYTRILRHENDADQDTTLSSQTKLIPDSCCRRIKQAFQGA 58
Db 37 YFTNEKLQMOKDVKSGIACF----LKED----DSYWDPDEESMNSPCWQKVW---- 82
Query 59 VOKELQHIVGSQHRAEKAAMDGSWLDAKRSLKEAQPF----AHLT----IN 103
Db 83 --QRLQVRLMRLTSEETI----STVQEQQONISPLVVERGPORVAHTGTRGRSN 134
Query 104 ATDIPSGSHKVSL---SSWHDR-GWAKISNMFTSNGKLVNQDGFPYLYANICFRHRHE 158
Db 135 TLSSPNSKNEKALGRKINSKESRSRGSFSPLSNUHLANGELTHEKGFPYIYSQTYFRFQE 194
Query 159 TSGDLATEDYOLMNVYVTTKTSKIPSSHTLMKGCGSTKTYWGNSEFHFSYNSVGGFKLRS 218
Db 195 EIKENTNDKQMVQYIYKTY-SYPDPILLMSKARNSCWSKDAEYGLSYIQQGIFELKEN 253
Query 219 BEISIEVSNSPLSDPDQDATYFGAKV 245
Db 254 DRIFVSVTNHLLIDMDHEASFFGAFLV 280

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:44:31 ; Search time 2.89836 Seconds

Copyright (c) 1993 - 2005 Compugen Ltd.

GenCore version 5.1.6

Title: Perfect score: US-09-211-297-34

Sequence: 1 VVVKTSKIPSSHNL M 17

Scoring table: BLOSUM62

Gappen 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued_Patents_AA:*

1: /cgn2_6/ptodata/1/iaa/6_COMB.pep:*

2: /cgn2_6/ptodata/1/iaa/6_COMB.pep:*

3: /cgn2_6/ptodata/1/iaa/H_COMB.pep:*

4: /cgn2_6/ptodata/1/iaa/PCTUS_COMB.pep:*

5: /cgn2_6/ptodata/1/iaa/RE_COMB.pep:*

6: /cgn2_6/ptodata/1/iaa/backfilled.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Length	DB ID	Description
1	84	100.0	17	2 US-09-052-521C-35
2	84	100.0	173	2 US-09-396-937-10
3	84	100.0	173	2 US-09-398-937-12
4	84	100.0	173	2 US-09-398-937-18
5	84	100.0	187	2 US-09-398-937-8
6	84	100.0	188	2 US-09-398-937-14
7	84	100.0	294	2 US-08-995-139-11
8	84	100.0	294	2 US-08-995-659-11
9	84	100.0	294	2 US-09-215-649A-11
10	84	100.0	294	2 US-09-577-780-11
11	84	100.0	294	2 US-09-577-800-11
12	84	100.0	294	2 US-09-466-496-11
13	84	100.0	294	2 US-09-871-856-11
14	84	100.0	294	2 US-09-871-291-11
15	84	100.0	294	2 US-09-871-650-11
16	84	100.0	294	2 US-09-865-363-11
17	84	100.0	294	2 US-09-459-11
18	84	100.0	316	1 US-09-842-842-7
19	84	100.0	316	2 US-09-989-362-2
20	84	100.0	316	2 US-09-521C-2
21	84	100.0	316	2 US-09-671-658A-2
22	84	100.0	316	2 US-09-396-937-4
23	84	100.0	316	2 US-09-396-937-5
24	84	100.0	316	2 US-09-957-944-8
25	88.1	317	2 US-08-996-139-13	
26	74	317	2 US-09-995-659-13	
27	88.1	317	2 US-09-215-649A-13	

ALIGNMENTS

RESULT 1
US-09-052-521C-35
; Sequence 35, Application US/09052521C
; Sequence ID: 6316408

GENERAL INFORMATION:
; PATENT NO.: 6316408

APPLICANT: Boyle, William J.

TITLE OF INVENTION: Osteoprotegerin Binding Proteins and Receptors

FILE REFERENCE: A-451Bv

CURRENT APPLICATION NUMBER: US/09/052,521C

CURRENT FILING DATE: 1998-03-30

PRIOR APPLICATION NUMBER: 08/880,855

PRIOR FILING DATE: 1997-06-23

PRIOR APPLICATION NUMBER: 08/842,842

PRIOR FILING DATE: 1997-04-16

NUMBER OF SEQ ID NOS: 40

SOFTWARE: PatentIn Ver. 2.1

SEQ_ID NO 35

LENGTH: 17

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE: OTHER INFORMATION: Description of Artificial Sequence: Synthetic

OTHER INFORMATION: Peptide

US-09-052-521C-35

Query Match Best Local Similarity 100.0%; Score 84; DB 2; Length 17; Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY Db

1 VVVKTSKIPSSHNL M 17
1 VVVKTSKIPSSHNL M 17

RESULT 2
US-09-396-937-10
; Sequence 10, Application US/09396937
; Sequence ID: 6645500

PATENT NO.: 6645500

GENERAL INFORMATION:
; APPLICANT: M&E Biotech A/S
; APPLICANT: HALKIER, Torben
; APPLICANT: HANNING, Jesper
TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand

TITLE OF INVENTION: Activity

FILE REFERENCE: 22021PC1

CURRENT APPLICATION NUMBER: US/09/396,937

CURRENT FILING DATE: 1999-09-15

NUMBER OF SEQ ID NOS: 35

SOFTWARE: PatentIn Ver. 2.1

SEQ_ID NO 10

```

; LENGTH: 173
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: DNA encoding
; OTHER INFORMATION: murine OPGL residues 158-316, fused to His tag
US-09-396-937-10

Query Match          100 %; Score 84; DB 2; Length 173;
Best Local Similarity 100.0%; Pred. No. 2.1e-06; Mismatches 0; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 VVVKTSIKIPSSHNL 17
Db      96 VVVKTSIKIPSSHNL 112

RESULT 3
US-09-396-937-12
; Sequence 12, Application US/09396937
; Patent No. 6645500
; GENERAL INFORMATION:
; APPLICANT: M&E Biotech A/S
; APPLICANT: HALKIER, Torben
; APPLICANT: HAANING, Jesper
; TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin ligand
; TITLE OF INVENTION: Activity
; FILE REFERENCE: 22021 PC 1
; CURRENT APPLICATION NUMBER: US/09/396,937
; NUMBER OF SEQ ID NOS: 35
; SEQ ID NO 12
; LENGTH: 173
; SOFTWARE: PatentIn Ver. 2.1
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Fusion of
; OTHER INFORMATION: murine OPGL residues 158-316 with C to S
; OTHER INFORMATION: mutation, and His tag
US-09-396-937-12

Query Match          100.0%; Score 84; DB 2; Length 173;
Best Local Similarity 100.0%; Pred. No. 2.1e-06; Mismatches 0; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 VVVKTSIKIPSSHNL 17
Db      96 VVVKTSIKIPSSHNL 112

RESULT 4
US-09-396-937-18
; Sequence 18, Application US/09396937
; Patent No. 6645500
; GENERAL INFORMATION:
; APPLICANT: M&E Biotech A/S
; APPLICANT: HALKIER, Torben
; APPLICANT: HAANING, Jesper
; TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand
; TITLE OF INVENTION: Activity
; FILE REFERENCE: 22021 PC 1
; CURRENT APPLICATION NUMBER: US/09/396,937
; NUMBER OF SEQ ID NOS: 35
; SEQ ID NO 18
; LENGTH: 173
; SOFTWARE: PatentIn Ver. 2.1
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Fusion of
; OTHER INFORMATION: murine OPGL residues 158-316 modified by
; OTHER INFORMATION: introduction of tetanus toxoid P30 epitope, and
; OTHER INFORMATION: His tag
US-09-396-937-14

Query Match          100.0%; Score 84; DB 2; Length 173;
Best Local Similarity 100.0%; Pred. No. 2.1e-06; Mismatches 0; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 VVVKTSIKIPSSHNL 17
Db      96 VVVKTSIKIPSSHNL 112

RESULT 5
US-09-396-937-8
; Sequence 8, Application US/09396937
; Patent No. 6645500
; GENERAL INFORMATION:
; APPLICANT: M&E Biotech A/S
; APPLICANT: HALKIER, Torben
; APPLICANT: HAANING, Jesper
; TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand
; TITLE OF INVENTION: Activity
; FILE REFERENCE: 22021 PC 1
; CURRENT APPLICATION NUMBER: US/09/396,937
; NUMBER OF SEQ ID NOS: 35
; SEQ ID NO 8
; LENGTH: 187
; SOFTWARE: PatentIn Ver. 2.1
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic PCR
; OTHER INFORMATION: Product with optimum codons for E. coli and P.
; OTHER INFORMATION: pastoris expression
US-09-396-937-8

Query Match          100.0%; Score 84; DB 2; Length 187;
Best Local Similarity 100.0%; Pred. No. 2.3e-06; Mismatches 0; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 VVVKTSIKIPSSHNL 17
Db      110 VVVKTSIKIPSSHNL 126

```

OM protein - protein search, using sw model					
Run on:	December 21, 2005, 13:02:07 (without alignments) 758.559 Million cell updates/sec				
Title:	US-09-211-297-34				
Perfect score:	84				
Sequence:	1 VVVKTKTSKIKPSHNL M 17				
Scoring table:	BLOSSUM62 Gapop 10.0 , Gapext 0.5				
Searched:	1867569 seqs, 417829326 residues				
Total number of hits satisfying chosen parameters:	1867569				
Minimum DB seq length:	0				
Maximum DB seq length:	200000000				
Post-processing:	Minimum Match 0% Maximum Match 100% Listing first 45 summaries				
Database :	Published Applications AA_Main:*				
1:	/cgn2_6/ptodata/1/pubpaas/US07_PUBCOMB.pep:*				
2:	/cgn2_6/ptodata/1/pubpaas/US08_PUBCOMB.pep:*				
3:	/cgn2_6/ptodata/1/pubpaas/US09_PUBCOMB.pep:*				
4:	/cgn2_6/ptodata/1/pubpaas/US10_PUBCOMB.pep:*				
5:	/cgn2_6/ptodata/1/pubpaas/US11_PUBCOMB.pep:*				
Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.					
SUMMARIES					
Result No.	Score	Query Match Length	DB ID	Description	
1	84	100.0	17	5 US-10-825-898-35	Sequence 35, Appl
2	84	100.0	17	5 US-10-825-898-36	Sequence 36, Appl
3	84	100.0	160	3 US-09-779-0504-14	Sequence 14, Appl
4	84	100.0	170	3 US-09-791-152A-76	Sequence 76, Appl
5	84	100.0	170	4 US-10-289-456-99	Sequence 99, Appl
6	84	100.0	173	4 US-10-664-801-10	Sequence 10, Appl
7	84	100.0	173	4 US-10-664-801-12	Sequence 12, Appl
8	84	100.0	173	4 US-10-664-801-18	Sequence 18, Appl
9	84	100.0	187	4 US-10-664-801-8	Sequence 8, Appl
10	84	100.0	188	4 US-10-664-801-14	Sequence 14, Appl
11	84	100.0	193	4 US-10-289-456-96	Sequence 96, Appl
12	84	100.0	199	4 US-10-050-902-224	Sequence 224, Appl
13	84	100.0	199	4 US-10-050-898-224	Sequence 224, Appl
14	84	100.0	199	4 US-10-289-456-86	Sequence 86, Appl
15	84	100.0	244	4 US-10-167-182-16	Sequence 16, Appl
16	84	100.0	244	4 US-10-460-623-16	Sequence 16, Appl
17	84	100.0	245	5 US-10-854-300-16	Sequence 16, Appl
18	84	100.0	244	6 US-11-135-521-16	Sequence 16, Appl
19	84	100.0	247	4 US-10-050-902-223	Sequence 223, Appl
20	84	100.0	247	4 US-10-050-898-223	Sequence 223, Appl
21	84	100.0	247	4 US-10-289-456-85	Sequence 85, Appl
22	84	100.0	249	4 US-0-338-785A-3	Sequence 3, Appl
23	84	100.0	249	4 US-0-161-363-3	Sequence 3, Appl
24	84	100.0	294	3 US-0-871-856-11	Sequence 11, Appl
25	84	100.0	294	3 US-0-865-363-11	Sequence 11, Appl
26	84	100.0	294	3 US-0-871-291-11	Sequence 11, Appl
27	84	100.0	294	3 US-0-877-650-11	Sequence 11, Appl

```

; PRIOR FILING DATE: 1998-03-30
; PRIOR APPLICATION NUMBER: US 08/880, 855
; PRIOR FILING DATE: 1997-06-23
; PRIOR APPLICATION NUMBER: US 08/842, 842
; PRIOR FILING DATE: 1997-04-16
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO: 36
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
; US-10-825-898-36

Query Match          100.0%; Score 84; DB 5; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.6e-07; Mismatches 0; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 VVVKTSKIPSSHNL 17
Db      1 VVVKTSKIPSSHNL 17

RESULT 3
US-09-779-050A-14
Sequence 14, Application US/09779050A
Patent No. US20030160416A1
GENERAL INFORMATION:
APPLICANT: HSU, HAILING
TITLE OF INVENTION: RECEPTOR FROM TNF FAMILY
FILE REFERENCE: A-570B
CURRENT APPLICATION NUMBER: US 09/779, 050A
CURRENT FILING DATE: 2001-02-12
PRIOR APPLICATION NUMBER: 60/181, 800
PRIOR FILING DATE: 2000-02-11
NUMBER OF SEQ ID NOS: 52
SOFTWARE: PatentIn version 3.0
SEQ ID NO: 14
LENGTH: 160
TYPE: PRT
ORGANISM: Mus musculus
US-09-779-050A-14

Query Match          100.0%; Score 84; DB 3; Length 160;
Best Local Similarity 100.0%; Pred. No. 1.8e-06; Mismatches 0; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 VVVKTSKIPSSHNL 17
Db      1 VVVKTSKIPSSHNL 99

RESULT 4
US-09-791-153A-76
Sequence 76, Application US/09791153A
Publication No. US2003010978A1
GENERAL INFORMATION:
APPLICANT: Deshpande, Rajendra
APPLICANT: Hitz, Anna
APPLICANT: Boyle, William
APPLICANT: Sullivan, John
TITLE OF INVENTION: SELECTIVE BINDING AGENTS OF OSTEOPROTEGERIN BINDING PROTEIN
FILE REFERENCE: A-633A
CURRENT APPLICATION NUMBER: US/09/791, 153A
CURRENT FILING DATE: 2001-07-17
PRIOR APPLICATION NUMBER: 09/511, 139
PRIOR FILING DATE: 2000-02-23
NUMBER OF SEQ ID NOS: 154
SOFTWARE: PatentIn version 3.0
SEQ ID NO: 76
LENGTH: 170

; TYPE: PRT
; ORGANISM: Mus musculus
; US-09-791-153A-76

Query Match          100.0%; Score 84; DB 3; Length 170;
Best Local Similarity 100.0%; Pred. No. 1.9e-05; Mismatches 0; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 VVVKTSKIPSSHNL 17
Db      1 VVVKTSKIPSSHNL 109

RESULT 5
US-10-289-456-99
Sequence 99, Application US/10289456
Publication No. US20040033211A1
GENERAL INFORMATION:
APPLICANT: Bachmann, Martin
APPLICANT: Maurer, Patrick
APPLICANT: Spohn, Gunther
TITLE OF INVENTION: Antigen Arrays for Treatment of Bone Disease
FILE REFERENCE: 17000_0330001
CURRENT APPLICATION NUMBER: US/10/289, 456
CURRENT FILING DATE: 2002-11-07
PRIOR APPLICATION NUMBER: PCT/IB02/00166
PRIOR FILING DATE: 2002-01-21
PRIOR APPLICATION NUMBER: US 10/050, 902
PRIOR FILING DATE: 2002-01-18
PRIOR APPLICATION NUMBER: US 60/396, 635
PRIOR FILING DATE: 2002-07-19
PRIOR APPLICATION NUMBER: US 60/331, 045
PRIOR FILING DATE: 2001-11-07
NUMBER OF SEQ ID NOS: 170
SOFTWARE: PatentIn version 3.2
SEQ ID NO: 99
LENGTH: 170
TYPE: PRT
ORGANISM: Mus sp.
US-10-289-456-99

Query Match          100.0%; Score 84; DB 4; Length 170;
Best Local Similarity 100.0%; Pred. No. 1.9e-05; Mismatches 0; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 VVVKTSKIPSSHNL 17
Db      1 VVVKTSKIPSSHNL 100

RESULT 6
US-10-664-801-10
Sequence 10, Application US/10664801
Publication No. US20040115199A1
GENERAL INFORMATION:
APPLICANT: M&E Biotech A/S
APPLICANT: HALKIER, Torben
APPLICANT: HAANING, Jesper
TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand
FILE REFERENCE: 2221 PC 1
CURRENT APPLICATION NUMBER: US/10/664, 801
CURRENT FILING DATE: 2003-03-17
PRIOR APPLICATION NUMBER: US/09/396, 937
PRIOR FILING DATE: 1999-09-15
NUMBER OF SEQ ID NOS: 35
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO: 10
LENGTH: 173
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: DNA encoding

```

Run on: December 21, 2005, 13:03:52 ; Search time 0.539508 Seconds
 Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Title:	US-09-211-297-34
Perfect score:	84
Sequence:	1 VVVKTSKIKPSSHNLW 17
Scoring table:	BLOSUM62
Gapop:	10.0 , Gapext 0.5
Searched:	53982 seqs, 7132107 residues
Total number of hits satisfying chosen parameters:	53982
Minimum DB seq length:	0
Maximum DB seq length:	200000000

Post-processing: Minimum Match 0%
 Maximum Match 100%
 Listing first 45 summaries

Database : Published Applications AA_New: *

1:	/cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep: *
2:	/cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep: *
3:	/cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep: *
4:	/cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep: *
5:	/cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep: *
6:	/cgn2_6/ptodata/2/pubpaa/US11_NEW_PUB.pep: *
7:	/cgn2_6/ptodata/2/pubpaa/US11_NEW_PUB.pep: *
8:	/cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Length	DB ID	Description	
1	53	63.1	109	US-11-065-669-8	
2	37	44.0	717	US-11-065-669-8	
3	35	41.7	6 US-10-793-626-3022	Sequence 8, Appli	
4	34	40.5	113	US-10-793-626-3282	Sequence 3022, Ap
5	34	40.5	351	US-10-467-657-088	Sequence 1684, Ap
6	33.5	39.9	374	US-11-050-023-10	Sequence 3282, Ap
7	33	39.3	39	US-10-467-657-2174	Sequence 5088, Ap
8	33	39.3	96	US-10-467-657-3984	Sequence 10, Appli
9	33	39.3	155	US-11-069-642-97	Sequence 2174, Ap
10	33	39.3	198	US-11-069-642-25	Sequence 8984, Ap
11	33	39.3	208	US-10-980-388-81	Best Local Similarity
12	33	39.3	7	US-11-059-642-127	91.7%; Pred. No. 0; Mismatches 0; Matches 11; Conservative
13	33	39.3	431	US-11-069-642-1	Qy 1 VVVKTSKIKPSSHNLW 17
14	33	39.3	437	US-11-069-642-92	Db 63 VVVKTSKIKPSSHNLW 17
15	33	39.3	438	US-11-069-642-47	RESULT 2
16	33	39.3	438	US-11-069-642-49	US-10-793-626-3022
17	33	39.3	438	US-11-069-642-51	; Sequence 3022, Application US/10793626
18	33	39.3	438	US-11-069-642-53	; Publication No. US0050255478A1
19	33	39.3	438	US-11-069-642-55	; GENERAL INFORMATION:
20	33	39.3	438	US-11-069-642-57	; APPLICANT: KIMMERLY, WILLIAM JOHN
21	33	39.3	438	US-11-069-642-59	; TITLE OF INVENTION: STAPHYLOCOCCUS EPIDERMIDIS NUCLEIC ACIDS AND PROTEINS
22	33	39.3	438	US-11-069-642-61	; FILE REFERENCE: PCT/GB0501024
23	33	39.3	438	US-11-069-642-63	; CURRENT APPLICATION NUMBER: US/10793-626
24	33	39.3	490	US-10-131-26A-310	
25	33	39.3	619	US-10-763-712A-35	

ALIGNMENTS

```

; CURRENT FILING DATE: 2004-03-04
; PRIOR APPLICATION NUMBER: 60/164,258
; PRIOR FILING DATE: 1999-11-09
; NUMBER OF SEQ ID NOS: 4472
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO: 3422
; LENGTH: 717
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE: 
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
; OTHER INFORMATION: amino acid sequence
; OTHER INFORMATION: amino acid sequence
US-10-793-626-3022

Query Match      44.0%; Score 37; DB 6; Length 717;
Best Local Similarity 46.2%; Pred. No. 39; Mismatches 6; Conservative 4; Mismatches 4; Indels 0; Gaps 0;
Matches          3; Indels 0; Gaps 0;

QY      2 YVVKTSIKPSSH 14
Db      198 YIVKQGQVKILNH 210

RESULT 3
US-10-821-234-1684
; Sequence 1684, Application US/10821234
; Publication No. US20050255114A1
; GENERAL INFORMATION:
; APPLICANT: Labat, Ivan
; APPLICANT: Stache-Crain, Birgit
; APPLICANT: Andermann, Susan
; APPLICANT: Tang, Y. Tom
; TITLE OF INVENTION: Methods for Diagnosis and Treatment of Preeclampsia
; FILE REFERENCE: 821A
; CURRENT APPLICATION NUMBER: US/10/821,234
; CURRENT FILING DATE: 2004-04-07
; PRIOR APPLICATION NUMBER: US 60/462,047
; PRIOR FILING DATE: 2003-04-07
; NUMBER OF SEQ ID NOS: 1704
; SOFTWARE: pt_SEQ_Genes Version 1.0
; SEQ ID NO 1684
; LENGTH: 269
; TYPE: PRT
; ORGANISM: Homo sapienB
; ORGANISM: Homo sapienB
US-10-821-234-1684

Query Match      41.7%; Score 35; DB 6; Length 269;
Best Local Similarity 50.0%; Pred. No. 28; Mismatches 6; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
Matches          3; Indels 0; Gaps 0;

QY      6 TSIKIPSSHNM 17
Db      186 TDIKATIGHNII 197

RESULT 4
US-10-793-626-3282
; Sequence 3282, Application US/10793626
; Publication No. US20050255478A1
; GENERAL INFORMATION:
; APPLICANT: KIMMELLY, WILLIAM JOHN
; TITLE OF INVENTION: STAPHYLOCOCCUS EPIDERMIDIS NUCLEIC ACIDS AND PROTEINS
; FILE REFERENCE: PU3490US
; CURRENT APPLICATION NUMBER: US 10/793,625
; CURRENT FILING DATE: 2004-03-04
; PRIOR APPLICATION NUMBER: 60/164,258
; PRIOR FILING DATE: 1999-11-09
; NUMBER OF SEQ ID NOS: 4472
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3282
; LENGTH: 113
; TYPE: PRT
; ORGANISM: Artificial Sequence
; ORGANISM: Artificial Sequence
US-10-793-626-3282

Query Match      40.5%; Score 34; DB 6; Length 113;
Best Local Similarity 42.9%; Pred. No. 16; Mismatches 6; Conservative 4; Mismatches 4; Indels 0; Gaps 0;
Matches          4; Indels 0; Gaps 0;

QY      1 VVVKTSIKPSSH 14
Db      55 VSVASTMKLPNTH 69

RESULT 5
US-10-467-657-5088
; Sequence 5088, Application US/10467657
; Publication No. US20050260581A1
; GENERAL INFORMATION:
; APPLICANT: CHIRON SPA
; APPLICANT: FONTANA, Maria Rita
; APPLICANT: PIZZA, Mariagrazia
; APPLICANT: MASIGNANI, Vega
; APPLICANT: MONACI, Elisabetta
; TITLE OF INVENTION: GONOCOCCAL PROTEINS AND NUCLEIC ACIDS
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/10/467,657
; CURRENT FILING DATE: 2003-08-11
; PRIOR APPLICATION NUMBER: GB-0103424.8
; PRIOR FILING DATE: 2001-02-12
; NUMBER OF SEQ ID NOS: 9218
; SOFTWARE: SeqWin99, version 1.04
; SEQ ID NO 5088
; LENGTH: 351
; TYPE: PRT
; ORGANISM: Neisseria gonorrhoeae
; ORGANISM: Neisseria gonorrhoeae
US-10-467-657-5088

Query Match      40.5%; Score 34; DB 6; Length 351;
Best Local Similarity 40.0%; Pred. No. 58; Mismatches 6; Conservative 4; Mismatches 5; Indels 0; Gaps 0;
Matches          5; Indels 0; Gaps 0;

QY      2 YVVKTSIKPSSHNL 16
Db      275 HIINPNNNCRPISHNL 289

RESULT 6
US-11-060-023-10
; Sequence 10, Application US/11060023
; Publication No. US2005025531A1
; GENERAL INFORMATION:
; APPLICANT: AVENTIS Pharma Deutschland GmbH
; TITLE OF INVENTION: Process for identifying modulators of G protein coupled receptors
; TITLE OF INVENTION: receptors
; FILE REFERENCE: AVE D-2000/A033 englisch
; CURRENT APPLICATION NUMBER: US/11/060,023
; CURRENT FILING DATE: 2005-02-17
; PRIOR APPLICATION NUMBER: US/09/899,295
; PRIOR FILING DATE: 2003-07-06
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 374
; TYPE: PRT
; ORGANISM: Mus musculus
; ORGANISM: Mus musculus
US-11-060-023-10

Query Match      39.9%; Score 33.5; DB 7; Length 374;
Best Local Similarity 47.1%; Pred. No. 76; Mismatches 8; Conservative 4; Mismatches 2; Indels 3; Gaps 1;
Matches          2; Indels 3; Gaps 1;

```

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

Om protein - protein search, using sw model

Run on: December 21, 2005, 12:34:10 ; Search time 11.5656 Seconds

(without alignments)
645.834 Million cell updates/sec

Title: US-09-211-297-34
Perfect score: 84
Sequence: 1 VVVKTSTKIPSSHNL M 17

Scoring table: BLOSUM62
GapOpen 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439318781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_GeneSeq_21:*

- 1: geneSeq21900s:*
- 2: geneSeq21900s:*
- 3: geneSeq2009s:*
- 4: geneSeq2019s:*
- 5: geneSeq2020B:*
- 6: geneSeq2003as:*
- 7: geneSeq2003bs:*
- 8: geneSeq2004B:*
- 9: geneSeq2005s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	84	100.0	17	2 AAWB3198
2	84	100.0	18	2 AAWB3199
3	84	100.0	139	3 AAY91023
4	84	100.0	155	6 ABR39854
5	84	100.0	155	7 ADC03334
6	84	100.0	155	7 ADJ02129
7	84	100.0	160	3 ABB08272
8	84	100.0	170	4 AUU08386
9	84	100.0	170	7 ADJ02132
10	84	100.0	173	3 AAY84422
11	84	100.0	173	3 AAY84425
12	84	100.0	173	3 AAY84421
13	84	100.0	187	3 AAY84420
14	84	100.0	188	3 AAY84423
15	84	100.0	193	7 ADJ02129
16	84	100.0	199	5 ABG94285
17	84	100.0	199	5 ABG80597
18	84	100.0	199	5 ADJ02119
19	84	100.0	216	7 ADR16999
20	84	100.0	244	2 AAWB3019
21	84	100.0	247	5 ABG94284
22	84	100.0	247	5 ABG80596
23	84	100.0	247	7 ADJ02118
24	84	100.0	249	6 ADA50081

ALIGNMENTS

25	84	100.0	294	2 AAW6956	NF- κ B rec
26	84	100.0	294	2 AAW6292	Aad68292 NF- κ B rec
27	84	100.0	294	7 AAE0873	Aad0873 Murine re
28	84	100.0	294	4 AAE0425	Aae0425 Murine re
29	84	100.0	294	4 AAE01992	Aae01992 Murine RA
30	84	100.0	294	5 AAE26102	Aae26102 Mouse RAN
31	84	100.0	294	7 ADB16986	Adb16986 Murine re
32	84	100.0	294	7 ADC73000	Adc73000 Murine RA
33	84	100.0	294	7 ADC78266	Adc78266 Murine RA
34	84	100.0	294	7 ADG46721	Adg46721 Murine RA
35	84	100.0	294	9 ADW05027	Adw05027 Murine re
36	84	100.0	316	2 AAW83017	Aaw83017 Osteoclast
37	84	100.0	316	2 AAW83194	Aaw83194 Human ost
38	84	100.0	316	2 AAW83654	Aaw83654 Amino aci
39	84	100.0	316	2 AAY17874	Aay17874 Murine TR
40	84	100.0	316	3 AAY91024	Aay91024 Mouse OBm
41	84	100.0	316	3 AAY84418	Aay84418 Amino aci
42	84	100.0	316	5 AAY84419	Aay84419 Amino aci
43	84	100.0	316	5 AAU78289	Aau78289 Mouse TRA
44	84	100.0	316	5 ADR29338	Adr29338 Mouse RAN
45	84	100.0	316	6 ABR42071	Abt42071 Human RAN

Aad69956 NF- κ B rec
Aad68292 NF- κ B rec
Aad0873 Murine re
Aae0425 Murine re
Aae01992 Murine RA
Aae26102 Mouse RAN
Adb16986 Murine re
Adc73000 Murine RA
Adc78266 Murine RA
Adg46721 Murine RA
Adw05027 Murine re
Aaw83017 Osteoclast
Aaw83194 Human ost
Aaw83654 Amino aci
Aay17874 Murine TR
Aay91024 Mouse OBm
Aay84418 Amino aci
Aay84419 Amino aci
Aau78289 Mouse TRA
Adr29338 Mouse RAN
Abt42071 Human RAN

RESULT 1
ID AAW83198 standard; peptide; 17 AA.
XX
AAW83198;
XX
DT 11-FEB-1999 (first entry)
XX
DE Murine osteoprotegerin binding protein EF loop peptide.
XX
Osteoprotegerin binding protein; OPG binding protein; arthritis;
osteoporosis; osteoclast maturation; bone disease; metastasis; ODAR;
hypercalcaemia; osteoclast differentiation and activation receptor;
RANK; disease.
XX
OS Mus sp.
XX
PN WO984751-A1.
XX
PD 22-OCT-1998.
XX
PP 15-APR-1998; 98WO-US007584.
XX
PR 16-APR-1997; 97US-0084842.
PR 23-JUN-1997; 97US-00880855.
PR 30-MAR-1998; 98US-00052521.
XX
XX
(AMGE-) AMGEN INC.
PR Boyle WJ;
XX
DR WPI; 1998-594578/50.
XX
PT Nucleic acid encoding osteoprotegerin binding protein - useful for, e.g.,
treating bone diseases by modulating osteoclast differentiation and for
diagnosis.
XX
PS Example 11; Page 55; 47pp; English.
XX
CC The present sequence represents peptide from murine osteoprotegerin (OPG).
The present sequence represents peptide from murine osteoprotegerin (OPG).
binding protein. Host cells transfected with vectors containing nucleic
acid molecules encoding OPG binding protein are used to produce
recombinant OPG binding protein. OPG binding protein is used in binding
assays to determine osteoprotegerin (OPG) in biological samples; to screen
for specific binding agents (particularly agonists and antagonists,
including intracellular proteins); to raise Ab (useful in immunoassays
for detection of OPG binding protein) and to identify compounds that

CC modulate binding of OPG binding protein to osteoclast differentiation and activation receptor (ODAR). The nucleic acid molecule encoding OPG
 CC binding protein can be used to detect OPG binding protein-encoding
 CC sequences, e.g. screening for related sequences, also to produce transgenic animal models, while complementary sequences are used for transgenic animal models, while complementary sequences are used for antisense regulation of OPG binding protein expression. Modulators of OPG binding protein, particularly soluble forms of OPG binding protein or Ab, are used to treat or prevent bone diseases, e.g. osteoporosis, bone loss caused by arthritis or metastases, e.g. osteoporosis, Paget's disease, periodontal disease, osteoporosis, loosening of prostheses, optionally in combination with agents that promote bone growth.

SQ Sequence 17 AA;

Query Match	100.0%	Score	84	DB	2	Length	17
Best Local Similarity	100.0%	Pred. No.	1.4e-07				
Matches	17	Conservative	0	Mismatches	0	Indels	0
QY	1	VVVKTSKIPSSHNL	17				
Db	1	VVVKTSKIPSSHNL	17				

RESULT 2

AAW83199	100.0%	Score	84	DB	2	Length	17
ID	AAW83199	Standard; Peptide;	18 AA.				
XX							
AC	AAW83199;						
XX							
DT	11-FEB-1999	(first entry)					
XX							
DE	Murine osteoprotegerin binding protein EF loop-Cys peptide.						
XX							
KW	Osteoprotegerin binding protein; OPG binding protein; arthritis;						
KW	osteoporosis; osteoclast maturation; bone disease; metastasis; ODAR;						
KW	hypercalcemia; osteoclast differentiation and activation receptor;						
KW	Paget's disease.						
XX							
OS	Mus sp.						
XX							
PN	W0946751-A1.						
XX							
PD	22-OCT-1998.						
XX							
PF	15-APR-1998;	98WO-US007584.					
XX							
PR	16-APR-1997;	97US-00842842.					
PR	23-JUN-1997;	97US-00800855.					
PR	30-MAR-1998;	98US-00052521.					
PR	AMGE-1 AMGEN INC.						
PI	Boyle WJ;						
XX							
DR	WPI; 1998-594378/50.						
PT	The present sequence represents peptide from murine osteoprotegerin (OPG) binding protein. Host cells transfected with vectors containing nucleic acid molecules encoding OPG binding protein are used to produce recombinant OPG binding protein. OPG binding protein is used in binding assays to determine osteoprotegerin (OPG) in biological samples; to screen for specific binding agents (particularly agonists and antagonists, including intracellular proteins); to raise Ab (useful in immunoassays, modulate binding of OPG binding protein to osteoclast differentiation and activation receptor (ODAR). The nucleic acid molecule encoding OPG - bijding protein can be used to detect OPG binding protein-encoding						

CC sequences, e.g. screening for related sequences, also to produce transgenic animal models, while complementary sequences are used for antisense regulation of OPG binding protein expression. Modulators of OPG binding protein, particularly soluble forms of OPG binding protein or Ab, are used to treat or prevent bone diseases, e.g. osteoporosis, bone loss caused by arthritis or metastases, e.g. osteoporosis, Paget's disease, periodontal disease, osteoporosis, loosening of prostheses, optionally in combination with agents that promote bone growth.

SQ Sequence 18 AA;

Query Match	100.0%	Score	84	DB	2	Length	18
Best Local Similarity	100.0%	Pred. No.	1.4e-07				
Matches	17	Conservative	0	Mismatches	0	Indels	0
QY	1	VVVKTSKIPSSHNL	17				
Db	1	VVVKTSKIPSSHNL	17				

RESULT 3

AAV91023	100.0%	Score	84	DB	2	Length	18
ID	AAV91023	Standard; protein;	139 AA.				
AC	AAV91023;						
XX							
DT	05-SEP-2000	(first entry)					
XX							
DE	Mouse OBM protein sequence SEQ ID NO: 8.						
XX							
KW	Mouse; osteoclastogenesis inhibitory factor binding molecule; OCIF; OBM; osteoclast; bone absorption promoting factor; vitamin D3; PTH; parathyroid hormone.						
XX							
OS	Mus sp.						
XX							
PN	JP2000102390-A.						
XX							
PD	11-APR-2000.						
XX							
PF	30-SEP-1998;	98JP-00292971.					
XX							
PR	(SNOW) SNOW BRAND MILK PROD CO LTD.						
PA	(YSNE-) VS NEW TECHNOLOGY KENKYUSHO.						
XX							
DR	WPI; 2000-332087/29.						
DR	N-PSDB; AAA39155.						
XX							
PT	A DNA and preparation of a protein by using it.						
XX							
PS	Example 2; Page 14; 18pp; Japanese.						
XX							
CC	The present invention describes a genomic DNA encoding a protein having an activity of supporting or promoting differentiation and maturation of osteoclasts. The genomic DNA encoding a protein has the following properties: (a) combines specifically with osteoclastogenesis inhibitory factor (OCIF) and has a high affinity; (b) shows a molecular weight (mw) of 30,000 to 40,000 by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) under a nonreductive condition and the apparent mw when crosslinked with monomer type OCIF is 90,000 to 110,000; and (c) has an activity of supporting or promoting differentiation and maturation of osteoclast in the co-culture of mouse osteoblast-like stroma cell and mouse B-lymph cell in the presence of a bone absorption promoting factor such as active type vitamin D3 and parathyroid hormone (PTH). The protein can be used as a drug and a research reagent. The present sequence represents a mouse OCIF binding molecule (OBM) from the present invention						
SQ	Sequence 139 AA;						

Query Match	100.0%	Score	84	DB	3	Length	139
Best Local Similarity	100.0%	Pred. No.	1.5e-06				

CC The present sequence represents peptide from murine osteoprotegerin (OPG) binding protein. Host cells transfected with vectors containing nucleic acid molecules encoding OPG binding protein are used to produce recombinant OPG binding protein. OPG binding protein is used in binding assays to determine osteoprotegerin (OPG) in biological samples; to screen for specific binding agents (particularly agonists and antagonists, including intracellular proteins); to raise Ab (useful in immunoassays, modulate binding of OPG binding protein to osteoclast differentiation and activation receptor (ODAR). The nucleic acid molecule encoding OPG - bijding protein can be used to detect OPG binding protein-encoding

GenCore version 5.1.6
 Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model

Run on: December 21, 2005, 12:35:06 ; Search time 18.5902 Seconds
 (without alignments)
 1024.696 Million cell updates/sec

Title: US-09-211-297-32

Perfect score: 148

Sequence: 1 NASIPGSGSHKVTLSSWYHDRGWAQIS 27

Scoring table: BLOSUM62

GapOp 10.0 , GapExt 0.5

Searched:

2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0
 Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
 Maximum Match 100%

Listing first 45 summaries

Database : UniProt 05.80;*

1: uniprot_sprot;*

2: uniprot_trembl;*

Pred No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	148	100.0	316	1 TNF11_MOUSE
2	140	94.6	318	1 TNF11_RAT
3	136	91.9	2 OSA9A8_HUMAN	
5	136	91.9	317	1 TNF11_HUMAN
6	88	59.5	117	2 OSX1HO_RABBIT
7	76	51.4	95	2 O6DT13_HUMAN
9	61.5	41.6	157	2 O9C4K2_HUMAN
10	59	39.9	456	1 MNTH_BRUSU
11	59	39.9	456	2 O5TC6B_BRUAB
13	58.5	39.5	456	2 O9C4G1_9EBRY
14	58.5	39.5	157	2 O9C4H7_9EBRY
15	58.5	39.5	157	2 O9C4H7_9EBRY
16	58.5	39.5	157	2 O9C4I3_9EBRY
17	58.5	39.5	157	2 O9C4J1_9EBRY
18	58.5	39.5	163	2 O7ZAB6_9EBRY
19	58	39.2	371	2 O8Q0C2_METMMA
20	57	38.5	255	2 O41VP8_AZOT
21	56.5	38.2	157	2 O9C4G6_9EBRY
22	56.5	38.2	157	2 O9C4H7_9EBRY
23	56.5	38.2	162	2 O6S11T_9EBRY
24	56.5	38.2	211	2 O75NC5_9ARCH
25	56.5	38.2	224	2 O6WVF0_9ARCH
26	56.5	38.2	235	2 O6WVF2_9ARCH
27	56.5	38.2	235	2 O6WVF3_9ARCH
28	56.5	38.2	235	2 O6WVF5_9ARCH
29	56.5	38.2	235	2 O6WVF6_9ARCH
30	56.5	38.2	233	2 OSEGO_9ARCH
31	56.5	38.2	233	2 OSEGO_9ARCH
254	2	38.2	233	2 OSEGO_9ARCH

RESULT 1	TNF11_MOUSE	STANDARD;	PRT;	316 AA.
ID	TNF11_MOUSE			
AC	O35235; O35306; O8UJK9; Q9R1Y0;			
DT	16-OCT-2001 (Rel. 40, Created)			
DT	16-OCT-2001 (Rel. 40, Last sequence update)			
DT	13-SEP-2005 (Rel. 48, Last annotation update)			
DE	Tumor necrosis factor ligand superfamily member 11 (Receptor activator of nuclear factor kappa B ligand) (RANKL) (TNF-related activation induced cytokine) (TRANCE) (Osteoprotegerin Ligand) (OPGL) (Osteoclast differentiation factor) (ODF) [Contains: Tumor necrosis factor ligand superfamily member 11, membrane form; Tumor necrosis factor ligand superfamily member 11, soluble form]			
GN	Name=Tramf1; Synonyms=Opgl, Rankl, Trance;			
OS	Mus musculus (Mouse);			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.			
OX	NCBI_TAXID=10090;			
RN	[1]			
RC	NUCLEOTIDE SEQUENCE (ISOFORM 1).			
RC	TISSUE=Hybridoma;			
RC	MEDLINE=9746012; PubMed=9312132; DOI=10.1074/jbc.272.40.25190; Wong B.R., Rho J., Arron J., Robinson B., Olinick J., Chao M., Ra Kalachikov S., Cayani E., Bartlett F.S. III, Frankel W.N., Lee S.Y., Choi Y.;			
RC	"TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells.";			
RL	J. Biol. Chem. 272:25190-25194(1997). [2]			
RP	NUCLEOTIDE SEQUENCE (ISOFORM 1).			
RP	MEDLINE=9746012; PubMed=9312132; DOI=10.1074/jbc.272.40.25190; Wong B.R., Rho J., Arron J., Robinson B., Olinick J., Chao M., Ra Kalachikov S., Cayani E., Bartlett F.S. III, Frankel W.N., Lee S.Y., Choi Y.;			
RC	TISSUE=Thymic lymphoma;			
RC	MEDLINE=98032979; PubMed=9367155; DOI=10.1038/36593; Anderson D.M., Maraskovsky E., Billington W.L., Douall W.C., Tomersko M.E., Roux E.R., Teipe M.C., Dubose R.F., Cosman D., Galibert L.;			
RT	"A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic cell function.";			
RL	Nature 390:175-179 (1997). [3]			
RN	NUCLEOTIDE SEQUENCE (ISOFORM 1).			
RC	TISSUE=Bone marrow;			
RC	MEDLINE=98227661; PubMed=9568710; DOI=10.1016/S0092-8674(00)81569-X; Lacey D.L., Timms E., Tan H.-M., Dunstan C.R., Burges T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Bla A., Olan Y.-X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W.J.;			
RT	"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.";			
RL	Cell 93:165-176 (1998). [4]			
RP	NUCLEOTIDE SEQUENCE (ISOFORM 1).			
RC	TISSUE=Bone marrow stroma;			

Q56gks uncultured
 Q56gj9 uncultured
 Q56gj0 uncultured
 Q7nru chromobacter
 Q41zg3 azotobacter
 Q6i192 uncultured
 Q6vne9 uncultured
 Q6vvb8 uncultured
 Q5egub_9ARCH
 Q5egj6 uncultured
 Q68y3 uncultured
 Q6vnu1_9ARCH
 Q41r89 erythrobact
 Q6xxa8 uncultured
 Q9c4h0 uncultured

RX MEDLINE=98188248; PubMed=9520411; DOI=10.1073/pnas.95.7.3597;
 RA Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinoshita M., Tsuda E.;
 RA Mochizuki S.-I., Tomoyasu A., Yano K., Yano M., Murakami A., Tsuda E.;
 RA Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T.;
 RT "Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical
 RT to TRANCE/RANKL.";
 RT Proc. Natl. Acad. Sci. U.S.A. 95:3597-3602(1998).
 RT [5]
 RN NUCLEOTIDE SEQUENCE (ISOFORM 1).
 RC STRAIN=129;
 RX MEDLINE=99214075; PubMed=10196481; DOI=10.1016/S0378-1119(99)00025-6;
 RA Kodaira K., Kodaira K., Mizuno A., Yasuda H., Shima N., Murakami A.,
 RA Ueda M., Higashio K.;
 RT "Cloning and characterization of the gene encoding mouse osteoclast
 RT differentiation factor.";
 RL Gene 230:1121-1127(1999).
 RN [6]
 RN NUCLEOTIDE SEQUENCE (ISOFORMS 1; 2 AND 3).
 RX MEDLINE=21150053; PubMed=11200921; DOI=10.1210/en.142.4.1419;
 RA Ikeda T., Kasai M., Utsuyoshi M., Hirokawa K.;
 RT "Determination of three isoforms of the receptor activator of nuclear
 RT factor-kappaB ligand and their differential expression in bone and
 RT thymus."; J. Endocrinology 142:1419-1426(2001).
 RN [7]
 RN PROTEIN SEQUENCE OF 139-147, PROCESSING, AND N-GLYCOSYLATION.
 RX MEDLINE=99240759; PubMed=10244132; DOI=10.1074/jbc.C214.19.13613;
 RA Lum L., Wong B.R., Josien R., Becherer J.D., Erdjument-Bromage H.,
 RA Schiendorff J., Tempst P., Choi Y., Blobel C.P.;
 RT "Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-
 RT converting enzyme-like protease in shedding of TRANCE, a TNF family
 member involved in osteoclastogenesis and dendritic cell survival.";
 RL J. Biol. Chem. 274:13613-13618(1999).
 RN [8]
 RX X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 150-316.
 MEDLINE=21464816; PubMed=11511298;
 RA Lam J., Nelson C.A., Ross F.P., Teitelbaum S.L., Fremont D.H.;
 RT "Crystal structure of the TRANCE/RANKL cytokine reveals determinants
 RT of receptor-ligand specificity.";
 RL J. Clin. Invest. 108:971-979(2001).
 RN [9]
 RX X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 137-316.
 MEDLINE=10239021; PubMed=11733492; DOI=10.1074/jbc.M106525200;
 RA Ito S., Wakabayashi O., Ubukata O., Hayashi S., Okada F., Hata T.;
 RT "Crystal structure of the extracellular domain of mouse RANK ligand at
 RT 2.2-A resolution.";
 RL J. Biol. Chem. 277:6631-6636(2002).
 CC -1- FUNCTION: Cytokine that binds to TNFRSF1B/OPG and to
 TNFRSF1A/RANK. Osteoclast differentiation and activation factor.
 CC Augments the ability of dendritic cells to stimulate naïve T-cell
 proliferation. May be an important regulator of interactions
 between T cells and dendritic cells and may play a role in the
 regulation of the T cell-dependent immune response. May also play
 an important role in enhanced bone resorption in humoral
 CC hypercalcemia or malignancy.
 CC -1- SUBUNIT: Homotrimer.
 CC -1- SUBCELLULAR LOCATION: Type II membrane protein and secreted
 CC (isoforms 1 and 2); Cytoplasmic (isoform 3).
 CC -1- ALTERNATIVE PRODUCTS:
 CC Event=Alternative splicing; Named isoforms=3;
 CC Name=;
 CC IsoId=035235-1; Sequence=Displayed;
 CC Name=;
 CC IsoId=035235-2; Sequence=VSP_00649;
 CC Name=;
 CC IsoId=035235-3; Sequence=VSP_00648;
 CC -1- TISSUE SPECIFICITY: Highly expressed in thymus and lymph nodes,
 CC but not in nonlymphoid tissues and is abundantly expressed in T
 CC cells but not in B cells. A high level expression is also seen in
 CC the trabecular bone and lung.
 CC -1- PTM: N-glycosylated.
 CC -1- PTM: The soluble form of isoform 1 derives from the membrane form

CC by proteolytic processing. The cleavage may be catalyzed by
 CC ADAM17. A further shorter soluble form was observed.
 CC -1- DISBASE: Deficiency in Trnsfil results in failure to form lobulo-
 CC aleolar mammary structures during pregnancy, resulting in death
 CC of newborns. Trance-deficient mice show severe osteopetrosis, with
 CC no osteoclasts, marrow spaces, or tooth eruption, and exhibit
 CC profound growth retardation at several skeletal sites, including
 CC the limbs, skull, and vertebrae and have marked chondrodyplasia,
 CC with thick, irregular growth plates and a relative increase in
 CC hypertrophic chondrocytes.

CC -1- SIMILARITY: Belongs to the tumor necrosis factor family.

CC This Swiss-Prot entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
 CC European Bioinformatics Institute. There are no restrictions on its
 CC use as long as its content is in no way modified and this statement is not
 removed.

CC -----

DR EMBL; AR013170; RACT7061.1; -; mRNA.
 DR EMBL; AR019048; BAB8812.1; -; mRNA.
 DR EMBL; AF05713; AAC4013.1; -; mRNA.
 DR EMBL; AB008426; BAA25425.1; -; mRNA.
 DR EMBL; AB022039; BAA36570.1; -; Genomic_C_DNA.
 DR EMBL; AB032771; BAA97258.1; -; mRNA.
 DR EMBL; AB036798; BAA97259.1; -; mRNA.
 DR PDB; 1TQ4; X-ray; A/B/C=157-316.
 DR Ensemble; ENMGSG0000022055; Mus musculus.
 DR MG1; MG10089; Trnsfil.
 DR GO; GO_0016201; C: integral to membrane; TAS.
 DR GO; GO_0005515; F:protein binding; IPI.
 DR GO; GO_0045453; P:bone resorption; IDA.
 DR GO; GO_0007515; P:lymph gland development; TAS.
 DR GO; GO_0009887; P:organogenesis; IMP.
 DR GO; GO_0005303; P:osification; IMP.
 DR GO; GO_0045472; P:positive regulation of osteoclast different. . . ; IDA.
 DR GO; GO_0051260; P:protein homooligomerization; IDA.
 DR InterPro; IPR00652; TNF_family.
 DR Pfam; PF00229; TNF_1.
 DR ProDom; PD00212; TNF_subf_1.
 DR SMART; SM00207; TNF_1.
 DR PROSITE; PS00251; TNF_1; FALSE_NEG.
 KW PROSITE; PS0049; TNF_2; 1.
 KW 3D-structure; Alternative splicing; Cytokine; Developmental protein;
 KW Differentiation; Direct protein sequencing; Glycoprotein; Receptor;
 KW Signal-anchor; Transmembrane.
 FT CHAIN 1 316 Tumor necrosis factor ligand superfamily
 FT member 11, membrane form.
 FT CHAIN 139 316 Tumor necrosis factor ligand superfamily
 FT member 11, soluble form.
 FT TOBO_DOM 1 48 Cytoplasmic (Potential).
 FT TRANSMEM 49 69 Signal-anchor for type II membrane
 FT protein (Potential).
 FT TOBO_DOM 70 316 Extracellular (Potential).
 FT SITE 138 139 Cleavage.
 FT CARBOHYD 197 197 N-linked (GlcNAc. . .) (Potential).
 FT CARBOHYD 262 262 N-linked (GlcNAc. . .) (Potential).
 FT VARSPLIC 1 117 Missing (in isoform 3).
 FT /Pfam-VSP_006448.
 FT SSBEMGSGPGVHEGPHLAPAPSAPAPPPA -> TP (in
 FT Isoform 2).
 FT /Pfam-VSP_006449.
 FT G -> D (in Ref. 2).
 FT Missing (in Ref. 5).
 FT STRAND 164 169
 FT TURN 171 172
 FT STRAND 181 182
 FT STRAND 186 187
 FT TURN 191 192
 FT STRAND 194 196
 FT STRAND 198 201

GenCore version 5.1.6
 Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model
 Run on: December 21, 2005, 12:34:10 ; Search time 18.3689 Seconds
 (without alignments)
 645.834 Million cell updates/sec.

Title: US-09-211-297-32
 Perfect score: 148
 Sequence: 1 NAASIPGSHKVTLSSWYHDRGWAKLS 27

Scoring table: BLOSUM62
 GapOp 10.0 , Gapext 0.5

Searched: 2443163 seqs, 43937871 residues

Total number of hits satisfying chosen parameters:

2443163

Minimum DB seq length: 0
 Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
 Maximum Match 100%
 Listing first 45 summaries

Database : A_GeneSeq_21,*

1: geneseq1980s,*
 2: geneseq1990s,*
 3: geneseqp2000s,*
 4: geneseqp2001s,*
 5: geneseqp2002s,*
 6: geneseqp2003bs,*
 7: geneseqp2004s,*
 8: geneseqp2005s,*
 9: geneseqp2005s,*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	148	100.0	27	AAW83196
2	148	100.0	28	AAW83197
3	148	100.0	155	ABR39854
4	148	100.0	155	ADC03334
5	148	100.0	155	ADL53055
6	148	100.0	160	ABD08272
7	148	100.0	170	AAU08386
8	148	100.0	170	ADJ82132
9	148	100.0	173	AAV84226
10	148	100.0	173	AAV84422
11	148	100.0	173	AAV84425
12	148	100.0	173	AAV84421
13	148	100.0	182	AAV84424
14	148	100.0	187	AAV84420
15	148	100.0	188	AAV84423
16	148	100.0	193	ADJ82129
17	148	100.0	199	ABG94285
18	148	100.0	199	ABG80597
19	148	100.0	199	ADJ82119
20	148	100.0	216	ADBL6999
21	148	100.0	244	AAW83019
22	148	100.0	247	ABG94284
23	148	100.0	247	ABG80596
24	100.0	247	5	ABG82118

Maximum DB seq length: 0
 Minimum DB seq length: 0

ALIGNMENTS

25	148	100.0	249	6	ADB50081	Adaa50081 Mouse wil
26	148	100.0	294	2	AAW69956	Adaw69956 Np-kb rec
27	148	100.0	294	2	AAW68292	Adaw68292 Np-kb rec
28	148	100.0	294	2	AEE08737	Aae08737 Murine re
29	148	100.0	294	4	AEE04425	Aae4425 Murine re
30	148	100.0	294	4	AEE01992	Aae01992 Murine re
31	148	100.0	294	5	ADB26102	Aae26102 Mouse ran
32	148	100.0	294	7	ADB16986	Adb16986 Murine re
33	148	100.0	294	7	ADC73000	Adc73000 Murine ra
34	148	100.0	294	7	ADC78265	Adc78266 Murine RA
35	148	100.0	294	7	ADG46721	Adg46721 Murine RA
36	148	100.0	294	9	ADM09227	Adw09227 Murine re
37	148	100.0	316	2	AAW83017	Aaw83017 Ostoclas
38	148	100.0	316	2	AAW83194	Aaw83194 Human ost
39	148	100.0	316	2	AAW59654	Aaw59654 Amino aci
40	148	100.0	316	2	AAV17874	Aay17874 Murine TR
41	148	100.0	316	3	AAV91024	Aay91024 Mouse OBM
42	148	100.0	316	3	AAV84418	Aay84418 Amino aci
43	148	100.0	316	3	AAV84419	Aay84419 Amino aci
44	148	100.0	316	5	AAU78289	Aau78289 Mouse TRA
45	148	100.0	316	5	ADR29338	Adr29338 Mouse ran

score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

The present sequence represents peptide from murine osteoprotegerin (OPG) binding protein. Host cells transfected with vectors containing nucleic acid molecules encoding OPG binding protein are used to produce recombinant OPG binding protein. OPG binding protein is used in binding assays to determine osteoprotegerin (OG) in biological samples; to screen for specific binding agents (particularly agonists and antagonists, including intracellular proteins); to raise Ab (useful in immunoassays for detection of OPG binding protein) and to identify compounds that

CC modulate binding of OPG binding protein to osteoclast differentiation and activation receptor (ODAR). The nucleic acid molecule encoding OPG CC binding protein can be used to detect OPG binding protein-encoding CC sequences, e.g. screening for related sequences, also to produce CC transgenic animal models, while complementary sequences are used for CC anti-sense regulation of OPG binding protein expression. Modulators of OPG binding protein, particularly soluble forms of OPG binding protein or Ab, CC are used to treat or prevent bone diseases, e.g. osteoporosis, bone loss CC caused by arthritis or metastases, hypercalcaemia, Paget's disease, CC periodontal disease, osteoporosis, loosening of prostheses, optionally in CC combination with agents that promote bone growth.

XX Sequence 27 AA;

Query Match 100.0%; Score 148; DB 2; Length 27;
Best Local Similarity 100.0%; Pred. No. 7.8e-16;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 NAASIPSGSHKVTLSSWYHDRGAKIS 27
Db 1 NAASIPSGSHKVTLSSWYHDRGAKIS 27

RESULT 2

AAW83197
ID AAW83197 standard; Peptide; 28 AA.

AC AAW83197;
XX

DT 11-FEB-1999 (first entry)

DE Murine osteoprotegerin binding protein BB' loop-Cys peptide.

KW Osteoprotegerin binding protein; OPG binding protein; arthritis;

KW osteoporosis; osteoclast maturation; bone disease; metastasis; ODAR;

KW hypercalcemia; osteoclast differentiation and activation receptor;

KW Paget's disease.

XX DE

DE Murine osteoprotegerin binding protein BB' loop-Cys peptide.

KW Osteoprotegerin binding protein; OPG binding protein; arthritis;

KW osteoporosis; osteoclast maturation; bone disease; metastasis; ODAR;

KW hypercalcemia; osteoclast differentiation and activation receptor;

KW Paget's disease.

XX OS

OS Mus sp.
XX

PN WO9846751-A1.
XX

PD 22-OCT-1998.
XX

PF 15-APR-1998; 98WO-US007584.
XX

PR 16-APR-1997; 97US-00842842.
PR 23-JUN-1997; 97US-00800855.
PR 30-MAR-1998; 98US-00052521.
XX

PA (AMGE-) AMGEN INC.
XX

PI Boyle WJ;
XX

DR WPI; 1998-594578/50.
XX

PT Nucleic acid encoding osteoprotegerin binding protein - useful for, e.g. treating bone diseases by modulating osteoclast differentiation and for diagnosis.

XX Example 11; Page 55; 47pp; English.

XX The present sequence represents peptide from murine osteoprotegerin (OPG) binding protein. Host cells transfected with vectors containing nucleic acid molecules encoding OPG binding protein are used to produce recombinant OPG binding protein. OPG binding protein is used in binding assays to determine osteoprotegerin (OPG) in biological samples; to screen for specific binding agents (particularly agonists and antagonists, including intracellular proteins); to raise Ab (useful in immunoassays for detection of OPG binding protein) and to identify compounds that modulate binding of OPG binding protein to osteoclast differentiation and activation receptor (ODAR). The nucleic acid molecule encoding OPG

CC sequences, e.g. screening for related sequences, also to produce CC transgenic animal models, while complementary sequences are used for CC antisense regulation of OPG binding protein expression. Modulators of OPG CC binding protein, particularly soluble forms of OPG binding protein or Ab, CC are used to treat or prevent bone diseases, e.g. osteoporosis, bone loss CC caused by arthritis or metastases, hypercalcaemia, Paget's disease, CC periodontal disease, osteoporosis, loosening of prostheses, optionally in CC combination with agents that promote bone growth.

XX Sequence 28 AA;

Query Match 100.0%; Score 148; DB 2; Length 28;
Best Local Similarity 100.0%; Pred. No. 8.1e-16;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 NAASIPSGSHKVTLSSWYHDRGAKIS 27
Db 1 NAASIPSGSHKVTLSSWYHDRGAKIS 27

RESULT 3

ABR39854
ID ABR39854 standard; protein; 155 AA.

XX ABR39854;
XX

DT 11-AUG-2003 (first entry)

DE RANK 1-ligand (RANKL) protein fragment.

XX RANK; receptor activator of necrosis factor kB; RANK ligand; RANKL; KW mouse.

XX OS Mus sp.
XX PN WO2003114077-A2.
XX DR 20-FEB-2003.

XX PD 09-AUG-2002; 2002WO-US025287.

XX PR 09-AUG-2001; 2001US-0311163P.
PR 22-MAR-2002; 2002US-00105057.

XX PA (BARN-) BARNES-JEWISH HOSPITAL.

XX PI Lam J, Ross FP, Teitelbaum SL, Nelson CA, Fremont DH;
XX DR WPI; 2003-356526/25.

XX PT Composition for identifying a compound with Receptor Activator of

PT Necrosis Factor kB, RANK modulating activity and for identifying RANK or

PT osteoprotegerin modulating compound, has a protein complex in crystalline form.

XX Disclosure; Fig 3; 66pp; English.

XX The invention relates to a composition (I) comprising a protein complex

CC in crystalline form, where the complex comprises an amino acid sequence

CC of a Receptor Activator of Necrosis Factor kB (RANK) Ligand (RANKL)

CC ectodomain. (I) is useful for identifying a compound with RANK modulating

CC activity, and for identifying a RANK or OPG modulating compound. (I) is

CC useful to intelligently design mutants that have altered biological

CC properties and for identifying and/or designing compounds that bind RANK

CC as an approach towards developing new therapeutic agents. (I) is also

CC useful to computationally screen small molecule databases for chemical

CC entities or compounds that can bind in whole, or in part, to RANK or

CC RANKL. The present sequence represents a murine RANKL protein fragment

XX Sequence 155 AA;

Query Match 100.0%; Score 148; DB 6; Length 155;

Best Local Similarity 100.0%; Pred. No. 6.6e-15;

Copyright (c) 1993 - 2005 Compugen Ltd. OM protein - protein search, using sw model

SUMMARIES

```
1:  pir1;*
2:  pir2;*
3:  pir3;*
4:  pir4;*
```

Copyright (c) 1993 - 2005 Gencore version 1.0

OM protein - protein search, using SW model

Run on: December 21, 2005, 12:47:51

Title:	US-09-211-297-32
Perfect score:	148
Sequence:	1 NAA\$IPSGSHKVTLSSWYH\$DRGWAKK
Scoring table:	BLOSUM62
	Gapop 10.0 , Gapext 0.5
Searched:	283416 seqs, 96216763 residues

Searched:

Scoring table: BLOSUM62
Sequence: I N H A S I F S S G S V D L S H M R D Q M H A K L

Run on: December 21, 2005, 12:47:51 { Search time 3.0541 Seconds
850.612 Million cell updates/sec

ALIGNMENTS

hypothetical protein
 protein kinase (EC-
 BVRP2 (EC-RP3) pro-
 hypothetical prote
 secretory protein
 phosphoenolpyruvate
 hypothetical prote
 hypothetical prote
 thymidylate kinase
 integral membrane
 probable mnp prot
 hypothetical prote
 conserved hypothet
 threonine synthase
 transcription regu
 hypothetical prote

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:44:31 (without alignments)

Copyright (c) 1993 - 2005 Compugen Ltd.

GenCore version 5.1.6

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database :

- 1: Issued_Patents_AA:*
- 2: /cgn2_6/pctodata/1/iaaa/5_COMB.pep:*
- 3: cgn2_6/pctodata/1/iaaa/H_COMB.pep:*
- 4: /cgn2_6/pctodata/1/iaaa/PCTUS_COMBO.pep:*
- 5: /cgn2_6/pctodata/1/iaaa/RE_COMBO.pep:*
- 6: /cgn2_6/pctodata/1/iaaa/backfilest.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	148	100.0	28	US-09-052-521C-34
2	148	100.0	77	US-09-632-287A-10
3	148	100.0	77	US-10-286-696-10
4	148	100.0	173	US-09-396-937-10
5	148	100.0	173	US-09-396-937-12
6	148	100.0	173	US-09-396-937-18
7	148	100.0	173	US-09-396-937-20
8	148	100.0	182	US-09-396-937-16
9	148	100.0	187	US-09-396-937-8
10	148	100.0	188	US-09-396-937-14
11	148	100.0	294	US-08-989-659-11
12	148	100.0	294	US-08-998-659-11
13	148	100.0	294	US-09-215-649A-11
14	148	100.0	294	US-09-577-800-11
15	148	100.0	294	US-09-577-800-11
16	148	100.0	294	US-09-466-496-11
17	148	100.0	294	US-09-871-856-11
18	148	100.0	294	US-09-871-291-11
19	148	100.0	294	US-09-877-650-11
20	148	100.0	294	US-09-865-363-11
21	148	100.0	294	US-09-688-459-11
22	148	100.0	316	US-08-842-842-7
23	148	100.0	316	US-989-362-2
24	148	100.0	316	US-09-052-521C-2
25	148	100.0	316	US-09-671-658A-2
26	148	100.0	316	US-09-396-937-4
27	148	100.0	316	US-09-396-937-6

ALIGNMENTS

RESULT 1
US-09-052-521C-34

Sequence 34, Appl

Patent No. 6316408

GENERAL INFORMATION:

APPLICANT: Boyle, William J.

TITLE OF INVENTION: Obsteoprotegerin Binding Proteins and Receptors

FILE REFERENCE: A-451BRV

CURRENT APPLICATION NUMBER: US/99/052,521C

CURRENT FILING DATE: 1998-03-30

PRIOR APPLICATION NUMBER: 08/880,855

PRIOR FILING DATE: 1997-06-23

PRIOR APPLICATION NUMBER: 08/842,842

PRIOR FILING DATE: 1997-04-16

NUMBER OF SEQ ID NOS: 40

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO: 34

LENGTH: 28

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE: OTHER INFORMATION: Description of Artificial Sequence: Synthetic

OTHER INFORMATION: Oligonucleotide

US-09-052-521C-34

Query Match 100.0%: Score 148; DB 2; Length 28;

Best Local Similarity 100.0%; Pred. No. 5.5e-10; Mismatches 0; Indels 0; Gaps 0;

Matches 27; Conservative 0;

QY 1 NAASIPGSGHKVTLSSWTHDRGKAKIS 27

Db 1 NAASIPGSGHKVTLSSWTHDRGKAKIS 27

RESULT 2
US-09-632-287A-10

Sequence 10, Appl

Patent No. 6521422

GENERAL INFORMATION:

APPLICANT: Hsu, Hailing

APPLICANT: Wooden, Scott K

APPLICANT: Boyle, William J

TITLE OF INVENTION: TNF Ligand Supergene Family

FILE REFERENCE: 0101735550A

CURRENT APPLICATION NUMBER: US/09/632,287A

CURRENT FILING DATE: 2000-08-03

PRIOR APPLICATION NUMBER: US 60/147,294

PRIOR FILING DATE: 1999-08-04

NUMBER OF SEQ ID NOS: 22

SOFTWARE: PatentIn Ver. 2.0

SEQ ID NO 10
; LENGTH: 77
; TYPE: PRT
; ORGANISM: Mouse
US-09-632-287A-10

Query Match 100.0%; Score 148; DB 2; Length 77;
Best Local Similarity 100.0%; Pred. No. 1.9e-14; Mismatches 0; Indels 0; Gaps 0;

QY 1 NAASIPSGSHKVTLSSWYHDRGWA~~KIS~~ 27
Db 14 NAASIPSGSHKVTLSSWYHDRGWA~~KIS~~ 40

RESULT 3 US-10-286-696-10
Sequence 10. Application US/10286696
Patent No. 6952839
GENERAL INFORMATION:
APPLICANT: HSU, Hailing
APPLICANT: Woden, Scott K
APPLICANT: Boyle, William J
TITLE OF INVENTION: FmN, A No. 6852839el Member of the TNF Ligand Supergene Family
FILE REFERENCE: 01017/3550A
CURRENT APPLICATION NUMBER: US/10/286,696
CURRENT FILING DATE: 2002-11-01
PRIOR APPLICATION NUMBER: US 60/147,294
PRIOR FILING DATE: 1999-06-04
NUMBER OF SEQ ID NOS: 22
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 10 LENGTH: 77
TYPE: PRT
ORGANISM: Mouse

SBQ ID NO 10
Length: 77

Query Match 100.0%; Score 148; DB 2; Length 77;
Best Local Similarity 100.0%; Pred. No. 1.9e-14; Mismatches 0; Indels 0; Gaps 0;

QY 1 NAASIPSGSHKVTLSSWYHDRGWA~~KIS~~ 27
Db 14 NAASIPSGSHKVTLSSWYHDRGWA~~KIS~~ 40

RESULT 4 US-09-937-10
Sequence 10. Application US/09396937
Patent No. 6645500
GENERAL INFORMATION:
APPLICANT: M&E Biotech A/S
APPLICANT: HALKIER, Torben
APPLICANT: HAANING, Jesper
TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand
TITLE OF INVENTION: Activity
FILE REFERENCE: 22021/PC 1
CURRENT APPLICATION NUMBER: US/09/396,937
CURRENT FILING DATE: 1999-09-15
NUMBER OF SEQ ID NOS: 35
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 10 LENGTH: 173
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: DNA encoding
OTHER INFORMATION: murine OPGL, residues 158-316, fused to His tag

SBQ ID NO 10 LENGTH: 173
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: DNA encoding
OTHER INFORMATION: murine OPGL, residues 158-316, fused to His tag

Query Match 100.0%; Score 148; DB 2; Length 173;
Best Local Similarity 100.0%; Pred. No. 5e-4; Mismatches 0; Indels 0; Gaps 0;

QY 1 NAASIPSGSHKVTLSSWYHDRGWA~~KIS~~ 27
Db 27 NAASIPSGSHKVTLSSWYHDRGWA~~KIS~~ 53

RESULT 5 US-09-336-937-12
Sequence 12. Application US/093396937
Patent No. 6645500
GENERAL INFORMATION:
APPLICANT: M&E Biotech A/S
APPLICANT: HALKIER, Torben
APPLICANT: HAANING, Jesper
TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand
TITLE OF INVENTION: Activity
FILE REFERENCE: 22021/PC 1
CURRENT APPLICATION NUMBER: US/09/396,937
CURRENT FILING DATE: 1999-09-15
NUMBER OF SEQ ID NOS: 35
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 18 LENGTH: 173
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Fusion between
OTHER INFORMATION: murine OPGL, residues 158-316 with tetanus toxoid
OTHER INFORMATION: P2 epitope introduced, and His tag

Query Match 100.0%; Score 148; DB 2; Length 173;
Best Local Similarity 100.0%; Pred. No. 5e-14; Mismatches 0; Indels 0; Gaps 0;

QY 1 NAASIPSGSHKVTLSSWYHDRGWA~~KIS~~ 27
Db 27 NAASIPSGSHKVTLSSWYHDRGWA~~KIS~~ 53

GenCore version 5.1.6
copyright (c) 1993 - 2005 Compugen Ltd.

PRIOR FILING DATE: 1998-03-30
; PRIOR APPLICATION NUMBER: US 08/880, 855
; PRIOR FILING DATE: 1997-06-23
; PRIOR APPLICATION NUMBER: US 08/842, 842
; PRIOR FILING DATE: 1997-04-16
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 34
; LENGTH: 28
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
; US-10-825-898-34

Query Match 100.0%; Score 148; DB 5; Length 28;
; Best Local Similarity 100.0%; Pred. No. 7.1e-13; 0; Mismatches 27; Conservative 0; Indels 0; Gaps 0;

QY 1 NAASIPSGSHKVTLSSWYHDRGAKIS 27
Db 1 NAASIPSGSHKVTLSSWYHDRGAKIS 27

RESULT 3
US-10-286-696-10
; Sequence 10, Application US/10286696
; Publication No. US20030129706A1
; GENERAL INFORMATION:
; APPLICANT: Hsu, Hailing
; APPLICANT: Wooden, Scott K
; APPLICANT: Boyle, William J
; TITLE OF INVENTION: Fhm, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY: ANTIBODY
; FILE REFERENCE: 01017/35550A
; CURRENT APPLICATION NUMBER: US/10/286,696
; CURRENT FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: US 09/632,287
; PRIOR FILING DATE: 2000-08-03
; CURRENT APPLICATION NUMBER: US/10/889,948
; CURRENT FILING DATE: 2004-07-13
; PRIOR APPLICATION NUMBER: US 10/286,696
; PRIOR FILING DATE: 1999-08-04
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 10
; LENGTH: 77
; TYPE: PRT
; ORGANISM: Mouse
; US-10-286-696-10

Query Match 100.0%; Score 148; DB 4; Length 77;
; Best Local Similarity 100.0%; Pred. No. 2e-12; 0; Mismatches 27; Conservative 0; Indels 0; Gaps 0;

QY 1 NAASIPSGSHKVTLSSWYHDRGAKIS 27
Db 14 NAASIPSGSHKVTLSSWYHDRGAKIS 40

RESULT 4
US-10-890-368-10
; Sequence 10, Application US/10890368
; Publication No. US20040240324A1
; GENERAL INFORMATION:
; APPLICANT: Hsu et al.
; TITLE OF INVENTION: METHODS FOR INTERACTION MODULATORS
; FILE REFERENCE: 01017/35550D
; CURRENT APPLICATION NUMBER: US/10/890,368
; CURRENT FILING DATE: 2004-07-13
; PRIOR APPLICATION NUMBER: US 10/286,696
; PRIOR FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: US 09/632,287
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: US 60/147,294
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 10
; LENGTH: 77
; TYPE: PRT
; ORGANISM: Mouse
; US-10-889-948-10

Query Match 100.0%; Score 148; DB 5; Length 77;
; Best Local Similarity 100.0%; Pred. No. 2e-12; 0; Mismatches 27; Conservative 0; Indels 0; Gaps 0;

QY 1 NAASIPSGSHKVTLSSWYHDRGAKIS 27
Db 14 NAASIPSGSHKVTLSSWYHDRGAKIS 40

RESULT 5
US-10-889-948-10
; Sequence 10, Application US/08899948
; Publication No. US20040265913A1
; GENERAL INFORMATION:
; APPLICANT: Hsu et al.
; TITLE OF INVENTION: MATERIALS AND METHODS
; FILE REFERENCE: 01017/35550C
; CURRENT APPLICATION NUMBER: US/10/889,948
; CURRENT FILING DATE: 2004-07-13
; PRIOR APPLICATION NUMBER: US 10/286,696
; PRIOR FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: US 09/632,287
; SEQ ID NO 10
; LENGTH: 77
; TYPE: PRT
; ORGANISM: Mouse
; US-10-889-948-10

Query Match 100.0%; Score 148; DB 5; Length 77;
; Best Local Similarity 100.0%; Pred. No. 2e-12; 0; Mismatches 27; Conservative 0; Indels 0; Gaps 0;

QY 1 NAASIPSGSHKVTLSSWYHDRGAKIS 27
Db 14 NAASIPSGSHKVTLSSWYHDRGAKIS 40

RESULT 6
US-09-779-050A-14
; Sequence 14, Application US/09779050A
; Patent No. US200206416A1
; GENERAL INFORMATION:
; APPLICANT: BOYLE, WILLIAM
; APPLICANT: HSU, HAILEING
; TITLE OF INVENTION: RECEPTOR FROM TNF FAMILY
; FILE REFERENCE: A-570B
; CURRENT APPLICATION NUMBER: US/09/779,050A
; CURRENT FILING DATE: 2001-02-12
; PRIOR APPLICATION NUMBER: 60/181,800
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 52
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 14
; LENGTH: 160
; TYPE: PRT
; ORGANISM: Mus musculus
; US-09-779-050A-14

Query Match 100.0%; Score 148; DB 3; Length 160;
; Best Local Similarity 100.0%; Pred. No. 4.2e-12;

GenCore version 5.1.6
 Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 13:03:52 ; Search time 0.840984 Seconds
 (without alignments)
 228,978 Million cell updates/sec

Title: US-09-211-297-32
 Perfect score: 148
 Sequence: NAASISGSGSHKVTLSSWYHDRGWAKIS 27

Scoring table: BLOSUM62

Gapop 10.0 , Gapext: 0.5

Searched: 53982 seqB, 7132107 residues

Total number of hits satisfying chosen parameters: 53982

Minimum DB seq length: 0
 Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
 Maximum Match 100%
 Listing first 45 summaries

Database : Published Applications AA New:
 1: /cggn2_6/prodata/2/pubpa/US08 NEW PUB.PEP: *
 2: /cggn2_6/prodata/2/pubpa/US6_NEW_PUB.PEP: *
 3: /cggn2_6/prodata/2/pubpa/US07_NEW_PUB.PEP: *
 4: /cggn2_6/prodata/2/pubpa/PCT_NEW_PUB.PEP: *
 5: /cggn2_6/prodata/2/pubpa/US05_NEW_PUB.PEP: *
 6: /cggn2_6/prodata/2/pubpa/US10_NEW_PUB.PEP: *
 7: /cggn2_6/prodata/2/pubpa/US11_NEW_PUB.PEP: *
 8: /cggn2_6/prodata/2/pubpa/US60_NEW_PUB.PEP: *

Pred No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	132	89.2	109	7 US-11-065-669-8
2	53.5	36.1	1649	6 US-10-995-511-974
3	53.5	36.1	1694	7 US-11-135-855-36
4	53.5	36.1	1709	6 US-10-995-511-973
5	53.5	36.1	1709	7 US-11-135-855-35
6	46	31.1	532	7 US-11-152-747-2
7	45	53	6	7 US-10-467-674-4496
8	44	29.7	401	6 US-10-510-386-68
9	43.5	29.4	367	6 US-10-821-224-1569
10	43.5	29.4	401	7 US-11-097-749-3
11	43.5	29.4	863	7 US-11-097-749-2
12	43	29.1	245	6 US-10-793-626-2910
13	43	29.1	245	6 US-10-467-657-2730
14	42.5	28.7	447	7 US-11-112-892-4
15	41	27.7	272	6 US-10-467-657-2730
16	41	27.7	288	6 US-10-131-826-316
17	41	27.7	987	6 US-10-70-726-61
18	40.5	27.4	250	6 US-10-454-437-388
19			378	7 US-11-050-091-3
20	40.5	27.4	378	7 US-11-050-091-11
21	40.5	27.4	378	7 US-11-057-177-39
22	40.5	27.4	378	7 US-11-087-177-41
23	40.5	27.4	488	6 US-10-821-234-1000
24	40	27.0	296	7 US-11-074-176-166
25			362	6 US-10-821-234-1148

RESULT 1	US-11-065-669-8
SEQUENCE 8, Application	US/11055669
Publication No. US2005024411A1	
GENERAL INFORMATION:	
APPLICANT:	Mackay, Fabienne
APPLICANT:	Kalled, Susan
TITLE OF INVENTION:	BAFF, INHIBITORS THEREOF AND THEIR USE IN THE MODULATION OF B-CELL RESPONSE
FILE REFERENCE:	08201-0024-04000
CURRENT APPLICATION NUMBER:	US11/065, 669
CURRENT FILING DATE:	2005-02-24
PRIOR APPLICATION NUMBER:	10/045, 574
PRIOR FILING DATE:	2001-11-07
PRIOR APPLICATION NUMBER:	09/911, 777
PRIOR FILING DATE:	2001-07-24
PRIOR APPLICATION NUMBER:	60/143, 228
PRIOR FILING DATE:	2001-07-09
PRIOR APPLICATION NUMBER:	PCT/US00/01788
PRIOR FILING DATE:	2000-01-25
PRIOR FILING DATE:	60/117, 169
NUMBER OF SEQ ID NOS: 26	
SOFTWARE:	PatentIn Ver. 2.1
SEQ ID NO 8	
LENGTH:	109
TYPE:	PTT
ORGANISM:	Homo sapiens
US-11-065-669-8	
Query Match	89.2%
Similarity	89.2%
Score	132
DB	7
Length	109
Best Local Similarity	85.2%
Matches	23
Conservative	1;
Mismatches	3;
Indels	0;
Gaps	0;
Qry	1 NAASISGSGSHKVTLSSWYHDRGWAKIS 27
Db	11 NATDPSGSHKVLSWYHDRGWAKIS 37
RESULT 2	
Sequence 388, Appli	US-10-995-511-974
Sequence 3, Appli	; Sequence 974, Application US/10995561
Sequence 11, Appli	; Publication No. US2005027054A1
Sequence 39, Appli	; GENERAL INFORMATION:
Sequence 2730, Appli	; APPLICANT: CARGILL, Michele et al.
Sequence 316, Appli	; TITLE OF INVENTION: GENETIC POLYMORPHISMS ASSOCIATED WITH
Sequence 61, Appli	; TITLE OF INVENTION: CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF
Sequence 388, Appli	; TITLE OF INVENTION: DETECTION AND USES THEREOF
Sequence 1148, Appli	

```

; FILE REFERENCE: CL001559
; CURRENT APPLICATION NUMBER: US/10/995, 561
; CURRENT FILING DATE: 2004-11-24
; NUMBER OF SEQ ID NOS: 85702
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 974
; LENGTH: 1649
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-995-561-974

Query Match 36.1%; Score 53.5; DB 6; Length 1649;
Best Local Similarity 31.2%; Pred. No. 4.2;
Matches 10; Conservative 5; Mismatches 6; Indels 11; Gaps 1;
QY 3 ASIPSG-----SHKVTLSSWYHDRGW 23
Db 1269 AA VPGAPAITVTCADPAHAPTYWYHNGRW 1300

RESULT 3
US-11-135-855-36
; Sequence 36, Application US/11135855
; Publication No. US20050255557A1
; GENERAL INFORMATION:
; APPLICANT: SMITHKLINE BEECHAM CORPORATION
; APPLICANT: SMITHKLINE BEECHAM P.L.C.
; TITLE OF INVENTION: NOVEL COMPOUNDS
; FILE REFERENCE: GPS0013
; CURRENT APPLICATION NUMBER: US/11/135, 855
; CURRENT FILING DATE: 2005-05-24
; PRIOR APPLICATION NUMBER: US/10/203, 708
; PRIOR FILING DATE: 2002-08-13
; PRIOR APPLICATION NUMBER: US/10/203, 708
; PRIOR FILING DATE: 2000-02-14
; PRIOR APPLICATION NUMBER: US/10/203, 708
; PRIOR FILING DATE: 2000-02-29
; PRIOR FILING DATE: 2001-02-14
; PRIOR FILING DATE: 2000-02-14
; PRIOR APPLICATION NUMBER: US/10/203, 708
; PRIOR FILING DATE: 2000-02-29
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO: 36
; LENGTH: 1694
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-135-855-36

Query Match 36.1%; Score 53.5; DB 7; Length 1694;
Best Local Similarity 31.2%; Pred. No. 4.3;
Matches 10; Conservative 5; Mismatches 6; Indels 11; Gaps 1;
QY 3 ASIPSG-----SHKVTLSSWYHDRGW 23
Db 1263 AA VPEGAPAITVTCADPAHAPTYWYHNGRW 1294

RESULT 4
US-10-995-561-973
; Sequence 973, Application US/10995561
; Publication No. US20050272054A1
; GENERAL INFORMATION:
; APPLICANT: CARGILL, Michele et al.
; TITLE OF INVENTION: GENETIC POLYMORPHISMS ASSOCIATED WITH
; TITLE OF INVENTION: CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF
; TITLE OF INVENTION: DETECTION AND USES THEREOF
; FILE REFERENCE: CL001559
; CURRENT APPLICATION NUMBER: US/10/995, 561
; CURRENT FILING DATE: 2004-11-24
; NUMBER OF SEQ ID NOS: 85702
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 973
; LENGTH: 1709
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-995-561-974

Query Match 36.1%; Score 53.5; DB 7; Length 1709;
Best Local Similarity 31.2%; Pred. No. 4.3;
Matches 10; Conservative 5; Mismatches 6; Indels 11; Gaps 1;
QY 3 ASIPSG-----SHKVTLSSWYHDRGW 23
Db 1269 AA VPEGAPAITVTCADPAHAPTYWYHNGRW 1300

RESULT 5
US-11-135-855-35
; Sequence 35, Application US/11135855
; Publication No. US20050255557A1
; GENERAL INFORMATION:
; APPLICANT: SMITHKLINE BEECHAM CORPORATION
; APPLICANT: SMITHKLINE BEECHAM P.L.C.
; TITLE OF INVENTION: NOVEL COMPOUNDS
; FILE REFERENCE: GPS0013
; CURRENT APPLICATION NUMBER: US/11/135, 855
; CURRENT FILING DATE: 2005-05-24
; PRIOR APPLICATION NUMBER: US/10/203, 708
; PRIOR FILING DATE: 2002-08-13
; PRIOR APPLICATION NUMBER: PCT/US01/04703
; CURRENT FILING DATE: 2001-02-14
; PRIOR FILING DATE: 2000-02-14
; PRIOR FILING DATE: 2000-02-14
; PRIOR APPLICATION NUMBER: US/10/203, 708
; PRIOR FILING DATE: 2000-02-29
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO: 35
; LENGTH: 1709
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-135-855-35

Query Match 36.1%; Score 53.5; DB 7; Length 1709;
Best Local Similarity 31.2%; Pred. No. 4.3;
Matches 10; Conservative 5; Mismatches 6; Indels 11; Gaps 1;
QY 3 ASIPSG-----SHKVTLSSWYHDRGW 23
Db 1263 AA VPEGAPAITVTCADPAHAPTYWYHNGRW 1294

RESULT 6
US-11-152-747-2
; Sequence 2, Application US/11152747
; Publication No. US20050251881A1
; GENERAL INFORMATION:
; APPLICANT: E. I. du Pont de Nemours, Inc.
; APPLICANT: Cheng, Qiong
; APPLICANT: Tso, Luan
; TITLE OF INVENTION: CAROTENOID KETOLASE GENE
; FILE REFERENCE: CL-1849 US NA
; CURRENT APPLICATION NUMBER: US/11/152, 747
; CURRENT FILING DATE: 2005-06-14
; PRIOR APPLICATION NUMBER:
; PRIOR FILING DATE:
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: Microsoft Office 97
; SEQ ID NO: 2
; LENGTH: 532
; TYPE: PRT
; ORGANISM: Rhodococcus erythropolis AN12
; US-11-152-747-2

Query Match 31.1%; Score 45; DB 7; Length 532;
Best Local Similarity 39.3%; Pred. No. 16;
Matches 11; Conservative 4; Mismatches 7; Indels 6; Gaps 2;

```